Escherichia coli compositions and methods thereof
By engineering E. coli strains to produce long-chain LPS through expression of the Salmonella enterica fepE gene, the vaccine generates robust immune responses against various E. coli serotypes, addressing the limitations of previous vaccines.
Patent Information
- Application Number
- JP2024121820
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-07-31
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-06
AI Technical Summary
Existing vaccines against Escherichia coli (E. coli) serotypes fail to generate robust functional immune responses due to variability in O polysaccharides, limiting their effectiveness in preventing bacterial sepsis.
Engineering E. coli strains to express the Salmonella enterica fepE gene, which produces long-chain LPS, allowing for the production of immunogenic O polysaccharides that can be purified and conjugated to carrier proteins, enhancing antibody response.
The engineered E. coli strains produce longer-chain O polysaccharides that are bactericidal and elicit functional antibodies, providing improved immunogenicity and protection against E. coli serotypes.
Smart Images

Figure 2024156772000043 
Figure 2024156772000044 
Figure 2024156772000045
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 722,370, filed August 24, 2018, U.S. Provisional Patent Application No. 62 / 784,940, filed December 26, 2018, and U.S. Provisional Patent Application No. 62 / 881,361, filed July 31, 2019, each of which is incorporated by reference in its entirety.
[0002] Technical Field The present invention relates to Escherichia coli compositions and methods thereof. [Background technology]
[0003] The cell wall of Gram-negative bacteria comprises an outer membrane and a layer of peptidoglycan inside the outer membrane. The outer membrane contains phospholipids, lipopolysaccharide (LPS), lipoproteins and membrane proteins. Lipopolysaccharides are found in the outer layer of the membrane and phospholipids are found in the inner layer.
[0004] LPS contains a lipid A membrane anchor that links the core oligosaccharide to a polymer of O polysaccharides that contain repeating sugar monomer units, forming short, long, or very long O chains. While the core oligosaccharide is mostly conserved within individual bacterial species, the O polysaccharide can be variable between serotypes.
[0005] Escherichia coli (E. coli) is a Gram-negative bacterium known to cause life-threatening bacterial sepsis. Both the capsule (K) and lipopolysaccharide (LPS) O antigens are important virulence factors.
[0006] There is considerable interest in using O polysaccharides as the basis of vaccines for E. coli. However, previous attempts to develop E. coli sugar conjugate vaccines using traditional chemical conjugation or bioconjugation approaches have failed to generate robust functional immune responses against all serotypes. Thus, there is an unmet need for immunogenic compositions against E. coli that generate robust functional immune responses. Summary of the Invention [Problem to be solved by the invention]
[0007] To meet these and other needs, the present invention relates to compositions and methods of use for eliciting an immune response against E. coli serotypes. [Means for solving the problem]
[0008] In one embodiment, the present invention relates to saccharides, conjugates, and compositions comprising same obtained from E. coli strains engineered to express longer O-antigen lipopolysaccharide (LPS) with improved properties and high density of immunogenic epitopes for bioprocess development. For example, in one embodiment, E. coli strains were engineered to express the Salmonella enterica fepE gene from a high copy plasmid, which resulted in the production of long chain LPS in E. coli strains of different O-antigen serotypes.
[0009] Initial strain development focused on serotype O25b O antigens, which are associated with difficult-to-treat, emerging multidrug-resistant isolates. The wzzB gene was deleted from a clinical E. coli O25b strain. After transformation with the Salmonella fepE plasmid, the E. coli O25b strain engineered here produced only long-chain LPS. After chemical extraction with acetic acid to release the O antigens from the bacterial surface, the resulting long-chain O25b polysaccharides were amenable to conventional purification and conjugation techniques. Unlike bioconjugation-produced O antigens, these longer chain O antigens retain the inner and outer core oligosaccharides that are independently capable of eliciting functional antibodies that are bactericidal and capable of blocking sepsis. The exemplary O25b saccharide conjugates were surprisingly significantly more immunogenic in mammals than the unconjugated polysaccharides.
[0010] Thus, in one aspect, the invention relates to a saccharide that comprises an increase of at least five repeating units compared to the corresponding wild-type O polysaccharide of E. coli.
[0011] In one embodiment, the composition is Formula O1, Formula O2, Formula O3, Formula O4, Formula O5, Formula O6, Formula O7, Formula O8, Formula O9, Formula O10, Formula O11, Formula O12, Formula O13, Formula O14, Formula O15, Formula O16, Formula O17, Formula O18, Formula O19, Formula O20, Formula O21, Formula O22, Formula O23, Formula O24, Formula O25, Formula O25b, Formula O26, Formula O27, Formula O28, Formula O29, Formula O30, Formula O32, Formula O33, Formula O34, Formula O35, Formula O36, Formula O37, Formula O38, Formula O39, Formula O40, Formula O41, Formula O42, Formula O43, Formula O44, Formula O45, Formula O46, Formula O48, Formula O49, Formula O50 , formula O51, formula O52, formula O53, formula O54, formula O55, formula O56, formula O57, formula O58, formula O59, formula O60, formula O61, formula O62, formula O62D1, formula O63, formula O64, formula O65, formula O66, formula O68, formula O69, formula O70, formula O71, formula O73, formula O74, formula O75, formula O76, O77, O78, O79, O80, O81, O82, O83, O84, O85, O86, O87, O88, O89, O90, O91, O92, O93, O95, O96, O97, O98, O99, O100, O101 , O102, O103, O104, O105, O106, O107, O108, O109, O110, O111, O112, O113, O114, O115, O116, O117, O118, O119, O120, O121, O122 23. O124, O125, O126, O127, O128, O129, O130, O131, O132, O133, O134, O135, O136, O137, O138, O139, O140, O141, O142, O143, O 144、O145、O146、O147、O148、O149、O150、O151、O152、O153、O154、O155、O156、O157、O158、O159、O160、O161、O162、O163、O164、 O165、O166、O167、O168、O169、O170、O171、O172、O173、O174、O175、O176、O177、O178、O179、O180、O181、O182、O183、O184、O185、Formula O186, and Formula O187, where n is an integer from 1 to 1000. See Table 1 and Figures 9A-C and 10A-B.
[0012] As used herein, unless expressly stated otherwise, the term "wherein n is" refers to "n" in a formula selected from the group. In one embodiment, the composition is selected from the group consisting of Formula O1 (e.g., Formula O1A, Formula O1B, and Formula O1C), Formula O2, Formula O3, Formula O4 (e.g., Formula O4:K52 and Formula O4:K6), Formula O5 (e.g., Formula O5ab and Formula O5ac (strain 180 / C3)), Formula O6 (e.g., Formula O6:K2;K13;K15 and Formula O6:K54), Formula O7, Formula O8, Formula O9, Formula O10, Formula O11, Formula O12, Formula O13, Formula O14, Formula O15, Formula O16, Formula O17, Formula O18 (e.g., Formula O18A, Formula O18ac, Formula O18A1, Formula O18B, and Formula O18C). B1), formula O19, formula O20, formula O21, formula O22, formula O23 (e.g., formula O23A), formula O24, formula O25 (e.g., formula O25a and formula O25b), formula O26, formula O27, formula O28, formula O29, formula O30, formula O32, formula O33, formula O34, formula O35, formula O36, formula O37, formula O38, formula O39, formula O40, formula O41, formula O42, formula O43, formula O44, formula O45 (e.g., formula O45 and formula O45rel), formula O46, formula O48, formula O49, formula O50, formula O51, formula O52, formula O53, formula O54, formula O55, formula O56, formula O57, formula O58, formula O59, formula O60, formula O61, formula O62, formula O62D1, formula O63, formula O64, formula O65, formula O66, formula O68, formula O69, formula O70, formula O71, formula O73 (e.g., formula O73 (strain 73-1)), formula O74, formula O75, formula O76, formula O77, formula O78, formula O79, formula O80, formula O81, formula O82, formula O83, formula O84, formula O85, formula O86, formula O87, formula O88, formula O89, formula O90, formula O91, formula O92, formula O93, formula O95, formula O96, formula O97, formula O98, formula O99, formula O100, formula O101 , formula O102, formula O103, formula O104, formula O105, formula O106, formula O107, formula O108, formula O109, formula O110, formula O1 11, Formula O112, Formula O113, Formula O114, Formula O115, Formula O116, Formula O117, Formula O118, Formula O119, Formula O120, Formula O 121, Formula O123, Formula O124, Formula O125, Formula O126, Formula O127, Formula O128, Formula O129, Formula O130, Formula O131, Formula O132, formula O133, formula O134, formula O135, formula O136, formula O137, formula O138, formula O139, formula O140, formula O141,Formula O142, Formula O143, Formula O144, Formula O145, Formula O146, Formula O147, Formula O148, Formula O149, Formula O150, Formula O151, Formula O152, Formula O153, Formula O154 , formula O155, formula O156, formula O157, formula O158, formula O159, formula O160, formula O161, formula O162, formula O163, formula O164, formula O165, formula O166, formula O167 , Formula O168, Formula O169, Formula O170, Formula O171, Formula O172, Formula O173, Formula O174, Formula O175, Formula O176, Formula O177, Formula O178, Formula O179, Formula O180, Formula O181, Formula O182, Formula O183, Formula O184, Formula O185, Formula O186, and Formula O187 (wherein n is an integer from 1 to 1000). See Table 1 and Figures 9A-C and 10A-B.
[0013] In one embodiment, the composition comprises an antibody of formula O1 (e.g., formula O1A, formula O1B, and formula O1C), formula O2, formula O3, formula O4 (e.g., formula O4:K52 and formula O4:K6), formula O5 (e.g., formula O5ab and formula O5ac (strain 180 / C3)), formula O6 (e.g., formula O6:K2;K13;K15 and formula O6:K54), formula O7, formula O10, formula O16, formula O17, , formula O18 (e.g., formula O18A, formula O18ac, formula O18A1, formula O18B, and formula O18B1), formula O21, formula O23 (e.g., formula O23A), formula O24, formula O25 (e.g., formula O25a and formula O25b), formula O26, formula O28, formula O44, formula O45 (e.g., formula O45 and formula O45rel), formula O55, formula O56, formula O58, formula O64, formula O 69, formula O73 (for example, formula O73 (stock 73-1)), formula O75, formula O77, formula O78, formula O86, formula O88, formula O90, formula O98, formula O104, formula O111, formula O113, formula O114, Formula O119, Formula O121, Formula O124, Formula O125, Formula O126, Formula O127, Formula O128, Formula O136, Formula O138, Formula O141, Formula O142, Formula O143, Formula O 147, Formula O149, Formula O152, Formula O157, Formula O158, Formula O159, Formula O164, Formula O173, Formula O62D1, Formula O22, Formula O35, Formula O65, Formula O66, Formula O83, Formula O91, Formula O105, Formula O116, Formula O117, Formula O139, Formula O153, Formula O167, and Formula O172 (wherein n is an integer from 1 to 1000). See Table 1 and Figures 9A-C and 10A.
[0014] In one embodiment, the composition comprises an amino acid sequence of Formula O1 (e.g., Formula O1A, Formula O1B, and Formula O1C), Formula O2, Formula O3, Formula O4 (e.g., Formula O4:K52 and Formula O4:K6), Formula O5 (e.g., Formula O5ab and Formula O5ac (strain 180 / C3)), Formula O6 (e.g., Formula O6:K2;K13;K15 and Formula O6:K54), Formula O7, Formula O10, Formula O16, Formula O17, Formula O18 (e.g., Formula O18A, Formula O18ac, Formula O18A1, Formula O18B, and Formula O18B1), Formula O21, Formula O23 (e.g., Formula O23A), Formula O24, Formula O25 (e.g., Formula O25a and Formula O25b), Formula O26, Formula O28, Formula O44, Formula O45 (e.g., Formula O45 and formula O45rel), formula O55, formula O56, formula O58, formula O64, formula O69, formula O73 (e.g., formula O73 (strain 73-1)), formula O75, formula O77, formula O78, formula O86, formula O88, formula O90, formula O98, formula O104, formula O111, formula O113, formula O114, formula O119, formula O121, formula O124, formula Formula O125, Formula O126, Formula O127, Formula O128, Formula O136, Formula O138, Formula O141, Formula O142, Formula O143, Formula O147, Formula O149, Formula O152, Formula O157, Formula O158, Formula O159, Formula O164, Formula O173, and Formula 62D1, where n is an integer from 1 to 1000. See Table 1 and Figures 9A-C.
[0015] In one embodiment, the composition does not include a structure selected from formula O8, formula O9a, formula O9, formula O20ab, formula O20ac, formula O52, formula O97, and formula O101. In another embodiment, the composition includes a structure selected from formula O8, formula O9a, formula O9, formula 20ab, formula O20ac, formula O52, formula O97, and formula O101, where n is an integer from 1 to 10. See Table 1 and Figure 10B.
[0016] In one embodiment, the E. coli is O1, O2, O3, O4, O5, O6, O7, O8, O9, O10, O11, O12, O13, O14, O15, O16, O17, O18, O19, O20, O21, O22, O23, O24, O25, O25b, O26, O27, O28, O29, O30, O32, O33, O34, O35, O36, O37, O38, O39, O40, O41, O42, O43, O44, O45, O46, O48, O49, O50, O51, O52 , O53, O54, O55, O56, O57, O58, O59, O60, O61, O62, 62D1, O63, O64, O65, O66, O68, O69, O70, O71, O73, O74, O75, O76, O77, O78, O79, O8 0, O81, O82, O83, O84, O85, O86, O87, O88, O89, O90, O91, O92, O93, O95, O96, O97, O98, O99, O100, O101, O102, O103, O104, O105, O106, O107, O108, O109, O110, 0111, O112, O113, O114, O115, O116, O117, O118, O119, O120, O121, O123, O124, O125, O126, O127, O128, O12 9, O130, O131, O132, O133, O134, O135, O136, O137, O138, O139, O140, O141, O142, O143, O144, O145, O146, O147, O148, O149, O150, O1 51, O152, O153, O154, O155, O156, O157, O158, O159, O160, O161, O162, O163, O164, O165, O166, O167, O168, O169, O170, O171, O172, O173, O174, O175, O176, O177, O178, O179, O180, O181, O182, O183, O184, O185, O186, and O187.
[0017] In one embodiment, the E. coli is O1, O2, O3, O4, O5, O6, O7, O8, O9, O10, O11, O12, O13, O14, O15, O16, O17, O18, O19, O20, O21, O22, O23, O24, O25, O25b, O26, O27, O28, O29, O30, O32, O33, O34, O35, O36, O37, O38, O39, O40, O41, O42, O43, O44, O45, O46, O48, O49, O50, O51, O52 , O53, O54, O55, O56, O57, O58, O59, O60, O61, O62, 62D1, O63, O64, O65, O66, O68, O69, O70, O71, O73, O74, O75, O76, O77, O78, O79, O8 0, O81, O82, O83, O84, O85, O86, O87, O88, O89, O90, O91, O92, O93, O95, O96, O97, O98, O99, O100, O101, O102, O103, O104, O105, O106 , O107, O108, O109, O110, 0111, O112, O113, O114, O115, O116, O117, O118, O119, O120, O121, O123, O124, O125, O126, O127, O128, O1 29, O130, O131, O132, O133, O134, O135, O136, O137, O138, O139, O140, O141, O142, O143, O144, O145, O146, O147, O148, O149, O150, The E. coli serotype is selected from the group consisting of O151, O152, O153, O154, O155, O156, O157, O158, O159, O160, O161, O162, O163, O164, O165, O166, O167, O168, O169, O170, O171, O172, O173, O174, O175, O176, O177, O178, O179, O180, O181, O182, O183, O184, O185, O186, and O187.
[0018] In one embodiment, the sugar is produced by expressing a wzz family protein in the gram-negative bacteria that produces said sugar. In one embodiment, the sugar is produced by increasing the repeating units of the O polysaccharide produced by the gram-negative bacteria in culture, including expressing (but not necessarily overexpressing) a wzz family protein in the gram-negative bacteria that produces said sugar. In a preferred embodiment, the wzz family protein is selected from the group consisting of wzzB, wzz, wzzB, wzzC, wzzD, wzzE, wzzF ... SF , wzz ST , fepE, wzz fepE In a preferred embodiment, the expressed (not necessarily overexpressed) wzz family protein is selected from any one of wzzB, wzz, wzz1 and wzz2. SF , wzz ST , fepE, wzz fepE , wzz1 and wzz2. In an alternative embodiment, the sugar is synthetic. In one embodiment, the sugar is covalently linked (conjugated) to a carrier protein. Preferably, the carrier protein is CRM 197 It is.
[0019] In one aspect, the present invention relates to a composition comprising a sugar and / or a conjugate thereof and a pharma- ceutically acceptable diluent.
[0020] In another aspect, the invention relates to a method for inducing an immune response in a subject, comprising administering to the subject an effective amount of the composition, hi one embodiment, the immune response comprises induction of anti-E. coli O-specific polysaccharide antibodies. [Brief description of the drawings]
[0021] [Figure 1] Figure 1A-B depict the pUC replicon, 500-700 copies per cell, chain length regulator (Figure 1A) and P15a replicon, 10-12 copies per cell, O-antigen operon (Figure 1B) plasmids. [Diagram 2]FIG. 2 is a WzzB amino acid sequence alignment showing K12\W3110\WzzB (SEQ ID NO:23); O25a\ETEC\ATCC\WzzB (SEQ ID NO:22); O25a:K5:H1\WzzB (SEQ ID NO:21); O25b\2401\WzzB (SEQ ID NO:20); and O25b\2401\WzzB (SEQ ID NO:20). [Diagram 3] Figures 3A-B show modulation of O-antigen chain length in serotypes O25a and O25b by plasmid-based expression of heterologous wzzB and fepE chain-length regulators. Genetic complementation of LPS expression in plasmid transformants of wzzB knockout strains O25K5H1 (O25a) and GAR2401 (O25b) is shown. On the left side of Figure 3A, the LPS profile of a plasmid transformant of O25a O25K5HΔwzzB is shown; on the right side, a similar profile of an O25b GAR 2401ΔwzzB transformant is shown. Immunoblots of replicate gels probed with O25-specific serum (Statens Serum Institut) are shown in Figure 3B. Lanes 1-7 correspond to the O25aΔwxxB (knockout) background; lanes 8-15 correspond to the O25b 2401ΔwzzB (knockout) background. [Figure 4] FIG. 4 shows long O antigen expression mediated by E. coli and Salmonella fepE plasmids in host O25K5H1ΔwzzB. [Diagram 5] Figure 5 shows the FepE amino acid sequence alignment. The O157 FepE amino acid sequence is SEQ ID NO: 18; the O25a ETEC ATCC FepE amino acid sequence is SEQ ID NO: 17; the O25a:K5:H1 FepE amino acid sequence is SEQ ID NO: 16; the O25b2401 FepE amino acid sequence is SEQ ID NO: 15; the Salmonella LT2 FepE amino acid sequence is SEQ ID NO: 19. [Figure 6] FIG. 6. Salmonella fepE expression produces long O-antigen LPS in various clinical isolates. [Figure 7]Figures 7A-B show plasmid-mediated arabinose-inducible expression of O25b long chain O-antigen LPS in an O25b O-antigen knockout host strain. Results from SDS PAGE are shown in Figure 7A, and results from an O25 immunoblot are shown in Figure 7B. In both Figures 7A and 7B, lane 1 is from clone 1, no arabinose; lane 2 is from clone 1, 0.2% arabinose; lane 3 is from clone 9, no arabinose; lane 4 is from clone 9, 0.2% arabinose; lane 5 is from an O55 E. coli LPS standard; and lane 6 is from an O111 E. coli LPS standard. [Figure 8] FIG. 8 shows plasmid-mediated arabinose-inducible expression of long-chain O-antigen LPS in a common host strain. [Figure 9] 9A-C show structures of O-antigens synthesized by the polymerase-dependent pathway that contain four or fewer residues in the backbone. [Figure 10] FIG. 10A depicts the structure of an O antigen synthesized by the polymerase-dependent pathway, containing five or six residues in the backbone; FIG. 10B depicts an O antigen thought to be synthesized by the ABC transporter-dependent pathway. [Figure 11] FIG. 11 shows expression of O25 O-antigen LPS in exploratory bioprocess lines. [Figure 12] Figures 12A-B show the SEC profiles and characteristics of short (Figure 12A, strain 1, O25b wt2831) and long O25b O antigens (Figure 12B, strain 2, O25b 2401ΔwzzB / LT2 FepE) purified from GAR2831 and '2401ΔwzzB / fepE strains. [Figure 13] (Figure 13A) Information regarding vaccination schedule for rabbit study 1 VAC-2017-PRL-EC-0723; (Figure 13B) Vaccination schedule for rabbit study 2 VAC-2018-PRL-EC-077. [Figure 14]Figures 14A-C show O25b glycoconjugate IgG responses. -●- represents pre-bleed results; -■- bleed 1 (week 6); -▲- bleed 2 (week 8); -◆- bleed 3 (week 12). Figure 14A depicts the results of rabbit 1-3 (medium activation); Figure 14B depicts the results of rabbit 2-3 (low activation); Figure 14C depicts the results of rabbit 3-1 (high activation). [Figure 15] Figures 15A-F show IgG responses to O25b long chain O antigen saccharide conjugates, i.e., low activated O25b-CRM197 conjugates (in Figures 15D-F, -●- represents pre-bleed results from rabbit 2-1, -■- represents week 12 antiserum results from rabbit 2-1) and non-conjugated polysaccharides, i.e., free O25b polysaccharides (in Figures 15A-C, -●- represents pre-bleed results from rabbit A-1, -■- represents week 6 antiserum results from rabbit A-1, -▲- represents week 8 antiserum results from rabbit A-1). Note that MFI is plotted on a logarithmic scale to highlight the difference between pre-immune and immune antibodies in the MFI range below 1000. Figure 15A depicts the results for rabbit A-1 (unconjugated poly); Figure 15B depicts the results for rabbit A-3 (unconjugated poly); Figure 15C depicts the results for rabbit A-4 (unconjugated poly); Figure 15D depicts the results for rabbit 2-1 (low activation); Figure 15E depicts the results for rabbit 2-2 (low activation); and Figure 15F depicts the results for rabbit 2-3 (low activation). [Figure 16]Figures 16A-C show surface expression of native and long chain O25b O antigens detected using O25b antiserum. Figure 16A depicts results where -●- represents results for O25b 2831 vs PD3 antiserum, -■- represents results for O25b 2831 wt vs pre-bleeding, -▲- represents results for O25b 2831 / fepE vs PD3 antiserum, and -▼- represents results for O25b 2831 / fepE vs pre-bleeding. Figure 16B depicts results where -●- represents results for O25b 2401 vs PD3 antiserum, -■- represents results for O25b 2401 vs pre-bleeding, -▲- represents results for O25b 2401 / fepE vs PD3 antiserum, and -▼- represents results for O25b 2401 / fepE vs pre-bleeding. FIG. 16C depicts the results, where -●- represents the results of E. coli K12 vs. PD3 antiserum, and -■- represents the results of E. coli K12 vs. pre-bleed. [Figure 17] Figure 17 shows the generalized structures of the carbohydrate backbones of the outer core oligosaccharides of the five known chemotypes. All glycoses are in the α-anomeric configuration unless otherwise indicated. The genes whose products catalyze the formation of each bond are indicated with dashed arrows. The asterisk indicates the residue of the core oligosaccharide at which attachment of the O antigen occurs. [Figure 18] Figure 18 shows that unconjugated free O25b polysaccharide is not immunogenic (dLIA).-●- represents the results of antisera from 4-1 at week 18 (1 week = PD4);-■- represents the results of antisera from 4-2 at week 18 (1 week = PD4);-▲- represents the results of antisera from 5-1 at week 18 (1 week = PD4);-▼- represents the results of antisera from 5-2 at week 18 (1 week = PD4);-*- represents the results of antisera from 6-1 at week 18 (1 week = PD4);-^- represents the results of antisera from 6-2 at week 18 (1 week = PD4). [Figure 19]Figures 19A-C are graphs showing the specificity of the BRC rabbit O25b RAC conjugate immune serum OPA titer. Figure 19A shows the OPA titer of rabbit 2-3 with pre-immune serum -●- and post-immune serum week 13 -■-. Figure 19B shows the OPA titer of rabbit 1-2 with pre-immune serum -●- and post-immune serum week 19 -■-. Figure 19C shows the OPA titer specificity of rabbit 1-2 at week 19. The OPA activity of rabbit 1-2's immune serum is blocked by pre-incubation with 100 μg / mL purified unconjugated O25b long chain O antigen polysaccharide. -■- represents the results of rabbit 1-2's immune serum at week 19, and -▼- represents the results of rabbit 1-2's w / R1 long chain OAg at week 19. [Figure 20] Figure 20A shows an exemplary dosing schedule. Figures 20B and 20C show graphs depicting O antigen O25b IgG levels elicited by unconjugated O25b long chain O antigen polysaccharide (Figure 20B, O25b free poly(2 μg)) and induced O25b RAC / DMSO long chain O antigen saccharide conjugate (Figure 20C, O25b-CRM197 RAC long chain(2 μg)). -...- (dotted line) represents naive CD1 O25b IgG levels. [Figure 21] Figures 21A-B are graphs depicting OPA immunogenicity of RAC, eTEC O25b long chain glycoconjugates, and single-end glycoconjugates after dose 2 (Figure 21A) and dose 3 (Figure 21B). -○- represents single-end short 2 μg results, -●- represents single-end long 2 μg results, -▲- represents RAC / DMSO long 2 μg results, -▼- represents eTEC long 2 μg results, * represents background control (n=20). †Response rate is % of mice with titers >2x unvaccinated baseline. [Figure 22] Figure 22 is a graph depicting OPA immunogenicity and altered levels of polysaccharide activation of eTEC chemistry. † Response rate is % of mice with titers greater than 2x unvaccinated baseline. [Diagram 23]Figure 23A shows an exemplary dosing schedule, and Figure 23B shows a graph depicting protection of mice immunized with doses of E. coli eTEC conjugates from a lethal challenge with an O25b isolate: -◇- represents 17% activation of eTEC long chains, -△- represents 10% activation of eTEC long chains, -▽- represents 4% activation of eTEC long chains, -□- represents O25b polysaccharide, and -○- represents unvaccinated controls. [Figure 24] Figure 24 is a schematic diagram showing an exemplary preparation of a single-terminated conjugate, where the conjugation process involves selective activation of 2-keto-3-deoxyoctanoic acid (KDO) with a disulfide amine linker upon unmasking of the thiol functional group. KDO is then conjugated to a bromo-activated CRM197 protein as depicted in Figure 24 (Preparation of a Single-Terminated Conjugate). [Diagram 25] 25A-B show exemplary process flow diagrams for the activation (FIG. 25A) and conjugation (FIG. 25B) processes used in the preparation of E. coli glycoconjugates to CRM197. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] Sequence Identifier SEQ ID NO:1 sets forth the primer sequence of LT2wzzB_S, which is described in Table 4. SEQ ID NO:2 sets forth the primer sequence of LT2wzzB_AS, which is set forth in Table 4. SEQ ID NO:3 sets forth the primer sequence for O25bFepE_S, which is set forth in Table 4. SEQ ID NO:4 sets forth the primer sequence for O25bFepE_A, as set forth in Table 4. SEQ ID NO:5 sets forth the primer sequence for wzzB P1_S, as described in Table 4. SEQ ID NO:6 sets forth the primer sequence for wzzB P2_AS, as set forth in Table 4. SEQ ID NO:7 sets forth the primer sequence for wzzB P3_S, as set forth in Table 4. SEQ ID NO:8 sets forth the primer sequence for wzzB P4_AS, as set forth in Table 4. SEQ ID NO:9 sets forth the primer sequence for O157 FepE_S, as set forth in Table 4. SEQ ID NO: 10 sets forth the primer sequence for O157 FepE_AS, as set forth in Table 4. SEQ ID NO:11 sets forth the primer sequence for pBAD33_adaptor_S, as described in Table 4. SEQ ID NO: 12 sets forth the primer sequence for pBAD33_adaptor_AS, as set forth in Table 4. SEQ ID NO: 13 sets forth the primer sequence of JUMPSTART_r, which is described in Table 4. SEQ ID NO: 14 sets forth the primer sequence for gnd_f, as described in Table 4. SEQ ID NO:15 sets forth the O25b 2401 FepE amino acid sequence shown in FIG. SEQ ID NO:16 sets forth the O25a:K5:H1 FepE amino acid sequence shown in FIG. SEQ ID NO:17 sets forth the O25a ETEC ATCC FepE amino acid sequence shown in FIG. SEQ ID NO:18 sets forth the O157 FepE amino acid sequence shown in FIG. SEQ ID NO:19 sets forth the Salmonella LT2 FepE amino acid sequence shown in FIG. SEQ ID NO:20 sets forth the O25b 2401 WzzB amino acid sequence shown in FIG. SEQ ID NO:21 sets forth the O25a:K5:H1 WzzB amino acid sequence shown in FIG. SEQ ID NO:22 sets forth the O25a ETEC ATCC WzzB amino acid sequence shown in FIG. SEQ ID NO:23 sets forth the K12 W3110 WzzB amino acid sequence shown in FIG. SEQ ID NO:24 sets forth the Salmonella LT2 WzzB amino acid sequence shown in FIG.
[0023] Detailed Description of the Invention The inventors have surprisingly discovered E. coli antigens resulting from the manipulation of different Wzz proteins (e.g., WzzB), including the surprising discovery of immunogenic conjugates and methods of their use. The inventors have further surprisingly discovered glycoconjugates containing such sugars covalently conjugated to carrier proteins, such as via a bivalent, heterobifunctional linker, referred to herein as a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer. The inventors have also surprisingly discovered glycoconjugates containing sugars conjugated to carrier proteins, such as via reductive amination (RAC). In particular, RAC is performed in an aprotic solvent, preferably DMSO (RAC / DMSO) or in an aqueous solution. The present invention further relates to immunogenic compositions comprising such glycoconjugates, as well as methods for the use of such glycoconjugates and immunogenic compositions. Furthermore, the inventors have surprisingly discovered that in some embodiments, glycoconjugates containing high molecular weight saccharides with medium or long O-antigen chains can be more immunogenic than glycoconjugates with relatively short O-antigen chains. Furthermore, the inventors have discovered that in some embodiments, glycoconjugates produced by multiple terminal activation of saccharides prior to conjugation to a carrier protein, such as by methods involving RAC or single terminal conjugation or eTEC, can be more immunogenic than glycoconjugates produced by single terminal activation of saccharides prior to conjugation to a carrier protein.
[0024] In one embodiment, the sugar is produced by expression (not necessarily overexpression) of a different Wzz protein (eg, WzzB) to control the size of the sugar.
[0025] As used herein, the term "sugar" refers to a single sugar moiety or monosaccharide unit and combinations of two or more single sugar moieties or units covalently linked to form disaccharides, oligosaccharides, and polysaccharides. Sugars may be linear or branched.
[0026] In one embodiment, the sugar is produced in a recombinant Gram-negative bacterium. In one embodiment, the sugar is produced in a recombinant E. coli cell. In one embodiment, the sugar is produced in a recombinant Salmonella cell. Exemplary bacteria include E. coli O25K5H1, E. coli BD559, E. coli GAR2831, E. coli GAR865, E. coli GAR868, E. coli GAR869, E. coli GAR872, E. coli GAR878, E. coli GAR896, E. coli GAR1902, E. coli O25a ETC NR-5, E. coli O157:H7:K-, Salmonella enterica Examples of suitable bacteria include E. coli GAR2401, Salmonella enterica serovar Typhimurium strain LT2, E. coli GAR2401, Salmonella enterica serovar Enteritidis CVD1943, Salmonella enterica serovar Typhimurium strain CVD1925, Salmonella enterica serovar Paratyphi A CVD1902, and Shigella flexneri CVD1208S. In one embodiment, the bacterium is not E. coli GAR2401. This genetic approach to sugar production allows for efficient production of O polysaccharide and O antigen molecules as vaccine components.
[0027] As used herein, the term "wzz protein" refers to, for example, wzzB, wzz, wzz SF , wzzST , fepE, wzz fepE AF011915 for C664-1992, AF011916 for C258-94, AF011917 for C722-89, and AF011919 for EDL933. The GenBank accession numbers for the G7 and Bi316-41 wzz gene sequences are U39305 and U39306, respectively. Additional GenBank accession numbers for exemplary wzz gene sequences are: NP_459581 for Salmonella enterica subsp. enterica serovar Typhimurium strain LT2 FepE; AIG66859 for E. coli O157:H7 strain EDL933 FepE; NP_461024 for Salmonella enterica subsp. enterica serovar Typhimurium strain LT2 WzzB; NP_416531 for E. coli K-12 substrain MG1655 WzzB; and NP_415119 for E. coli K-12 substrain MG1655 FepE. In a preferred embodiment, the wzz family proteins are selected from the group consisting of wzzB, wzz, wzz SF , wzz ST , fepE, wzz fepE , wzz1 and wzz2, most preferably wzzB, and more preferably fepE.
[0028] Exemplary wzzB sequences include: >O25b 2401 WzzB MRVENNNVSGQNHDPEQIDLIDLLVQLWRGKMTIIISVIVAIALAIGYLAVAKEKWTSTAIITQPDVGQIAGYNNAMNVIYGQAAPKVSDLQETLIGRFSSAFSALAETLDNQEEPEKLTIEPSVKNQQLPLTVSYVGQTAEGAQMKLAQYIQQVDDKVNQELEKDLKDNIALGRKNLQDSLRTQEVVAQEQKDLRIRQIQEALQYANQEQVTKPQVQQTEDVTQDTLFLLGSEALESMIKHEATRPLVFSSNYYQTRQNLLDIESLKVDDLDIHAYRYVMKPTLPIRRDSPKKAITLILAVLLGGMVGAGIVLGRNALRNYNAK(SEQ ID NO: 20) >O25a:K5:H1 WzzB MRVENNNVSGQNNDPEQIDLIDLLVQLWRGKMTIIISVIVAIALAIGYLAVAKEKWTSTAIITQPDVGQIAGYNNAMNVIYGQAAPKVSDLQETLIGRFSSAFSALAETLDNQDEPEKLTIEPSVKNQQLPLTVSYVGQTAEGAQMKLAQYIQQVDDKVNQELEKDLKDNIALGRKNLQDSLRTQEVVAQEQKDLRIRQIQEALQYANQAQVTKPQIQQTGEDITQDTLFLLGSEALESMIKHEATRPLVFSPNYYQTRQNLLDIESLKVDDLDIHAYRYVMKPTLPIRRDSPKKAITLILAVLLGGMVGAGIVLGRNALRNYNAK(SEQ ID NO: 21) >O25a ETEC ATCC WzzB MRVENNNVSGQNHDPEQIDLIDLLVQLWRGKMTIIISVVVAIALAIGYLAVAKEKWTSTAIITQPDVGQIAGYNNAMNVIYGQAAPKVSDLQETLIGRFSFAFSALAETLDNQKEPEKLTIEPSVKNQQLPLTVSYVGQTAEDAQMKLAQYIQQVDDKVNQELEKDL KDNLALGRKNLQDSLRTQEVVAQEQKDLRIRQIQEALQYANQAQVTKPQIQQTGEDITQDTLFLLGSEALESMIKHEATRPLVFSPNYYQTRQNLLDIENLKVDDLDIHAYRYVMKPTLPIRRDSPKKAITLILAVLLGGMVGAGIVLGRNALRNYNSK (SEQ ID NO: 22) >K12 W3110 WzzB MRVENNNVSGQNHDPEQIDLIDLLVQLWRGKMTIIISVIVAIALAIGYLAVAKEKWTSTAIITQPDVGQIAGYNNAMNVIYGQAAPKVSDLQETLIGRFSSAFSALAETLDNQEEREKLTIEPSVKNQQLPLTVSYVGQTAEGAQMKLAQYIQQVDDKVNQELEKDL KDNIALGRKNLQDSLRTQEVVAQEQKDLRIRQIQEALQYANQAQVTKPQIQQTGEDITQDTLFLLGSEALESMIKHEATRPLVFSPNYYQTRQNLLDIESLKVDDLDIHAYRYVMKPMLPIRRDSPKKAITLILAVLLGGMVGAGIVLGRNALRNYNAK (SEQ ID NO: 23) >Salmonella LT2 WzzB MTVDSNTSSGRGNDPEQIDLIELLLQLWRGKMTIIVAVIIAILLAVGYLMIAKEKWTSTAIITQPDAAQVATYTNALNVLYGGNAPKISEVQANFISRFSSAFSALSEVLDNQKEREKLTIEQSVKGQALPLSVSYVSTTAEGAQRRLAEYIQQVDEEVAKELEVDLKDNITLQTKTLQESLETQEVVAQEQKDLRIKQIEEALRYADEAKITQPQIQQTQDVTQDTMFLLGSDALKSMIQNEATRPLVFSPAYYQTKQTLLDIKNLKVTADTVHVYRYVMKPTLPVRRDSPKTAITLVLAVLLGGMIGAGIVLGRNALRSYKPKAL (SEQ ID NO: 24) Examples include:
[0029] Exemplary FepE sequences include: >O25b GAR2401 FepE MSSLNIKQGSDAHFPDYPLASPSNNEIDLLNLISVLWRAKKTVMAVVFAFACAGLLISFILPQKWTSAAVVTPPEPVQWQELEKSFTKLRVLDLDIKIDRTEAFNLFIKKFQSVSLLEEYLRSSPYVMDQLKEAKIDELDLHRAIVALSEKMKAVDDNASKKKDEPSLYTSWTLSFTAPTSEEAQTVLSGYI DYISTLVVKESLENVRNKLEIKTQFEKEKLAQDRIKTKNQLDANIQRLNYSLDIANAAGIKKPVYSNGQAVKDDPDFSISLGADGIERKLEIEKAVTDVAELNGELRNRQYLVEQLTKAHVNDVNFTPFKYQLSPSLPVKKDGPGKAIIVILSALIGGMVACGGVLLRYAMASRKQDAMMADHLV (Sequence number 15) >O25a:K5:H1 FepE MSSLNIKQGSEAHFPEYPLASPSNNEIDLLNLIEVLWRAKKTVMAVVFAFACAGLLISFILPQKWTSAAVVTPPEPVQWQELEKTFTKLRVLDLDIKIDRTEAFNLFIKKFQSVSLLEEYLRSSPYVMDQLKEAKIDPLDLHRAIVALSEKMKAVDDNASKKKDESALYTSWTLSFTAPTSEEAQKVLAGYIDYISALVVKESIENVRNKLEIKTQFEKEKLAQDRIKTKNQLDANIQRLNYSLDIANAAGIKKPVYSNGQAVKDDPDFSISLGADGIERKLEIEKAVTDVAELNGELRNRQYLVEQLTKTNINDVNFTPFKYQLRPSLPVKKDGQGKAIIVILSALVGGMVACGGVLLRHAMASRKQDAMMADHLV(SEQ ID NO:16) >O25a ETEC ATCC FepE MSSLNIKQGSDAHFPDYPLASPSNNEIDLLNLISVLWRAKKTVMAVVFAFACAGLLISFILPQKWTSAAVVTPPEPVQWQELEKSFTKLRVLDLDIKIDRTEAFNLFIKKFQSVSLLEEYLRSSPYVMDQLKEAKIDELDLHRAIVALSEKMKAVDDNASKKKDEPSLYTSWTLSFTAPTSEEAQTVLSGYIDYISTLVVKESLENVRNKLEIKTQFEKEKLAQDRIKTKNQLDANIQRLNYSLDIANAAGIKKPVYSNGQAVKDDPDFSISLGADGIERKLEIEKAVTDVAELNGELRNRQYLVEQLTKAHVNDVNFTPFKYQLSPSLPVKKDGPGKAIIVILSALIGGMVACGGVLLRYAMASRKQDAMMADHLV(SEQ ID NO:17) >O157 FepE MSSLNIKQGSDAHFPDYPLASPSNNEIDLLNLISVLWRAKKTVMAVVFAFACAGLLISFILPQKWTSAAVVTPPEPVQWQELEKTFTKLRVLDLDIKIDRTEAFNLFIKKFQSVSLLEEYLRSSPYVMDQLKEAKIDELDLHRAIVALSEKMKAVDDNASKKKDEPSLYTSWTLSFTAPTSEEAQTVLSGYIDYISALVVKESIENVRNKLEIKTQFEKEKLAQDRIKMKNQLDANIQRLNYSLDIANAAGIKKPVYSNGQAVKDDPDFSISLGADGIERKLEIEKAVTDVAELNGELRNRQYLVEQLTKANINDVNFTPFKYQLSPSLPVKKDGPGKAIIVILSALIGGMVACGSVLLRYAMASRKQDAMMADHLV (SEQ ID NO: 18) >Salmonella LT2 FepE MPSLNVKQEKNQSFAGYSLPPANSHEIDLFSLIEVSLIEVLWQAKRRILATVFAFACVGLLLSFLLPQKWTSQAIVTPAESVQWQGLERTLTALRVLDMEVSVDRGSVFNLFIKKFSSPSLLEEYLRSSPYVMDQLKGAQIDEQDLHRAIVLLSEKMKAVDSNVGKKNETSLFTSWTLSFTAPTREEAQKVLAGYIQYISDIVVKETLENIRNQLEIKTRYEQEKLAMDRVRLKNQLDANIQRLHYSLEIANAAGIKRPVYSNGQAVKDDPDFSISLGADGISRKLEIEKGVTDVAEIDGDLRNRQYHVEQLAAMNVSDVKFTPFKYQLSPSLPVKKDGPGKAIIIILAALIGGMMACGGVLLRHAMVSRKMENALAIDERLV (SEQ ID NO: 19) Examples include:
[0030] In some embodiments, modified sugars (modified relative to the corresponding wild-type sugars) can be produced in Gram-negative bacteria by expressing (not necessarily overexpressing) a wzz family protein (e.g., fepE) from a Gram-negative bacterium and / or by switching off (i.e., suppressing, deleting, removing) a second wzz gene (e.g., wzzB) to generate high molecular weight sugars, such as lipopolysaccharides, containing intermediate or long O-antigen chains. For example, modified sugars can be produced by expressing (not necessarily overexpressing) wzz2 and switching off wzz1. Or, in another method, modified sugars can be produced by expressing (not necessarily overexpressing) wzzfepE and switching off wzzB. In another embodiment, modified sugars can be produced by expressing (not necessarily overexpressing) wzzB but switching off wzzfepE. In another embodiment, modified sugars can be produced by expressing fepE. Preferably, the wzz family protein is from a strain that is heterologous to the host cell.
[0031] In some embodiments, the sugar is produced by expressing a wzz family protein having an amino acid sequence having at least 30%, 50%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity to any one of SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19. In one embodiment, the wzz family protein comprises a sequence selected from any one of SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19. Preferably, the wzz family protein has at least 30%, 50%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity to SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19. In some embodiments, the sugar is produced by expressing a protein having an amino acid sequence with at least 30%, 50%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or 100% sequence identity to the fepE protein.
[0032] In one aspect, the invention relates to saccharides produced by expressing a wzz family protein, preferably fepE, in Gram-negative bacteria to generate high molecular weight saccharides containing medium or long O antigen chains with at least 1, 2, 3, 4, or 5 increased repeat units compared to the corresponding wild-type O polysaccharide. In one aspect, the invention relates to saccharides produced by expressing (but not necessarily overexpressing) a wzz family protein (e.g., wzzB) in Gram-negative bacteria to generate high molecular weight saccharides containing medium or long O antigen chains with at least 1, 2, 3, 4, or 5 increased repeat units compared to the corresponding wild-type O antigen. See the description of O polysaccharides and O antigens below for further exemplary saccharides with an increased number of repeat units compared to the corresponding wild-type saccharide. Desirable chain lengths are those that provide improved or maximal immunogenicity in the context of a given vaccine construct.
[0033] In another embodiment, the saccharide comprises any one of the formulas selected from Table 1, wherein the number of repeating units in the saccharide, n, is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 110, 111, 112, 13, 14, , 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, and more than 100 repeating units. Preferably, the saccharide comprises an increase of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 repeating units compared to the corresponding wild-type O polysaccharide. See, for example, Table 21. Methods for determining the length of a saccharide are known in the art. Such methods include nuclear magnetic resonance, mass spectrometry, and size exclusion chromatography, as described in Example 5.
[0034] In a preferred embodiment, the invention relates to saccharides produced in recombinant E. coli host cells in which the endogenous wzz O-antigen length regulator gene (e.g., wzzB) has been deleted and replaced with a (second) wzz gene from a Gram-negative bacterium heterologous to the recombinant E. coli host cell (e.g., Salmonella fepE), producing high molecular weight saccharides, such as lipopolysaccharides, containing intermediate or long O-antigen chains. In some embodiments, the recombinant E. coli host cell comprises a wzz gene from Salmonella, preferably Salmonella enterica.
[0035] In one embodiment, the host cell comprises a heterologous gene for a wzz family protein as a stably maintained plasmid vector. In another embodiment, the host cell comprises a heterologous gene for a wzz family protein as an integrated gene in the chromosomal DNA of the host cell. Methods for stable expression of a plasmid vector in an E. coli host cell and for integration of a heterologous gene into the chromosome of an E. coli host cell are known in the art. In one embodiment, the host cell comprises a heterologous gene for an O antigen as a stably maintained plasmid vector. In another embodiment, the host cell comprises a heterologous gene for an O antigen as an integrated gene in the chromosomal DNA of the host cell. Methods for stable expression of a plasmid vector in E. coli and Salmonella host cells are known in the art. Methods for integration of a heterologous gene into the chromosome of an E. coli and Salmonella host cell are known in the art.
[0036] In one aspect, the recombinant host cell is cultured in a medium that includes a carbon source. Carbon sources for culturing E. coli are known in the art. Exemplary carbon sources include, but are not limited to, sugar alcohols, polyols, aldol sugars, or keto sugars, such as arabinose, cellobiose, fructose, glucose, glycerol, inositol, lactose, maltose, mannitol, mannose, rhamnose, raffinose, sorbitol, sorbose, sucrose, trehalose, pyruvate, succinate, and methylamine. In a preferred embodiment, the medium includes glucose. In some embodiments, the medium includes polyols or aldol sugars, such as mannitol, inositol, sorbose, glycerol, sorbitol, lactose, and arabinose, as carbon sources. All carbon sources may be added to the medium before starting the culture, or may be added in portions or continuously during the culture.
[0037] An exemplary culture medium for recombinant host cells includes elements selected from any one of KH2PO4, K2HPO4, (NH4)2SO4, sodium citrate, Na2SO4, aspartic acid, glucose, MgSO4, FeSO4-7H2O, Na2MoO4-2H2O, H3BO3, CoCl2-6H2O, CuCl2-2H2O, MnCl2-4H2O, ZnCl2, and CaCl2-2H2O. Preferably, the medium includes KH2PO4, K2HPO4, (NH4)2SO4, sodium citrate, Na2SO4, aspartic acid, glucose, MgSO4, FeSO4-7H2O, Na2MoO4-2H2O, H3BO3, CoCl2-6H2O, CuCl2-2H2O, MnCl2-4H2O, ZnCl2, and CaCl2-2H2O.
[0038] As used herein, a medium may be solid or liquid, synthetic (i.e., artificial) or natural, and may contain sufficient nutrients for the culture of recombinant host cells. Preferably, the medium is a liquid medium.
[0039] In some embodiments, the medium may further comprise suitable inorganic salts. In some embodiments, the medium may further comprise micronutrients. In some embodiments, the medium may further comprise growth factors. In some embodiments, the medium may further comprise an additional carbon source. In some embodiments, the medium may further comprise suitable inorganic salts, micronutrients, growth factors, and additional carbon sources. Suitable inorganic salts, micronutrients, growth factors, and supplemental carbon sources for culturing E. coli are known in the art.
[0040] In some embodiments, the medium may optionally contain additional components such as peptone, NZ amine, soybean enzymatic hydrolysate, additional yeast extract, malt extract, supplemental carbon source and various vitamins. In some embodiments, the medium does not optionally contain such additional components such as peptone, NZ amine, soybean enzymatic hydrolysate, additional yeast extract, malt extract, supplemental carbon source and various vitamins.
[0041] Examples of suitable supplemental carbon sources include, but are not limited to, other carbohydrates such as glucose, fructose, mannitol, starch or starch hydrolysates, cellulose hydrolysates, and molasses; organic acids such as acetic acid, propionic acid, lactic acid, formic acid, malic acid, citric acid, and fumaric acid; and alcohols such as glycerol, inositol, mannitol, and sorbitol.
[0042] In some embodiments, the medium further comprises a nitrogen source. Suitable nitrogen sources for culturing E. coli are known in the art. Examples of suitable nitrogen sources include, but are not limited to, ammonia, including ammonia gas and aqueous ammonia; ammonium salts of inorganic or organic acids, such as ammonium chloride, ammonium nitrate, ammonium phosphate, ammonium sulfate and ammonium acetate; urea; nitrate or nitrite, and other nitrogen-containing materials, including amino acids, meat extracts, peptones, fish meal, fish hydrolysates, corn infusions, casein hydrolysates, soybean meal hydrolysates, yeast extracts, dry yeast, ethanol-yeast distillates, soybean flour, cottonseed flour, and the like, in pure or unrefined preparations.
[0043] In some embodiments, the medium comprises inorganic salts. Examples of suitable inorganic salts include, but are not limited to, salts of potassium, calcium, sodium, magnesium, manganese, iron, cobalt, zinc, copper, molybdenum, tungsten and other trace elements, and phosphate.
[0044] In some embodiments, the medium includes suitable growth factors. Examples of suitable micronutrients, growth factors, etc. include, but are not limited to, coenzyme A, pantothenic acid, pyridoxine-HCl, biotin, thiamine, riboflavin, flavin mononucleotide, flavin adenine dinucleotide, DL-6,8-thioctic acid, folic acid, vitamin B, either as pure or partially purified compounds or present in natural sources. 12, other vitamins, amino acids such as cysteine and hydroxyproline, bases such as adenine, uracil, guanine, thymine and cytosine, sodium thiosulfate, p- or r-aminobenzoic acid, niacinamide, nitriloacetate, etc. Those skilled in the art can empirically determine the amount according to methods and techniques known in the art.
[0045] In another embodiment, the modified sugars described herein (as compared to the corresponding wild-type sugars) are synthetically produced, e.g., in vitro. Synthetic production or synthesis of sugars can facilitate avoidance of costly and time-intensive production processes. In one embodiment, sugars are synthesized, e.g., by using a sequential glycosylation strategy or a combination of a sequential glycosylation strategy and a [3+2] block synthesis strategy from a suitably protected monosaccharide intermediate. For example, thiol glycosides and glycosyl trichloroacetimidate derivatives can be used as glycosyl donors in glycosylation. In one embodiment, sugars synthesized in vitro have the same structure as sugars produced by recombinant means, such as the manipulation of wzz family proteins described above.
[0046] The sugars produced (by recombinant or synthetic means) can be, for example, from the following E. coli serotypes: O1 (e.g., O1A, O1B, and O1C), O2, O3, O4 (e.g., O4:K52 and O4:K6), O5 (e.g., O5ab and O5ac (180 / C3 strain)), O6 (e.g., O6:K2;K13;K15 and O6:K54), O7, O8, O9, O10, O11, O12, O13, O14, O15, O16, O17, O18 (e.g., O18A, O18ac, O18A1, O18B, and O18B1), O19, O20, O21, O22, O23 (e.g., O23A), O24, O25 (e.g., O25a and O25b), O26, O27, O28, O29, O30, O32, O33, O34, O35, O36, O37, O38, O39, O40, O41, O42, O43, O44, O45 (e.g., O45 and O45rel), O46, O48, O49, O50, O51, O52, O53, O54, O55, O56, O57, O58, O59, O60, O61, O62, 62D1, O63, O64, O65, O66, O68, O69, O70, O71, O73 (e.g., O73 (73-1 strain)), O74, O75, O76, O77, O78, O79, O80, O81, O82, O83, O84, O85, O86, O87, O88, O89, O90, O91, O92, O93, O95, O96, O97, O98, O99, O100, O1 01, O102, O103, O104, O105, O106, O107, O108, O109, O110, 0111, O112, O 113, O114, O115, O116, O117, O118, O119, O120, O121, O123, O124, O125, O126, O127, O128, O129, O130, O131, O132, O133, O134, O135, O136, O137 , O138, O139, O140, O141, O142, O143, O144, O145, O146, O147, O148, O14 9, comprising a structure derived from any E. coli serotype, including any one of O150, O151, O152, O153, O154, O155, O156, O157, O158, O159, O160, O161, O162, O163, O164, O165, O166, O167, O168, O169, O170, O171, O172, O173, O174, O175, O176, O177, O178, O179, O180, O181, O182, O183, O184, O185, O186, and O187;
[0047] Individual polysaccharides are typically purified (enriched with respect to the amount of polysaccharide-protein conjugate) by methods known in the art, such as, for example, dialysis, concentration operations, diafiltration operations, tangential flow filtration, sedimentation, elution, centrifugation, sedimentation, ultrafiltration, depth filtration, and / or column chromatography (ion exchange chromatography, multimode ion exchange chromatography, DEAE, and hydrophobic interaction chromatography). Preferably, the polysaccharides are purified by methods that include tangential flow filtration.
[0048] The purified polysaccharides can be activated (e.g., chemically activated) to render them capable of reacting (e.g., directly to a carrier protein or via a linker such as an eTEC spacer) and then incorporated into a glycoconjugate of the invention, as further described herein.
[0049] In one preferred embodiment, the saccharide of the invention is derived from the E. coli serotype O25a. In another preferred embodiment, the serotype is O25b. In another preferred embodiment, the serotype is O1A. In another preferred embodiment, the serotype is O2. In another preferred embodiment, the serotype is O6. In another preferred embodiment, the serotype is O17. In another preferred embodiment, the serotype is O15. In another preferred embodiment, the serotype is O18A. In another preferred embodiment, the serotype is O75. In another preferred embodiment, the serotype is O4. In another preferred embodiment, the serotype is O16. In another preferred embodiment, the serotype is O13. In another preferred embodiment, the serotype is O7. In another preferred embodiment, the serotype is O8. In another preferred embodiment, the serotype is O9.
[0050] As used herein, reference to any of the above serotypes refers to a serotype that includes a repeating unit structure (O unit as described below) that is known in the art and unique to the corresponding serotype. For example, the term "O25a" serotype (also known in the art as serotype "O25") refers to a serotype that includes formula O25 as shown in Table 1. As another example, the term "O25b" serotype refers to a serotype that includes formula O25b as shown in Table 1.
[0051] As used herein, serotypes are generally referred to herein unless otherwise specified, such as, for example, the term "O18" is generally intended to include O18A, O18ac, O18A1, O18B, and O18B1.
[0052] As used herein, the term "O1" generally refers to encompassing species of formulae that include the generic designation "O1" in the formula name set forth in Table 1, such as any one of formulae O1A, O1A1, O1B, and O1C, respectively, as set forth in Table 1. Thus, "O1 serotype" generally refers to serotypes that include any one of formulae O1A, O1A1, O1B, and O1C.
[0053] As used herein, the term "O6" generally refers to species of formulae that include the generic name "O6" in the formula name set forth in Table 1, such as any one of the formulae O6:K2;K13;K15; and O6:K54, respectively, as set forth in Table 1. Thus, "O6 serotype" generally refers to serotypes that include any one of the formulae O6:K2;K13;K15; and O6:K54.
[0054] Other examples of terms generally referring to species of formulae that include a generic term in the formula name listed in Table 1 include "O4", "O5", "O18", and "O45".
[0055] As used herein, the term "O2" refers to formula O2 as shown in Table 1. The term "O2 O antigen" refers to a saccharide that encompasses formula O2 as shown in Table 1.
[0056] As used herein, references to O antigens from the above serotypes refer to the saccharide that includes the formula labeled with the corresponding serotype name. For example, the term "O25B O antigen" refers to the saccharide that includes the formula O25B as shown in Table 1.
[0057] As another example, the term "O1 O antigen" refers generally to saccharides that include formulas that include the term "O1," such as formula O1A, formula O1A1, formula O1B, and formula O1C, each of which is shown in Table 1.
[0058] As another example, the term "O6 O antigen" refers generally to saccharides that include formulas that include the term "O6," such as formula O6:K2; formula O6:K13; formula O6:K15 and formula O6:K54, each of which are shown in Table 1.
[0059] O polysaccharide As used herein, the term "O polysaccharide" refers to any structure that contains an O antigen, provided that the structure does not contain whole cells or lipid A. For example, in one embodiment, the O polysaccharide comprises lipopolysaccharide that does not have lipid A attached. Steps for removing lipid A are known in the art and include, for example, heat treatment with the addition of acid. An exemplary process includes treatment with 1% acetic acid at 100°C for 90 minutes. This process is combined with a process for isolating the removed lipid A. An exemplary process for isolating lipid A includes ultracentrifugation.
[0060] In one embodiment, O polysaccharide refers to a structure consisting of O antigen, in which case O polysaccharide is synonymous with the term O antigen. In one preferred embodiment, O polysaccharide refers to a structure comprising repeating units of O antigen, without the core saccharide. Thus, in one embodiment, O polysaccharide does not comprise the E. coli R1 core portion. In another embodiment, O polysaccharide does not comprise the E. coli R2 core portion. In another embodiment, O polysaccharide does not comprise the E. coli R3 core portion. In another embodiment, O polysaccharide does not comprise the E. coli R4 core portion. In another embodiment, O polysaccharide does not comprise the E. coli K12 core portion. In another preferred embodiment, O polysaccharide refers to a structure comprising the O antigen and the core saccharide. In another embodiment, O polysaccharide refers to a structure comprising the O antigen, the core saccharide, and the KDO portion.
[0061] Methods for purifying O polysaccharide, including the core oligosaccharide, from LPS are known in the art. For example, after purification of LPS, the purified LPS can be hydrolyzed by heating in 1% (v / v) acetic acid at 100° C. for 90 minutes, followed by ultracentrifugation at 142,000×g for 5 hours at 4° C. The supernatant containing O polysaccharide is lyophilized and stored at 4° C. In certain embodiments, deletion of capsule synthesis genes to allow simple purification of O polysaccharide is described.
[0062] O polysaccharide can be isolated by methods including, but not limited to, mild acid hydrolysis to remove lipid A from LPS. Other embodiments may include the use of hydrazine as an agent for O polysaccharide preparation. Preparation of LPS can be accomplished by methods known in the art.
[0063] In certain embodiments, O polysaccharides purified from wild-type, modified, or attenuated Gram-negative bacterial strains expressing (but not necessarily overexpressing) a Wzz protein (e.g., wzzB) are provided for use in conjugate vaccines. In a preferred embodiment, O polysaccharide chains are purified from Gram-negative bacterial strains expressing (but not necessarily overexpressing) a wzz protein for use as a vaccine antigen as a conjugate or complexed vaccine.
[0064] In one embodiment, the O polysaccharide is about 1 fold, 2 fold, 3 fold, 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 11 fold, 12 fold, 13 fold, 14 fold, 15 fold, 16 fold, 17 fold, 18 fold, 19 fold, 20 fold, 21 fold, 22 fold, 23 fold, 24 fold, 25 fold, 26 fold, 27 fold, 28 fold, 29 fold, 30 fold, 31 fold, 32 fold, 33 fold, 34 fold, 35 fold, 36 fold, 37 fold, 38 fold, 39 fold, 40 fold, 41 fold, 42 fold, 43 fold, 44 fold, 45 fold, 46 fold, 47 fold, 48 fold, 49 fold, The O polysaccharide has a molecular weight that is increased by 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more times. In a preferred embodiment, the O polysaccharide has a molecular weight that is increased by at least 1 fold and at most 5 fold compared to the corresponding wild type O polysaccharide. In another embodiment, the O polysaccharide has a molecular weight that is increased by at least 2-fold and at most 4-fold compared to the corresponding wild-type O polysaccharide. The increase in molecular weight of the O polysaccharide compared to the corresponding wild-type O polysaccharide is preferably associated with an increase in the number of O antigen repeating units. In one embodiment, the increase in molecular weight of the O polysaccharide is due to a wzz family protein.
[0065] In one embodiment, the O polysaccharide has about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 102, 104, 105, 106, 107, 108, 109, 109, 109, 110 The O polysaccharide of the present invention has a molecular weight increased by 0, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 kDa or more. In one embodiment, the O polysaccharide of the present invention has a molecular weight increased by at least 1 kDa and at most 200 kDa compared to the corresponding wild-type O polysaccharide. In one embodiment, the molecular weight is increased by at least 5 kDa and at most 200 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 200 kDa. In one embodiment, the molecular weight is increased by at least 12 kDa and at most 200 kDa. In one embodiment, the molecular weight is increased by at least 15 kDa and at most 200 kDa. In one embodiment, the molecular weight is increased by at least 18 kDa and at most 200 kDa. In one embodiment, the molecular weight is increased by at least 20 kDa and at most 200 kDa. In one embodiment, the molecular weight is increased by at least 21 kDa and at most 200 kDa. In one embodiment, the molecular weight is increased by at least 22 kDa and at most 200 kDa. In one embodiment, the molecular weight is increased by at least 30 kDa and at most 200 kDa. In one embodiment, the molecular weight is increased by at least 1 kDa and at most 100 kDa. In one embodiment, the molecular weight is increased by at least 5 kDa and at most 100 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 100 kDa. In one embodiment, the molecular weight is increased by at least 12 kDa and at most 100 kDa, In one embodiment, the molecular weight is increased by at least 15 kDa and at most 100 kDa.In one embodiment, the molecular weight is increased by at least 20 kDa and at most 100 kDa. In one embodiment, the molecular weight is increased by at least 1 kDa and at most 75 kDa. In one embodiment, the molecular weight is increased by at least 5 kDa and at most 75 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 75 kDa. In one embodiment, the molecular weight is increased by at least 12 kDa and at most 75 kDa. In one embodiment, the molecular weight is increased by at least 15 kDa and at most 75 kDa. In one embodiment, the molecular weight is increased by at least 18 kDa and at most 75 kDa. In one embodiment, the molecular weight is increased by at least 20 kDa and at most 75 kDa. In one embodiment, the molecular weight is increased by at least 30 kDa and at most 75 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 90 kDa. In one embodiment, the molecular weight is increased by at least 12 kDa and at most 85 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 75 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 70 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 60 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 50 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 49 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 48 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 47 kDa. In one embodiment, the molecular weight is increased by at least 10 kDa and at most 46 kDa. In one embodiment, the molecular weight is increased by at least 20 kDa and at most 45 kDa. In one embodiment, the molecular weight is increased by at least 20 kDa and at most 44 kDa. In one embodiment, the molecular weight is increased by at least 20 kDa and at most 43 kDa. In one embodiment, the molecular weight is increased by at least 20 kDa and at most 42 kDa. In one embodiment, the molecular weight is increased by at least 20 kDa and at most 41 kDa.Such an increase in the molecular weight of the O polysaccharide compared to the corresponding wild-type O polysaccharide is preferably associated with an increase in the number of O antigen repeating units. In one embodiment, the increase in the molecular weight of the O polysaccharide is due to a wzz family protein. See, e.g., Table 21.
[0066] In another embodiment, the O polysaccharide comprises any one of the formulas selected from Table 1, wherein the number of repeating units, n, in the O polysaccharide is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 108, 109, 109, 110, 111, 1 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more repeating units. Preferably, the saccharide comprises an increase of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 repeating units compared to the corresponding wild-type O polysaccharide. See, e.g., Table 21.
[0067] O antigen O antigens are part of the lipopolysaccharide (LPS) in the outer membrane of gram-negative bacteria. O antigens are found on the cell surface and are variable cellular components. The variability of O antigens provides the basis for serotyping of gram-negative bacteria. The current Escherichia coli (E. coli) serotyping scheme includes O polysaccharides 1 to 181.
[0068] O antigens comprise oligosaccharide repeating units (O units), whose wild-type structures typically contain 2-8 residues from a wide range of sugars. Exemplary E. coli O antigen O units are shown in Table 1, see also Figures 9A-C and 10A-B.
[0069] In one embodiment, the saccharide of the invention may be one oligosaccharide unit. In one embodiment, the saccharide of the invention is one repeating oligosaccharide unit of the relevant serotype. In such an embodiment, the saccharide may comprise a structure selected from any one of formula O8, formula O9a, formula O9, formula O20ab, formula O20ac, formula O52, formula O97, and formula O101.
[0070] In one embodiment, the saccharide of the present invention may be an oligosaccharide. Oligosaccharides have a small number of repeating units (typically 5-15 repeating units) and are typically derived synthetically or by hydrolysis of a polysaccharide. In such an embodiment, the saccharide may comprise a structure selected from any one of formula O8, formula O9a, formula O9, formula O20ab, formula O20ac, formula O52, formula O97, and formula O101.
[0071] Preferably, all saccharides of the present invention and in the immunogenic compositions of the present invention are polysaccharides. High molecular weight polysaccharides can induce a certain antibody immune response due to the epitopes present on their antigenic surface. Isolation and purification of high molecular weight polysaccharides are preferably contemplated for use in the conjugates, compositions and methods of the present invention.
[0072] In some embodiments, the number of repeating O units in each individual O-antigen polymer (and thus the length and molecular weight of the polymer chain) depends on the wzz chain length regulator, an inner membrane protein. Different wzz proteins result in different ranges of mode lengths (from 4 to over 100 repeat units). The term "mode length" refers to the number of repeating O units. Gram-negative bacteria often have two different Wzz proteins that result in two different OAg mode chain lengths, one long and one short. Expression (not necessarily overexpression) of a wzz family protein (e.g., wzzB) in Gram-negative bacteria can allow for manipulation of O-antigen length to shift or bias bacterial production of a certain length range of O-antigens and enhance production of high yields of high molecular weight lipopolysaccharides. In one embodiment, a "short" mode length as used herein refers to a small number of repeating O units, e.g., 1 to 20. In one embodiment, a "long" mode length as used herein refers to a number of repeating O units greater than 20, up to 40. In one embodiment, a "very long" mode length as used herein refers to greater than 40 repeating O units.
[0073] In one embodiment, the saccharide produced has an increase of at least 10 repeat units, 15 repeat units, 20 repeat units, 25 repeat units, 30 repeat units, 35 repeat units, 40 repeat units, 45 repeat units, 50 repeat units, 55 repeat units, 60 repeat units, 65 repeat units, 70 repeat units, 75 repeat units, 80 repeat units, 85 repeat units, 90 repeat units, 95 repeat units, or 100 repeat units compared to the corresponding wild-type O polysaccharide.
[0074] In another embodiment, the saccharide of the invention has a saccharide sequence that is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 2 , 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more increase in repeat units. Preferably, the saccharide comprises an increase of at least 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 repeating units compared to the corresponding wild-type O polysaccharide. See, for example, Table 21. Methods for determining the length of a saccharide are known in the art. Such methods include nuclear magnetic resonance, mass spectrometry, and size exclusion chromatography, as described in Example 5.
[0075] Methods for determining the number of repeating units in a saccharide are also known in the art. For example, the number of repeating units (or "n" in the formula) can be calculated by dividing the molecular weight of the polysaccharide (not including the molecular weight of the core sugar or KDO residue) by the molecular weight of the repeating unit (i.e., the molecular weight of the structure in the corresponding formula shown in Table 1, which can theoretically be calculated as the sum of the molecular weights of each monosaccharide in the formula). The molecular weight of each monosaccharide in the formula is known in the art. For example, the molecular weight of the repeating unit of formula O25b is about 862 Da. For example, the molecular weight of the repeating unit of formula O1a is about 845 Da. For example, the molecular weight of the repeating unit of formula O2 is about 829 Da. For example, the molecular weight of the repeating unit of formula O6 is about 893 Da. When determining the number of repeating units in a conjugate, the molecular weight of the carrier protein and the protein:polysaccharide ratio are taken into account. As defined herein, "n" refers to the number of repeating units in a polysaccharide molecule (shown in parentheses in Table 1). As is known in the art, in biopolymers, the repeating structures may incorporate regions of imperfect repeats, e.g., missing branches. Furthermore, it is known in the art that polysaccharides isolated and purified from natural sources, such as bacteria, may be heterogeneous in size and branching. In such cases, n may represent the average or median value for n of the molecules in the population.
[0076] In one embodiment, the O polysaccharide has an increase of at least one repeating unit of the O antigen compared to the corresponding wild type O polysaccharide. The repeating units of the O antigen are shown in Table 1. In one embodiment, the O polysaccharide has an increase of at least one repeating unit of the O antigen compared to the corresponding wild type O polysaccharide. The repeating units of the O antigen are shown in Table 1. In one embodiment, the O polysaccharide has an increase of at least one repeating unit of the O antigen compared to the corresponding wild type O polysaccharide. 2, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more total repeating units. Preferably, the saccharide has a total of at least 3 and at most 80 repeating units. In another embodiment, the O polysaccharide has a nucleotide sequence similar to that of the corresponding wild-type O polysaccharide, but is more similar to that of the corresponding wild-type O polysaccharide, and is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 108, 109, 110, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more increase in repeat units.
[0077] In one embodiment, the saccharide is an O-antigen formula (such as the formulae shown in Table 1 (see also Figures 9A-C and 10A-B)) in which n is at least 1, 2, 3, 4, 5, 10, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, and up to The O antigens include an integer between n and 200, 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, 65, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, or 50. Any minimum value can be combined with any maximum value to define a range. Exemplary ranges include, for example, at least 1 and at most 1000; at least 10 and at most 500; and at least 20 and at most 80, preferably at most 90. In one preferred embodiment, n is at least 31 and at most 90. In a preferred embodiment, n is 40 to 90, more preferably 60 to 85.
[0078] In one embodiment the saccharide comprises an O antigen, wherein n in any one of the O antigen formulas is at least 1 and at most 200. In one embodiment n in any one of the O antigen formulas is at least 5 and at most 200. In one embodiment n in any one of the O antigen formulas is at least 10 and at most 200. In one embodiment n in any one of the O antigen formulas is at least 25 and at most 200. In one embodiment n in any one of the O antigen formulas is at least 50 and at most 200. In one embodiment n in any one of the O antigen formulas is at least 75 and at most 200. In one embodiment n in any one of the O antigen formulas is at least 100 and at most 200. In one embodiment n in any one of the O antigen formulas is at least 125 and at most 200. In one embodiment n in any one of the O antigen formulas is at least 150 and at most 200. In one embodiment, n in any one of the O antigen formulas is at least 175 and at most 200. In one embodiment, n in any one of the O antigen formulas is at least 1 and at most 100. In one embodiment, n in any one of the O antigen formulas is at least 5 and at most 100. In one embodiment, n in any one of the O antigen formulas is at least 10 and at most 100. In one embodiment, n in any one of the O antigen formulas is at least 25 and at most 100. In one embodiment, n in any one of the O antigen formulas is at least 50 and at most 100. In one embodiment, n in any one of the O antigen formulas is at least 75 and at most 100. In one embodiment, n in any one of the O antigen formulas is at least 1 and at most 75. In one embodiment, n in any one of the O antigen formulas is at least 5 and at most 75. In one embodiment, n in any one of the O antigen formulas is at least 10 and at most 75. In one embodiment, n in any one of the O antigen formulas is at least 20 and at most 75.In one embodiment, n in any one of the O antigen formulas is at least 25 and at most 75. In one embodiment, n in any one of the O antigen formulas is at least 30 and at most 75. In one embodiment, n in any one of the O antigen formulas is at least 40 and at most 75. In one embodiment, n in any one of the O antigen formulas is at least 50 and at most 75. In one embodiment, n in any one of the O antigen formulas is at least 30 and at most 90. In one embodiment, n in any one of the O antigen formulas is at least 35 and at most 85. In one embodiment, n in any one of the O antigen formulas is at least 35 and at most 75. In one embodiment, n in any one of the O antigen formulas is at least 35 and at most 70. In one embodiment, n in any one of the O antigen formulas is at least 35 and at most 60. In one embodiment, n in any one of the O antigen formulas is at least 35 and at most 50. In one embodiment, n in any one of the O antigen formulas is at least 35 and at most 49. In one embodiment, n in any one of the O antigen formulas is at least 35 and at most 48. In one embodiment, n in any one of the O antigen formulas is at least 35 and at most 47. In one embodiment, n in any one of the O antigen formulas is at least 35 and at most 46. In one embodiment, n in any one of the O antigen formulas is at least 36 and at most 45. In one embodiment, n in any one of the O antigen formulas is at least 37 and at most 44. In one embodiment, n in any one of the O antigen formulas is at least 38 and at most 43. In one embodiment, n in any one of the O antigen formulas is at least 39 and at most 42. In one embodiment, n in any one of the O antigen formulas is at least 39 and at most 41.
[0079] For example, in one embodiment, n in the sugar is 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, or 90, most preferably 40. In another embodiment, n is at least 35 and at most 60. For example, in one embodiment, n is any one of 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, and 60, preferably 50. In another preferred embodiment, n is at least 55 and at most 75. For example, in one embodiment, n is 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, or 69, most preferably 60.
[0080] Sugar structures can be determined by methods and means known in the art, such as, for example, NMR, including 1D, 1H, and / or 13C, 2D TOCSY, DQF-COSY, NOESY, and / or HMQC.
[0081] In some embodiments, the purified polysaccharide prior to conjugation has a molecular weight of between 5 kDa and 400 kDa. In other such embodiments, the saccharide has a molecular weight of between 10 kDa and 400 kDa; 5 kDa and 400 kDa; 5 kDa and 300 kDa; 5 kDa and 200 kDa; 5 kDa and 150 kDa; 10 kDa and 100 kDa; 10 kDa and 75 kDa; 10 kDa and 60 kDa; 10 kDa and 40 kDa; 10 kDa and 100 kDa; 10 kDa and 20 kDa. 00kDa; 15kDa to 150kDa; 12kDa to 120kDa; 12kDa to 75kDa; 12kDa to 50kDa; 12 to 60kDa; 35kDa to 75kDa; 40kDa to 60kDa; 35kDa to 60kDa; 20kDa to 60kDa; 12kDa to 20kDa; or 20kDa to 50kDa. In further embodiments, the polysaccharide has a molecular weight of 7 kDa to 15 kDa; 8 kDa to 16 kDa; 9 kDa to 25 kDa; 10 kDa to 100 kDa; 10 kDa to 60 kDa; 10 kDa to 70 kDa; 10 kDa to 160 kDa; 15 kDa to 600 kDa; 20 kDa to 1000 kDa; 20 kDa to 600 kDa; 20 kDa to 400 kDa; 30 kDa to 1,000 kDa; 30 kDa to 60 kDa; 30 kDa to 50 kDa or 5 kDa to 60 kDa. Any whole integer within any of the above ranges is contemplated as an embodiment of the present disclosure.
[0082] As used herein, the term "molecular weight" of a polysaccharide or a carrier protein-polysaccharide conjugate refers to the molecular weight calculated by size exclusion chromatography (SEC) in combination with a multi-angle laser light scattering detector (MALLS).
[0083] Polysaccharides may become slightly reduced in size during normal purification procedures. Additionally, polysaccharides may be subjected to sizing techniques prior to conjugation, as described herein. Mechanical or chemical sizing may be used. Chemical hydrolysis may be performed using acetic acid. Mechanical sizing may be performed using high pressure homogenization shear. The molecular weight ranges above refer to purified polysaccharides prior to conjugation (e.g., prior to activation).
[0084] [Table 1-1]
[0085] [Table 1-2]
[0086] [Table 1-3]
[0087] [Table 1-4]
[0088] [Table 1-5]
[0089] [Table 1-6]
[0090] [Table 1-7]
[0091] [Table 1-8]
[0092] [Table 1-9]
[0093] Core Oligosaccharides The core oligosaccharide is located between lipid A and the O-antigen outer region in wild-type E. coli LPS. More specifically, the core oligosaccharide is the portion of the polysaccharide that contains the bond between the O-antigen and lipid A in wild-type E. coli. This bond includes a ketosidic bond between the hemiketal function of the innermost 3-deoxy-d-manno-octa-2-ulosonic acid (KDO) residue and the hydroxyl group of the GlcNAc residue of lipid A. The core oligosaccharide region shows a high degree of similarity among wild-type E. coli strains. It usually contains a limited number of sugars. The core oligosaccharide includes an inner core region and an outer core region.
[0094] More specifically, the inner core is composed primarily of L-glycero-D-manno-heptose (heptose) and KDO residues. The inner core is highly conserved. The KDO residue has the following formula KDO:
[0095] [ka] Includes.
[0096] The outer region of the core oligosaccharide shows greater variation than the inner core region, and differences in this region distinguish the five chemotypes in E. coli: R1, R2, R3, R4, and K-12. See FIG. 17, which illustrates the general structure of the carbohydrate backbone of the outer core oligosaccharides of the five known chemotypes. HepII is the last residue of the inner core oligosaccharide. The outer core oligosaccharides all share a structural theme, with a (hexose)3 carbohydrate backbone and two side chain residues, although the order of the hexoses in the backbone and the nature, position, and linkage of the side chain residues can all vary. The structures of the R1 and R4 outer core oligosaccharides are very similar, differing only in a single β-linked residue.
[0097] The core oligosaccharide of wild-type E. coli is classified in the art into five different chemotypes based on the structure of the distal oligosaccharide: E. coli R1, E. coli R2, E. coli R3, E. coli R4, and E. coli K12.
[0098] In a preferred embodiment, the compositions described herein comprise a saccharide conjugate comprising a core oligosaccharide in which the O polysaccharide is bound to an O antigen. In one embodiment, the composition induces an immune response against at least one of the core E. coli chemotypes: E. coli R1, E. coli R2, E. coli R3, E. coli R4, and E. coli K12. In another embodiment, the composition induces an immune response against at least two core E. coli chemotypes. In another embodiment, the composition induces an immune response against at least three core E. coli chemotypes. In another embodiment, the composition induces an immune response against at least four core E. coli chemotypes. In another embodiment, the composition induces an immune response against all five core E. coli chemotypes.
[0099] In another preferred embodiment, the compositions described herein comprise saccharide conjugates in which the O polysaccharide does not comprise a core oligosaccharide bound to an O antigen. In one embodiment, such compositions induce an immune response against at least one of the core E. coli chemotypes: E. coli R1, E. coli R2, E. coli R3, E. coli R4, and E. coli K12, even though the saccharide conjugate having an O polysaccharide does not comprise a core oligosaccharide.
[0100] E. coli serotypes can be characterized according to one of five chemotypes. Table 2 lists exemplary serotypes characterized according to chemotype. The bold serotypes represent the serotypes most commonly associated with the indicated core chemotype. Thus, in a preferred embodiment, the composition induces an immune response against at least any one of the core E. coli chemotypes: E. coli R1, E. coli R2, E. coli R3, E. coli R4, and E. coli K12, including an immune response against any one of the respective corresponding E. coli serotypes.
[0101] [Table 2]
[0102] In some embodiments, a composition comprises a saccharide that comprises a structure derived from a serotype having an R1 chemotype, e.g., selected from saccharides having formula O25a, formula O6, formula O2, formula O1, formula O75, formula O4, formula O16, formula O8, formula O18, formula O9, formula O13, formula O20, formula O21, formula O91, and formula O163, where n is 1 to 100. In some embodiments, the saccharide in the composition further comprises an E. coli R1 core moiety, e.g., as shown in Figure 17.
[0103] In some embodiments, the composition comprises a saccharide comprising a structure derived from a serotype having an R1 chemotype, e.g., selected from saccharides having formula O25a, formula O6, formula O2, formula O1, formula O75, formula O4, formula O16, formula O18, formula O13, formula O20, formula O21, formula O91, and formula O163, where n is 1-100, preferably 31-100, more preferably 35-90, and most preferably 35-65. In some embodiments, the saccharide in the composition further comprises an E. coli R1 core moiety in the saccharide.
[0104] In some embodiments, the composition comprises a saccharide comprising a structure derived from a serotype having an R2 chemotype, e.g., selected from saccharides having formula O21, formula O44, formula O11, formula O89, formula O162, and formula O9, where n is 1-100, preferably 31-100, more preferably 35-90, and most preferably 35-65. In some embodiments, the saccharide in the composition further comprises an E. coli R2 core moiety, e.g., as shown in Figure 17.
[0105] In some embodiments, the composition comprises a saccharide comprising a structure derived from a serotype having an R3 chemotype, e.g., selected from saccharides having formula O25b, formula O15, formula O153, formula O21, formula O17, formula O11, formula O159, formula O22, formula O86, and formula O93, where n is 1-100, preferably 31-100, more preferably 35-90, and most preferably 35-65. In some embodiments, the saccharide in the composition further comprises an E. coli R3 core moiety, e.g., as shown in Figure 17.
[0106] In some embodiments, the composition comprises a saccharide comprising a structure derived from a serotype having an R4 chemotype, e.g., selected from saccharides having formula O2, formula O1, formula O86, formula O7, formula O102, formula O160, and formula O166, where n is 1-100, preferably 31-100, more preferably 35-90, and most preferably 35-65. In some embodiments, the saccharide in the composition further comprises an E. coli R4 core moiety, e.g., as shown in Figure 17.
[0107] In some embodiments, the composition comprises a saccharide comprising a structure derived from a serotype having a K-12 chemotype (e.g., selected from a saccharide having the formula O25b and a saccharide having the formula O16, where n is 1-100, preferably 31-100, more preferably 35-90, most preferably 35-65). In some embodiments, the saccharide in the composition further comprises an E. coli K-12 core moiety, e.g., as shown in Figure 17.
[0108] In some embodiments, the saccharide comprises a core saccharide. Thus, in one embodiment, the O polysaccharide further comprises an E. coli R1 core portion. In another embodiment, the O polysaccharide further comprises an E. coli R2 core portion. In another embodiment, the O polysaccharide further comprises an E. coli R3 core portion. In another embodiment, the O polysaccharide further comprises an E. coli R4 core portion. In another embodiment, the O polysaccharide further comprises an E. coli K12 core portion.
[0109] In some embodiments, the saccharide does not include a core saccharide. Thus, in one embodiment, the O polysaccharide does not include an E. coli R1 core portion. In another embodiment, the O polysaccharide does not include an E. coli R2 core portion. In another embodiment, the O polysaccharide does not include an E. coli R3 core portion. In another embodiment, the O polysaccharide does not include an E. coli R4 core portion. In another embodiment, the O polysaccharide does not include an E. coli K12 core portion.
[0110] Conjugated O antigen Chemical conjugation of O antigens, or preferably O polysaccharides, to protein carriers can improve the immunogenicity of O antigens or O polysaccharides. However, variability in polymer size is a real challenge for production. In commercial use, the size of the sugar can affect compatibility with various conjugation synthesis strategies, uniformity of the product, and immunogenicity of the conjugate. Controlling the expression of Wzz family protein chain length regulators by engineering the O antigen synthesis pathway allows the production of O antigen chains of desired length in various Gram-negative bacterial strains, including E. coli.
[0111] In one embodiment, the purified sugar is chemically activated to produce an activated sugar that can react with a carrier protein. Once activated, each sugar is separately conjugated to a carrier protein to form a conjugate, i.e., a sugar conjugate. As used herein, the term "sugar conjugate" refers to a sugar covalently bound to a carrier protein. In one embodiment, the sugar is directly bound to the carrier protein. In another embodiment, the sugar is bound to the carrier protein via a spacer / linker.
[0112] Conjugates can be prepared by schemes in which a carrier is attached to the O antigen at one or more sites along the O antigen, or by schemes in which at least one residue of the core oligosaccharide is activated.
[0113] In one embodiment, each saccharide is conjugated to the same carrier protein.
[0114] Where the protein carrier is the same for two or more sugars in the composition, the sugars can be conjugated to the same molecule of carrier protein (e.g., a carrier molecule having two or more different sugars conjugated thereto).
[0115] In a preferred embodiment, the sugars are each individually conjugated to different molecules of the protein carrier (each molecule of the protein carrier has only one type of sugar conjugated to it), in which embodiment the sugars are said to be individually conjugated to the carrier protein.
[0116] Chemical activation of saccharides and subsequent conjugation to carrier proteins can be achieved by the activation and conjugation methods disclosed herein.After conjugation of polysaccharides to carrier proteins, the saccharide conjugates are purified (enriched in terms of the amount of polysaccharide-protein conjugates) by various techniques.These techniques include concentration / diafiltration operations, precipitation / elution, column chromatography, and depth filtration.After the individual saccharide conjugates are purified, they are mixed to formulate the immunogenic composition of the present invention.
[0117] Activation. The present invention further relates to an activated polysaccharide produced from any of the embodiments described herein, where the polysaccharide is activated with a chemical reagent that generates a reactive group for conjugation to a linker or carrier protein. In some embodiments, the saccharide of the present invention is activated prior to conjugation to a carrier protein. In some embodiments, the degree of activation does not substantially reduce the molecular weight of the polysaccharide. For example, in some embodiments, the degree of activation does not cleave the polysaccharide backbone. In some embodiments, the degree of activation is not a significant reduction in the molecular weight of the polysaccharide. 197 The degree of activation does not significantly affect the degree of conjugation as measured by the number of modified lysine residues in the carrier protein (determined by amino acid analysis), such as. For example, in some embodiments, the degree of activation does not significantly increase the number of modified lysine residues in the carrier protein (determined by amino acid analysis) by 3-fold compared to the number of modified lysine residues in the carrier protein of a conjugate with a reference polysaccharide at the same degree of activation. In some embodiments, the degree of activation does not increase the level of unconjugated free sugar. In some embodiments, the degree of activation does not reduce the optimal sugar / protein ratio.
[0118] In some embodiments, the activated saccharide has a percentage of activation in which the number of moles of thiol per saccharide repeat unit of the activated saccharide is 1-100%, such as 2-80%, 2-50%, 3-30%, and 4-25%. The degree of activation is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more, or about 100%. Preferably, the degree of activation is at most 50%, more preferably at most 25%. In one embodiment, the degree of activation is at most 20%. Any minimum value can be combined with any maximum value to define a range.
[0119] In one embodiment, the polysaccharide is activated with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activated polysaccharide is then coupled to a carrier protein, preferably a CRMP. 197 or tetanus toxoid) directly or via a spacer (linker) group.
[0120] For example, the spacer may be cystamine or cysteamine to obtain a thiolated polysaccharide that can be coupled to the carrier by a thioether bond obtained after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-maleimidobutyryloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (e.g., using iodoacetimide, N-succinimidyl bromoacetate (SBA;SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SIAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetamido]propionate (SBAP)). In one embodiment, a cyanate ester (which may be generated by CDAP chemistry) is coupled with hexanediamine or adipic dihydrazide (ADH) and the amino-derivatized sugar is coupled to a carrier protein (e.g., CRMP) using carbodiimide (e.g., EDAC or EDC) chemistry via a carboxyl group on the protein carrier. 197 ) to be conjugated.
[0121] Other suitable techniques for conjugation use carbodiimides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, TSTU. Conjugation may involve a carbonyl linker that can be formed by reaction of the free hydroxyl group of the sugar with CDI, followed by reaction with the protein to form a carbamate bond. This may involve reduction of the anomeric terminus to a primary hydroxyl group, optional protection / deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling of the CDI carbamate intermediate with an amino group on the protein (CDI chemistry).
[0122] Molecular Weight. In some embodiments, the saccharide conjugate comprises a saccharide having a molecular weight between 10 kDa and 2,000 kDa. In other embodiments, the saccharide has a molecular weight between 50 kDa and 1,000 kDa. In other embodiments, the saccharide has a molecular weight between 70 kDa and 900 kDa. In other embodiments, the saccharide has a molecular weight between 100 kDa and 800 kDa. In other embodiments, the saccharide has a molecular weight between 200 kDa and 600 kDa. In a further embodiment, the sugars are from 100 kDa to 1000 kDa; 100 kDa to 900 kDa; 100 kDa to 800 kDa; 100 kDa to 700 kDa; 100 kDa to 600 kDa; 100 kDa to 500 kDa; 100 kDa to 400 kDa; 100 kDa to 300 kDa; 150 kDa to 1,000 kDa; 150 kDa to 900 kDa; 150 kDa to 8 00kDa;150kDa~700kDa;150kDa~600kDa;150kDa~500kDa;150kDa~400kDa;150kDa~300kDa;200kDa~ 1,000kDa;200kDa~900kDa;200kDa~800kDa;200kDa~700kDa;200kDa~600kDa;200kDa~500kDa;200kDa Da~400kDa;200kDa~300kDa;250kDa~1,000kDa;250kDa~900kDa;250kDa~800kDa;250kDa~700kDa;2 50kDa~600kDa;250kDa~500kDa;250kDa~400kDa;250kDa~350kDa;300kDa~1,000kDa;300kDa~900kDa a;300kDa-800kDa;300kDa-700kDa;300kDa-600kDa;300kDa-500kDa;300kDa-400kDa;400kDa-1,000kDa;400kDa-900kDa;400kDa-800kDa;400kDa-700kDa;400kDa-600kDa;500kDa-600kDa. In one embodiment, the sugar conjugates having such molecular weights are produced by single-end conjugation. In another embodiment, the sugar conjugates having such molecular weights are produced by reductive amination chemistry (RAC) prepared in an aqueous buffer.Any whole integer within any of the above ranges is contemplated as an embodiment of the present disclosure.
[0123] In some embodiments, the glycoconjugates of the present invention have a molecular weight of 400 kDa to 15,000 kDa; 500 kDa to 10,000 kDa; 2,000 kDa to 10,000 kDa; 3,000 kDa to 8,000 kDa; or 3,000 kDa to 5,000 kDa. In other embodiments, the glycoconjugates have a molecular weight of 500 kDa to 10,000 kDa. In other embodiments, the glycoconjugates have a molecular weight of 1,000 kDa to 8,000 kDa. In still other embodiments, the glycoconjugates have a molecular weight of 2,000 kDa to 8,000 kDa or 3,000 kDa to 7,000 kDa.In a further embodiment, the glycoconjugates of the invention are from 200 kDa to 20,000 kDa; from 200 kDa to 15,000 kDa; from 200 kDa to 10,000 kDa; from 200 kDa to 7,500 kDa; from 200 kDa to 5,000 kDa; from 200 kDa to 3,000 kDa; from 200 kDa to 1,000 kDa; from 500 kDa to 20,000 kDa; from 500 kDa to 15,000 kDa; from 500 kDa to 12,500 kDa; from 500 kDa to 10,000 kDa. Da;500kDa~7,500kDa;500kDa~6,000kDa;500kDa~5,000kDa;500kDa~4,000kDa;500kDa~3,000kDa;500kDa~2,000kDa;500 kDa~1,500kDa;500kDa~1,000kDa;750kDa~20,000kDa;750kDa~15,000kDa;750kDa~12,500kDa;750kDa~10,000kDa;750kDa ~7,500kDa;750kDa~6,000kDa;750kDa~5,000kDa;750kDa~4,000kDa;750kDa~3,000kDa;750kDa~2,000kDa;750kDa~1,500 kDa;1,000kDa~15,000kDa;1,000kDa~12,500kDa;1,000kDa~10,000kDa;1,000kDa~7,500kDa;1,000kDa~6,000kDa;1,000k Da to 5,000 kDa; 1,000 kDa to 4,000 kDa; 1,000 kDa to 2,500 kDa; 2,000 kDa to 15,000 kDa; 2,000 kDa to 12,500 kDa; 2,000 kDa to 10,000 kDa; 2,000 kDa to 7,500 kDa; 2,000 kDa to 6,000 kDa; 2,000 kDa to 5,000 kDa; 2,000 kDa to 4,000 kDa; or 2,000 kDa to 3,000 kDa. In one embodiment, glycoconjugates having such molecular weights are produced by eTEC conjugation as described herein. In another embodiment, glycoconjugates having such molecular weights are produced by reductive amination chemistry (RAC).In another embodiment, glycoconjugates having such molecular weights are produced by reductive amination chemistry (RAC) prepared in DMSO.
[0124] In further embodiments, the glycoconjugates of the invention have a molecular weight of from 1,000 kDa to 20,000 kDa; from 1,000 kDa to 15,000 kDa; from 2,000 kDa to 10,000 kDa; from 2000 kDa to 7,500 kDa; from 2,000 kDa to 5,000 kDa; from 3,000 kDa to 20,000 kDa; from 3,000 kDa to 15,000 kDa; from 3,000 kDa to 12,500 kDa; from 4,000 kDa to 10,000 kDa; from 4,000 kDa to 7,500 kDa; from 4,000 kDa to 6,000 kDa; or from 5,000 kDa to 7,000 kDa. In one embodiment, glycoconjugates having such molecular weights are produced by reductive amination chemistry (RAC). In another embodiment, glycoconjugates having such molecular weights are produced by reductive amination chemistry (RAC) prepared in DMSO. In another embodiment, glycoconjugates having such molecular weights are produced by eTEC conjugation as described herein.
[0125] In a further embodiment, the glycoconjugates of the invention have a molecular weight of from 5,000 kDa to 20,000 kDa; from 5,000 kDa to 15,000 kDa; from 5,000 kDa to 10,000 kDa; from 5,000 kDa to 7,500 kDa; from 6,000 kDa to 20,000 kDa; from 6,000 kDa to 15,000 kDa; from 6,000 kDa to 12,500 kDa; from 6,000 kDa to 10,000 kDa or from 6,000 kDa to 7,500 kDa.
[0126] The molecular weight of the glycoconjugate can be measured by SEC-MALLS. Any whole integer within any of the above ranges is contemplated as an embodiment of the present disclosure. The glycoconjugates of the present invention can also be characterized by the sugar to carrier protein ratio (w / w). In some embodiments, the polysaccharide to carrier protein ratio (w / w) in the glycoconjugate is 0.5 to 3 (e.g., about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, or about 3.0). In other embodiments, the sugar to carrier protein ratio (w / w) is 0.5-2.0, 0.5-1.5, 0.8-1.2, 0.5-1.0, 1.0-1.5, or 1.0-2.0. In further embodiments, the sugar to carrier protein ratio (w / w) is 0.8-1.2. In preferred embodiments, the polysaccharide to carrier protein ratio in the conjugate is 0.9-1.1. In some such embodiments, the carrier protein is a CRM. 197 It is.
[0127] The glycoconjugates were also analyzed to determine their molecular size distribution (K d ) can also be characterized. A size exclusion chromatography medium (CL-4B) can be used to determine the relative molecular size distribution of the conjugates. Size exclusion chromatography (SEC) is used in a gravity-fed column to profile the molecular size distribution of the conjugates. Large molecules that are excluded from small pores in the medium elute more quickly than small molecules. A fraction collector is used to collect the column eluate. Fractions are tested colorimetrically with a sugar assay. K d For the determination of d =0), and the fraction showing maximum retention (V i ), (K d The column is calibrated to establish the fraction at which a particular sample characteristic is reached (V e ) into the formula K d=(V e -V0) / (V i -V0) by K d Associate with.
[0128] Free saccharides. The saccharide conjugates and immunogenic compositions of the present invention may comprise free saccharides that are not covalently conjugated to a carrier protein but are nevertheless present in the saccharide conjugate composition. The free saccharides may be non-covalently associated with the saccharide conjugate (i.e., non-covalently bound, adsorbed, or entrapped within or with it). In a preferred embodiment, the saccharide conjugate comprises at most 50%, 45%, 40%, 35%, 30%, 25%, 20% or 15% free polysaccharides relative to the total amount of polysaccharides. In a preferred embodiment, the saccharide conjugate comprises less than about 25% free polysaccharides relative to the total amount of polysaccharides. In a preferred embodiment, the saccharide conjugate comprises at most about 20% free polysaccharides relative to the total amount of polysaccharides. In a preferred embodiment, the saccharide conjugate comprises at most about 15% free polysaccharides relative to the total amount of polysaccharides. In another preferred embodiment, the saccharide conjugate comprises at most about 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% free polysaccharides compared to the total amount of polysaccharides. In a preferred embodiment, the saccharide conjugate comprises less than about 8% free polysaccharides compared to the total amount of polysaccharides. In a preferred embodiment, the saccharide conjugate comprises at most about 6% free polysaccharides compared to the total amount of polysaccharides. In a preferred embodiment, the saccharide conjugate comprises at most about 5% free polysaccharides compared to the total amount of polysaccharides. See, for example, Table 12, Table 13, Table 14, Table 15, Table 16, Table 17, and Table 18.
[0129] Covalent bond. In other embodiments, the conjugate comprises at least one covalent bond between the carrier protein and the saccharide every 5-10 saccharide repeat units; every 2-7 saccharide repeat units; every 3-8 saccharide repeat units; every 4-9 saccharide repeat units; every 6-11 saccharide repeat units; every 7-12 saccharide repeat units; every 8-13 saccharide repeat units; every 9-14 saccharide repeat units; every 10-15 saccharide repeat units; every 2-6 saccharide repeat units; every 3-7 saccharide repeat units; every 4-8 saccharide repeat units; every 6-10 saccharide repeat units; every 7-11 saccharide repeat units; every 8-12 saccharide repeat units; every 9-13 saccharide repeat units; every 10-14 saccharide repeat units; every 10-20 saccharide repeat units; every 4-25 saccharide repeat units, or every 2-25 saccharide repeat units. In a frequent embodiment, the carrier protein is a CRM 197 In another embodiment, at least one bond between the carrier protein and the saccharide is present every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 saccharide repeat units of the polysaccharide. 197 Any whole integer within any of the above ranges is contemplated as an embodiment of the present disclosure.
[0130] Another method of characterizing the glycoconjugates of the present invention is to characterize the extent of conjugated lysine (degree of conjugation) by the amount of carrier protein (e.g., CRMP) that becomes conjugated to the saccharide. 197) depending on the number of lysine residues in the polysaccharide. Evidence for lysine modification of the carrier protein due to covalent attachment to the polysaccharide can be obtained by amino acid analysis using routine methods known to those skilled in the art. Conjugation results in a reduction in the number of lysine residues recovered compared to the carrier protein starting material used to generate the conjugate material. In preferred embodiments, the conjugation degree of the glycoconjugates of the invention is 2-15, 2-13, 2-10, 2-8, 2-6, 2-5, 2-4, 3-15, 3-13, 3-10, 3-8, 3-6, 3-5, 3-4, 5-15, 5-10, 8-15, 8-12, 10-15 or 10-12. In one embodiment, the conjugation degree of the glycoconjugates of the invention is about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14 or about 15. In preferred embodiments, the degree of conjugation of the glycoconjugates of the invention is between 4 and 7. In some such embodiments, the carrier protein is a CRM 197 It is.
[0131] The frequency of attachment of glycans to lysines on the carrier protein is another parameter for characterizing the glycoconjugates of the invention. For example, in some embodiments, at least one covalent bond between the carrier protein and the polysaccharide occurs for every 4 saccharide repeat units of the polysaccharide. In another embodiment, a covalent bond between the carrier protein and the polysaccharide occurs at least once for every 10 saccharide repeat units of the polysaccharide. In another embodiment, a covalent bond between the carrier protein and the polysaccharide occurs at least once for every 15 saccharide repeat units of the polysaccharide. In another embodiment, a covalent bond between the carrier protein and the polysaccharide occurs at least once for every 25 saccharide repeat units of the polysaccharide. O-acetylation. In some embodiments, the saccharides of the invention are O-acetylated. In some embodiments, the glycoconjugate comprises a sugar having a degree of O-acetylation of 10-100%, 20-100%, 30-100%, 40-100%, 50-100%, 60-100%, 70-100%, 75-100%, 80-100%, 90-100%, 50-90%, 60-90%, 70-90% or 80-90%. In other embodiments, the degree of O-acetylation is 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, or 90% or more, or about 100%. Percent O-acetylation refers to the percentage of a given sugar relative to 100% (each repeat unit is fully acetylated relative to its acetylated structure).
[0132] In some embodiments, the saccharide conjugate is prepared by reductive amination. In some embodiments, the saccharide conjugate is a single-end-linked conjugated saccharide in which the saccharide is directly covalently attached to the carrier protein. In some embodiments, the saccharide conjugate is covalently attached to the carrier protein via a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer.
[0133] Reductive amination. In one embodiment, the sugar is conjugated to the carrier protein by reductive amination (such as described in U.S. Patent Application Publication Nos. 2006 / 0228380, 2007 / 0231340, 2007 / 0184071 and 2007 / 0184072, WO2006 / 110381, WO2008 / 079653, and WO2008 / 143709).
[0134] Reductive amination involves (1) oxidation of the sugar, and (2) reduction of the activated sugar and the carrier protein to form a conjugate. Prior to oxidation, the sugar may be hydrolyzed. Mechanical or chemical hydrolysis may be used. Chemical hydrolysis may be carried out using acetic acid.
[0135] The oxidation step may include reaction with periodate. As used herein, the term "periodate" refers to both periodate and periodic acid. The term also refers to metaperiodate (IO4 - ) and orthoperiodate (IO6 5- ) and various salts of periodic acid (e.g., sodium periodate and potassium periodate). In one embodiment, the polysaccharide is oxidized in the presence of a metaperiodate, preferably in the presence of sodium periodate (NaIO4). In another embodiment, the polysaccharide is oxidized in the presence of an orthoperiodate, preferably in the presence of periodic acid.
[0136] In one embodiment, the oxidizing agent is a stable nitroxyl or nitroxide radical compound, such as a piperidine-N-oxy or pyrrolidine-N-oxy compound, in the presence of an oxidizing agent to selectively oxidize the primary hydroxyl. In the reaction, the actual oxidizing agent is an N-oxoammonium salt in the catalytic cycle. In one aspect, the stable nitroxyl or nitroxide radical compound is a piperidine-N-oxy or pyrrolidine-N-oxy compound. In one aspect, the stable nitroxyl or nitroxide radical compound bears a TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy) or PROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety. In one aspect, the stable nitroxyl radical compound is TEMPO or a derivative thereof. In one aspect, the oxidizing agent is a molecule bearing an N-halo moiety. In one embodiment, the oxidizing agent is selected from any one of N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, diiodoisocyanuric acid, and 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. Preferably, the oxidizing agent is N-chlorosuccinimide.
[0137] After the sugar oxidation step, the sugar is said to be activated and is referred to hereinafter as "activated". The activated sugar and the carrier protein can be lyophilized (freeze-dried) independently (individual lyophilization) or together (co-lyophilization). In one embodiment, the activated sugar and the carrier protein are co-lyophilized. In another embodiment, the activated polysaccharide and the carrier protein are lyophilized independently.
[0138] In one embodiment, lyophilization is carried out in the presence of a non-reducing sugar, possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melezitose, dextran, mannitol, lactitol and palatinit.
[0139] The next step of the conjugation process is the reduction of the activated sugar and carrier protein with a reducing agent (so-called reductive amination) to form a conjugate.Suitable reducing agents include cyanoborohydrides such as sodium cyanoborohydride, sodium triacetoxyborohydride or sodium or zinc borohydride in the presence of Bronsted or Lewis acid, amine boranes such as pyridine borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMe'PrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane (PEMB), borane-pyridine, or borohydride exchange resin.In one embodiment, the reducing agent is sodium cyanoborohydride.
[0140] In certain embodiments, the reduction reaction is carried out in an aqueous solvent (e.g., selected from PBS, MES, HEPES, Bis-Tris, ADA, PIPES, MOPSO, BES, MOPS, DIPSO, MOBS, HEPPSO, POPSO, TEA, EPPS, bicine or HEPB at pH 6.0-8.5, 7.0-8.0 or 7.0-7.5), and in other embodiments, the reaction is carried out in an aprotic solvent. In certain embodiments, the reduction reaction is carried out in DMSO (dimethyl sulfoxide) or DMF (dimethylformamide) solvent. DMSO or DMF solvent can be used to reconstitute the lyophilized activated sugar and carrier protein.
[0141] At the end of the reduction reaction, there may be unreacted aldehyde groups remaining in the conjugate, which can be capped using a suitable capping agent. In one embodiment, the capping agent is sodium borohydride (NaBH4). After conjugation (reduction reaction and, if necessary, capping), the glycoconjugate can be purified (enriched in terms of the amount of polysaccharide-protein conjugate) by various techniques known to those skilled in the art. These techniques include dialysis, concentration / diafiltration operations, tangential flow filtration sedimentation / elution, column chromatography (DEAE or hydrophobic interaction chromatography), and depth filtration. The glycoconjugate can be purified by diafiltration and / or ion exchange chromatography and / or size exclusion chromatography. In an embodiment, the glycoconjugate is purified by diafiltration or ion exchange chromatography or size exclusion chromatography. In one embodiment, the glycoconjugate is sterile filtered.
[0142] In a preferred embodiment, glycoconjugates derived from E. coli serotypes selected from any one of O25B, O1, O2, and O6 are prepared by reductive amination. In a preferred embodiment, glycoconjugates derived from E. coli serotypes O25B, O1, O2, and O6 are prepared by reductive amination.
[0143] In one aspect, the present invention provides a carrier protein, e.g.
[0144] [ka] (wherein n is any integer greater than 1 or equal to 1), 197In a preferred embodiment, n is an integer of at least 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, and at most 200, 100, 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 81, 80, 79, 78, 77, 76, 75, 74, 73, 72, 71, 70, 69, 68, 67, 66, 65, 60, 59, 58, 57, 56, 55, 54, 53, 52, 51, or 50. Any minimum value can be combined with any maximum value to define a range. Exemplary ranges include, for example, at least 1 and at most 1000; at least 10 and at most 500; and at least 20 and at most 80. In one preferred embodiment, n is at least 31 and at most 90, more preferably 40-90, and most preferably 60-85.
[0145] In another aspect, the present invention provides a carrier protein, e.g., CRM, conjugated to a saccharide having any one of the following structures shown in Table 1 (see also Figures 9A-C and 10A-B), where n is an integer greater than or equal to 1: 197 The present invention relates to a conjugate comprising:
[0146] Without being bound by theory or mechanism, it is believed that in some embodiments, a stable conjugate requires a level of antigen modification that balances preservation of the structural integrity of the antigen's important immunogenic epitopes.
[0147] Activation and formation of aldehydes. In some embodiments, the sugars of the present invention are activated, resulting in the formation of aldehydes. In such embodiments in which the sugars are activated, the percentage (%) of activation (or degree of oxidation (DO)) refers to the moles of sugar repeating units per mole of aldehyde of the activated polysaccharide. For example, in some embodiments, the sugars are activated by periodate oxidation of vicinal diols on the repeating units of the polysaccharide, resulting in the formation of aldehydes. Varying the molar equivalent (meq) of sodium periodate relative to the sugar repeating units and the temperature during oxidation results in varying levels of degree of oxidation (DO).
[0148] Sugar and aldehyde concentrations are typically determined by colorimetric assays. An alternative reagent is the TEMPO (2,2,6,6-tetramethylpiperidine 1-oxyl radical)-N-chlorosuccinimide (NCS) mixture, which leads to the formation of aldehydes from primary alcohol groups.
[0149] In some embodiments, the activated saccharide has a degree of oxidation between 1 and 100, such as between 2 and 80, between 2 and 50, between 3 and 30, and between 4 and 25 moles of saccharide repeating units per mole of aldehyde of the activated saccharide. The degree of activation is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, or 90 or more, or about 100. Preferably, the degree of oxidation (DO) is at least 5 and at most 50, more preferably at least 10 and at most 25. In one embodiment, the degree of activation is at least 10 and at most 25. Any minimum value and any maximum value can be combined to define a range. The value of the degree of oxidation can be expressed as a percentage (%) of activation. For example, in one embodiment, a DO value of 10 refers to 1 activated saccharide repeat unit out of a total of 10 saccharide repeat units in the activated saccharide, in which case a DO value of 10 can be expressed as 10% activation.
[0150] In some embodiments, the conjugates prepared by reductive amination chemistry include a carrier protein and a sugar, the sugar being selected from the group consisting of Formula O1 (e.g., Formula O1A, Formula O1B, and Formula O1C), Formula O2, Formula O3, Formula O4 (e.g., Formula O4:K52 and Formula O4:K6), Formula O5 (e.g., Formula O5ab and Formula O5ac (strain 180 / C3)), Formula O6 (e.g., Formula O6:K2;K13;K15 and Formula O6:K54), Formula O7, Formula O8, Formula O9, Formula O10, Formula O11, Formula O12, Formula O13, Formula O14, Formula O15, Formula O16, Formula O17, Formula O18 (e.g., Formula O18A, , Formula O18ac, Formula O18A1, Formula O18B, and Formula O18B1), Formula O19, Formula O20, Formula O21, Formula O22, Formula O23 (e.g., Formula O23A), Formula O24, Formula O25 (e.g., Formula O25a and Formula O25b), Formula O26, Formula O27, Formula O28, Formula O29, Formula O30, Formula O32, Formula O33, Formula O34, Formula O35, Formula O36, Formula O37, Formula O38, Formula O39, Formula O40, Formula O41, Formula O42, Formula O43, Formula O44, Formula O45 (e.g., Formula O45 and Formula O45rel), Formula O46, Formula O48, Formula O49, Formula O50, Formula O51, Formula O52, Formula O53, Formula O5 4, formula O55, formula O56, formula O57, formula O58, formula O59, formula O60, formula O61, formula O62, formula O62D1, formula O63, formula O64, formula O65, formula O66, formula O68, formula O69, formula O70, formula O71, formula O73 (e.g., formula O73 (strain 73-1)), formula O74, formula O75, formula O76 , formula O77, formula O78, formula O79, formula O80, formula O81, formula O82, formula O83, formula O84, formula O85, formula O86, formula O87, formula O88, formula O89, Formula O90, Formula O91, Formula O92, Formula O93, Formula O95, Formula O96, Formula O97, Formula O98, Formula O99, Formula O100, Formula O101, Formula O 102, Formula O103, Formula O104, Formula O105, Formula O106, Formula O107, Formula O108, Formula O109, Formula O110, Formula O111, Formula O11 2, Formula O113, Formula O114, Formula O115, Formula O116, Formula O117, Formula O118, Formula O119, Formula O120, Formula O121, Formula O123, Formula O124, formula O125, formula O126, formula O127, formula O128, formula O129, formula O130, formula O131, formula O132, formula O133, formula O1 34, Formula O135, Formula O136, Formula O137, Formula O138, Formula O139, Formula O140, Formula O141, Formula O142, Formula O143, Formula O144,Formula O145, Formula O146, Formula O147, Formula O148, Formula O149, Formula O150, Formula O151, Formula O152, Formula O153, Formula O154, Formula O155, Formula O15 6, Formula O157, Formula O158, Formula O159, Formula O160, Formula O161, Formula O162, Formula O163, Formula O164, Formula O165, Formula O166, Formula O167, Formula O 168, Formula O169, Formula O170, Formula O171, Formula O172, Formula O173, Formula O174, Formula O175, Formula O176, Formula O177, Formula O178, Formula O179, Formula O180, Formula O181, Formula O182, Formula O183, Formula O184, Formula O185, Formula O186, and Formula O187. In some embodiments, the sugar in the conjugate comprises a formula where n is an integer between 1 and 1000, between 5 and 1000, preferably between 31 and 100, more preferably between 35 and 90, and most preferably between 35 and 65.
[0151] Single-end linked conjugates. In some embodiments, the conjugates are single-end linked conjugated saccharides, where the saccharide is covalently linked to the carrier protein at one end of the saccharide. In some embodiments, the single-end linked conjugated polysaccharide has a terminal saccharide. For example, a conjugate is single-end linked when one end of the polysaccharide (the terminal saccharide residue) is covalently linked to the carrier protein. In some embodiments, a conjugate is single-end linked when the terminal saccharide residue of the polysaccharide is covalently linked to the carrier protein via a linker. Such linkers may include, for example, cystamine linker (A1), 3,3'-dithiobis(propanoic acid dihydrazide) linker (A4), and 2,2'-dithio-N,N'-bis(ethane-2,1-diyl)bis(2-(aminooxy)acetamide) linker (A6).
[0152] In some embodiments, the sugar is conjugated to the carrier protein via a 3-deoxy-d-manno-octa-2-ulosonic acid (KDO) residue to form a single-end linked conjugate. See, e.g., Example 18, Example 19, Example 20, and FIG. 24.
[0153] In some embodiments, the conjugate is preferably not a bioconjugate. The term "bioconjugate" refers to a conjugate of a protein (e.g., a carrier protein) and an antigen, such as an O antigen (e.g., O25B), prepared in a host cell background, where the host cell machinery binds the antigen to the protein (e.g., N-linkage). Sugar conjugates include bioconjugates prepared by means that do not require preparation of the conjugate in a host cell, such as conjugation by chemical linkage of the protein with the sugar, as well as sugar antigen (e.g., oligosaccharides and polysaccharides)-protein conjugates.
[0154] Thiol-activated sugars. In some embodiments, the sugars of the present invention are thiol-activated. In such embodiments in which the sugar is thiol-activated, the percentage of activation (%) refers to the moles of thiol per sugar repeat unit of the activated polysaccharide. Sugar and thiol concentrations are typically determined by Ellman's assay for quantification of sulfhydryls. For example, in some embodiments, the sugar comprises activation of 2-keto-3-deoxyoctanoic acid (KDO) with a disulfide amine linker. See, for example, Example 18 and FIG. 24. In some embodiments, the sugar is covalently attached to the carrier protein via a bivalent heterobifunctional linker (also referred to herein as a "spacer"). The linker preferably provides a thioether bond between the sugar and the carrier protein, resulting in a sugar conjugate referred to herein as a "thioether sugar conjugate". In some embodiments, the linker further provides a carbamate and amide bond, such as, for example, (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC). See, for example, Example 13.
[0155] In some embodiments, the single-end linked conjugate comprises a carrier protein and a saccharide, wherein the saccharide is selected from the group consisting of Formula O1 (e.g., Formula O1A, Formula O1B, and Formula O1C), Formula O2, Formula O3, Formula O4 (e.g., Formula O4:K52 and Formula O4:K6), Formula O5 (e.g., Formula O5ab and Formula O5ac (strain 180 / C3)), Formula O6 (e.g., Formula O6:K2;K13;K15 and Formula O6:K54), Formula O7, Formula O8, Formula O9, Formula O10, Formula O11, Formula O12, Formula O13, Formula O14, Formula O15, Formula O16, Formula O17, Formula O18 (e.g., Formula O18A, Formula O18ac, Formula O18A1, Formula O18B1, Formula O18C1, Formula O18D1, Formula O18E1, Formula O18F1, Formula O18F2, Formula O18F3, Formula O18F4, Formula O18F5, Formula O18F6, Formula O18F7, Formula O18F8, Formula O18F9, Formula O18F10, Formula O18F11, Formula O18F12, Formula O18F13, Formula O18F14, Formula O18F15, Formula O18F16, Formula O18F17, Formula O18F18, Formula O18F20, Formula O18F30, Formula O18F40, Formula O18F50, Formula O18F60, Formula O18F70, Formula O18F80, Formula O18F90, Formula O18F18, Formula O18F18, Formula O18F18, Formula O18F18, Formula O18F18, Formula O18F18, Formula O18 , Formula O18B, and Formula O18B1), Formula O19, Formula O20, Formula O21, Formula O22, Formula O23 (e.g., Formula O23A), Formula O24, Formula O25 (e.g., Formula O25a and Formula O25b), Formula O26, Formula O27, Formula O28, Formula O29, Formula O30, Formula O32, Formula O33, Formula O34, Formula O35, Formula O36, Formula O37, Formula O38, Formula O39, Formula O40, Formula O41, Formula O42, Formula O43, Formula O44, Formula O45 (e.g., Formula O45 and Formula O45rel), Formula O46, Formula O48, Formula O49, Formula O50, Formula O51, Formula O52, Formula O53, Formula O54, Formula O55, Formula O56, Formula O57, formula O58, formula O59, formula O60, formula O61, formula O62, formula O62D1, formula O63, formula O64, formula O65, formula O66, formula O68, formula O69, formula O70, formula O71, formula O73 (e.g., formula O73 (strain 73-1)), formula O74, formula O75, formula O76, formula O77, formula O78, formula O79, formula O80, formula O81, formula O82, formula O83, formula O84, formula O85, formula O86, formula O87, formula O88, formula O89, formula O90, formula O9 1, Formula O92, Formula O93, Formula O95, Formula O96, Formula O97, Formula O98, Formula O99, Formula O100, Formula O101, Formula O102, Formula O103, Formula O 104, Formula O105, Formula O106, Formula O107, Formula O108, Formula O109, Formula O110, Formula O111, Formula O112, Formula O113, Formula O11 4, Formula O115, Formula O116, Formula O117, Formula O118, Formula O119, Formula O120, Formula O121, Formula O123, Formula O124, Formula O125, Formula O126, formula O127, formula O128, formula O129, formula O130, formula O131, formula O132, formula O133, formula O134, formula O135, formula O1 36, Formula O137, Formula O138, Formula O139, Formula O140, Formula O141, Formula O142, Formula O143, Formula O144, Formula O145, Formula O146,Formula O147, Formula O148, Formula O149, Formula O150, Formula O151, Formula O152, Formula O153, Formula O154, Formula O155, Formula O156, Formula O157, Formula O158, Formula O159, Formula O160, Formula O161, Formula O162, Formula O163, Formula O164, Formula O165, Formula O166, Formula O167, Formula O168, Formula O 169, Formula O170, Formula O171, Formula O172, Formula O173, Formula O174, Formula O175, Formula O176, Formula O177, Formula O178, Formula O179, Formula O180, Formula O181, Formula O182, Formula O183, Formula O184, Formula O185, Formula O186, and Formula O187. In some embodiments, the sugar in the conjugate comprises a formula where n is an integer between 1 and 1000, between 5 and 1000, preferably between 31 and 100, more preferably between 35 and 90, and most preferably between 35 and 65.
[0156] For example, in one embodiment, a single-end linked conjugate comprises a carrier protein and a sugar having a structure selected from formula O8, formula O9a, formula O9, formula O20ab, formula O20ac, formula O52, formula O97, and formula O101, where n is an integer from 1 to 10.
[0157] eTEC conjugates In one aspect, the invention generally relates to glycoconjugates comprising saccharides derived from Escherichia coli (E. coli) as described above covalently conjugated to a carrier protein via a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer (e.g., as described in U.S. Pat. No. 9,517,274 and International Patent Publication WO2014027302, the entireties of which are incorporated herein by reference), immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions. The glycoconjugates comprise saccharides covalently conjugated to a carrier protein via one or more eTEC spacers, where the saccharide is covalently conjugated to the eTEC spacer by a carbamate bond and the carrier protein is covalently conjugated to the eTEC spacer by an amide bond. The eTEC spacer contains seven linear atoms (i.e., -C(O)NH(CH2)2SCH2C(O)-) and provides stable thioether and amide bonds between the sugar and the carrier protein.
[0158] The eTEC-binding glycoconjugates of the present invention may be represented by the general formula (I):
[0159] [ka] where the atoms comprising the eTEC spacer are in the central box.
[0160] In the saccharide conjugate of the present invention, the saccharide may be a polysaccharide or an oligosaccharide.
[0161] The carrier protein to be incorporated into the glycoconjugates of the present invention is selected from the group of carrier proteins generally suitable for such purposes, as further described herein or as known to those skilled in the art. In certain embodiments, the carrier protein is a CRM 197 It is.
[0162] In another aspect, the invention provides a method of making a sugar conjugate comprising a sugar as described herein conjugated to a carrier protein via an eTEC spacer, comprising the steps of: a) reacting the sugar with a carbonic acid derivative in an organic solvent to produce an activated sugar; b) reacting the activated sugar with cystamine or cysteamine, or a salt thereof, to produce a thiolated sugar; c) reacting the thiolated sugar with a reducing agent to produce an activated thiolated sugar comprising one or more free sulfhydryl residues; d) reacting the activated thiolated sugar with one or more α-haloacetate residues to produce an activated thiolated sugar comprising one or more α-haloacetate residues; and e) reacting the thiolated sugar-carrier protein conjugate with (i) a first capping reagent capable of capping unconjugated α-haloacetamide groups of the activated carrier protein; and / or (ii) a second capping reagent capable of capping unconjugated free sulfhydryl residues of the activated thiolated sugar, thereby producing an eTEC-bound sugar conjugate.
[0163] In a common embodiment, the carbonate derivative is 1,1'-carbonyl-di-(1,2,4-triazole) (CDT) or 1,1'-carbonyldiimidazole (CDI). Preferably, the carbonate derivative is CDT and the organic solvent is a polar aprotic solvent such as dimethylsulfoxide (DMSO). In a preferred embodiment, the thiolated sugar is produced by reaction of an activated sugar with a bifunctional symmetric thioalkylamine reagent, cystamine or a salt thereof. Alternatively, the thiolated sugar can be formed by reaction of an activated sugar with cysteamine or a salt thereof. The eTEC-binding sugar conjugate produced by the method of the present invention can be represented by the general formula (I):
[0164] In a common embodiment, the first capping reagent is N-acetyl-L-cysteine, which reacts with unconjugated α-haloacetamide groups on lysine residues of the carrier protein to form S-carboxymethylcysteine (CMC) residues that are covalently attached to the activated lysine residues via a thioether bond.
[0165] In other embodiments, the second capping reagent is iodoacetamide (IAA), which reacts with the unconjugated free sulfhydryl groups of the activated thiolated sugar to provide a capped thioacetamide. Step e) often includes capping with both the first capping reagent and the second capping reagent. In certain embodiments, step e) includes capping with N-acetyl-L-cysteine as the first capping reagent and IAA as the second capping reagent.
[0166] In some embodiments, the capping step e) further comprises, after reaction with the first and / or second capping reagent, reaction with a reducing agent, such as DTT, TCEP, or mercaptoethanol.
[0167] The eTEC-linked saccharide conjugates and immunogenic compositions of the present invention may contain free sulfhydryl residues. In some cases, the activated thiolated saccharides formed by the methods provided herein contain multiple free sulfhydryl residues, some of which may not undergo covalent conjugation to the carrier protein during the conjugation step. Such remaining free sulfhydryl residues are capped by reaction with an thiol-reactive capping reagent, such as iodoacetamide (IAA), to cap the potentially reactive functional groups. Other thiol-reactive capping reagents, such as maleimide-containing reagents, are also contemplated.
[0168] Additionally, the eTEC-bound glycoconjugates and immunogenic compositions of the present invention may contain residual unconjugated carrier protein, or may contain activated carrier protein that has undergone modification during the capping process step.
[0169] In some embodiments, step d) further comprises providing an activated carrier protein comprising one or more α-haloacetamide groups prior to reacting the activated thiolated sugar with the activated carrier protein. In a frequent embodiment, the activated carrier protein comprises one or more α-bromoacetamide groups.
[0170] In another aspect, the invention provides an eTEC-linked glycoconjugate comprising a sugar as described herein conjugated to a carrier protein via an eTEC spacer produced according to any of the methods disclosed herein.
[0171] In some embodiments, the carrier protein is a CRM 197 And CRM 197 The covalent bond between the eTEC spacer and the polysaccharide occurs at least once per 4, 10, 15 or 25 saccharide repeat units of the polysaccharide.
[0172] For each of the aspects of the invention, and in particular embodiments of the methods and compositions described herein, the eTEC-binding sugar conjugate comprises a sugar as described herein, such as a sugar derived from E. coli.
[0173] In another aspect, the invention provides a method of preventing, treating, or ameliorating a bacterial infection, disease, or condition in a subject, comprising administering to the subject an immunologically effective amount of an immunogenic composition of the invention, wherein the immunogenic composition comprises an eTEC-binding saccharide conjugate comprising a saccharide as described herein. In some embodiments, the saccharide is derived from E. coli.
[0174] In some embodiments, the eTEC-binding glycoconjugate comprises a carrier protein and a glycoconjugate of Formula O1 (e.g., Formula O1A, Formula O1B, and Formula O1C), Formula O2, Formula O3, Formula O4 (e.g., Formula O4:K52 and Formula O4:K6), Formula O5 (e.g., Formula O5ab and Formula O5ac (strain 180 / C3)), Formula O6 (e.g., Formula O6:K2;K13;K15 and Formula O6:K54), Formula O7, Formula O8, Formula O9, Formula O10, Formula O11, Formula O12, Formula O13, Formula O14, Formula O15, Formula O16, Formula O17, Formula O18 (e.g., Formula O18A, Formula O18ac, Formula O18A1, Formula O18B, and formula O18B1), formula O19, formula O20, formula O21, formula O22, formula O23 (e.g., formula O23A), formula O24, formula O25 (e.g., formula O25a and formula O25b), formula O26, formula O27, formula O28, formula O29, formula O30, formula O32, formula O33, formula O34, formula O35, formula O36, formula O37, formula O38, formula O39, formula O40, formula O41, formula O42, formula O43, formula O44, formula O45 (e.g., formula O45 and formula O45rel), formula O46, formula O48, formula O49, formula O50, formula O51, formula O52, formula O53, formula O54, formula O55, formula O56, formula O57, formula O5 8, formula O59, formula O60, formula O61, formula O62, formula O62D1, formula O63, formula O64, formula O65, formula O66, formula O68, formula O69, formula O70, formula O71, formula O73 (e.g., formula O73 (strain 73-1)), formula O74, formula O75, formula O76, formula O77, formula O78, formula O79, formula O8 0, Formula O81, Formula O82, Formula O83, Formula O84, Formula O85, Formula O86, Formula O87, Formula O88, Formula O89, Formula O90, Formula O91, Formula O92, Formula O93, Formula O95, Formula O96, Formula O97, Formula O98, Formula O99, Formula O100, Formula O101, Formula O102, Formula O103, Formula O104, Formula O1 05, Formula O106, Formula O107, Formula O108, Formula O109, Formula O110, Formula O111, Formula O112, Formula O113, Formula O114, Formula O115 , formula O116, formula O117, formula O118, formula O119, formula O120, formula O121, formula O123, formula O124, formula O125, formula O126, formula O127, Formula O128, Formula O129, Formula O130, Formula O131, Formula O132, Formula O133, Formula O134, Formula O135, Formula O136, Formula O1 37, Formula O138, Formula O139, Formula O140, Formula O141, Formula O142, Formula O143, Formula O144, Formula O145, Formula O146, Formula O147,Formula O148, Formula O149, Formula O150, Formula O151, Formula O152, Formula O153, Formula O154, Formula O155, Formula O156, Formula O157, Formula O158, Formula O159, Formula O160, Formula O161, Formula O162, Formula O163, Formula O164, Formula O165, Formula O166, Formula O167, Formula O168, Formula O169, Formula and a sugar comprising a structure selected from any one of formula O170, formula O171, formula O172, formula O173, formula O174, formula O175, formula O176, formula O177, formula O178, formula O179, formula O180, formula O181, formula O182, formula O183, formula O184, formula O185, formula O186, and formula O187. In some embodiments, the sugar in the conjugate comprises a formula where n is an integer from 1 to 1000, 5 to 1000, preferably 31 to 100, more preferably 35 to 90, and most preferably 35 to 65.
[0175] The number of lysine residues in the carrier protein that become conjugated to a saccharide can be characterized as the extent of the conjugated lysines. For example, in some embodiments of the immunogenic composition, the CRM 197 may contain 4 to 16 of the 39 lysine residues covalently attached to the sugar. Another way to express this parameter is the CRM 197 In another embodiment, the CRM has between about 10% and about 41% of the lysines covalently bound to a sugar. 197 may contain 2-20 of the 39 lysine residues covalently attached to the sugar. Another way to express this parameter is the CRM 197 Approximately 5% to 50% of the lysines are covalently bonded to sugars.
[0176] In a frequent embodiment, the carrier protein is a CRM 197 And CRM 197 The covalent bond between the eTEC spacer and the polysaccharide occurs at least once per 4, 10, 15 or 25 saccharide repeat units of the polysaccharide.
[0177] In other embodiments, the conjugate comprises at least one covalent bond between the carrier protein and the saccharide for every 5-10 saccharide repeating units; every 2-7 saccharide repeating units; every 3-8 saccharide repeating units; every 4-9 saccharide repeating units; every 6-11 saccharide repeating units; every 7-12 saccharide repeating units; every 8-13 saccharide repeating units; every 9-14 saccharide repeating units; every 10-15 saccharide repeating units; every 2-6 saccharide repeating units; every 3-7 saccharide repeating units; every 4-8 saccharide repeating units; every 6-10 saccharide repeating units; every 7-11 saccharide repeating units; every 8-12 saccharide repeating units; every 9-13 saccharide repeating units; every 10-14 saccharide repeating units; every 10-20 saccharide repeating units; or every 4-25 saccharide repeating units.
[0178] In another embodiment, at least one bond between the carrier protein and the saccharide is present every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 saccharide repeat units of the polysaccharide.
[0179] Carrier Proteins A component of the glycoconjugate of the present invention is a carrier protein to which the sugar is conjugated. The terms "protein carrier" or "carrier protein" or "carrier" can be used interchangeably herein. The carrier protein should be suitable for standard conjugation procedures.
[0180] One component of the conjugate is a carrier protein to which the O polysaccharide is conjugated. In one embodiment, the conjugate comprises a carrier protein conjugated to the core oligosaccharide of the O polysaccharide (see FIG. 17). In one embodiment, the conjugate comprises a carrier protein conjugated to the O antigen of the O polysaccharide.
[0181] The terms "protein carrier" or "carrier protein" or "carrier" can be used interchangeably herein. The carrier protein should be suitable for standard conjugation procedures.
[0182] In a preferred embodiment, the carrier protein of the conjugate is TT, DT, DT variant (CRM 197 and the like), H. influenzae protein D, PhtX, PhtD, PhtDE fusions (particularly those described in WO01 / 98334 and WO03 / 54007), detoxified pneumolysin, PorB, N19 protein, PspA, OMPC, C. difficile toxin A or B, and PsaA. In one embodiment, the carrier protein of the conjugate of the invention is DT (diphtheria toxoid). In another embodiment, the carrier protein of the conjugate of the invention is TT (tetanus toxoid). In another embodiment, the carrier protein of the conjugate of the invention is PD (Haemophilus influenzae protein D - see, e.g., EP0594610B).
[0183] In a preferred embodiment, the sugar is a CRM 197 Conjugated to protein. CRM 197 The protein is a non-toxic form of diphtheria toxin, but is immunologically indistinguishable from diphtheria toxin. CRM 197 The nontoxigenic phage β197tox was generated by nitrosoguanidine mutagenesis of the toxigenic corynebacterium β. - CRM is produced by Clostridium difficile (C. difficile) infected by 197 The protein has the same molecular weight as diphtheria toxin but differs from it by a single base change in the structural gene (guanine to adenine) that causes an amino acid substitution in the mature protein (glutamic acid to glycine) and eliminates the toxicity of diphtheria toxin. 197 Proteins are safe and effective T cell-dependent carriers for sugars.
[0184] Thus, in some embodiments, the conjugates of the invention comprise a saccharide that is a CRM197 CRM as a carrier protein covalently bound to 197 Includes.
[0185] In a preferred embodiment, the carrier protein of the glycoconjugate is selected from the group consisting of DT (diphtheria toxin), TT (tetanus toxoid) or fragment C of TT, CRM197 (a non-toxic but antigenically identical variant of diphtheria toxin), other DT mutants (CRM176, CRM228, CRM45 (Uchida et al., J. Biol. Chem. 218:3838-3844, 1973), CRM9, CRM45, CRM102, CRM103 or CRM107; and Nicholls and Youle in Genetically Engineered Toxins, Ed: Frankel, Maecel Dekker, et al., J. Toxicology, 1999, 1021-1024, 1999). and other mutations described by Inc. 1992; deletions or mutations of Glu-148 to Asp, Gln or Ser and / or Ala158 to Gly and other mutations disclosed in U.S. Pat. Nos. 4,709,017 and 4,950,740; mutations of at least one or more residues of Lys516, Lys526, Phe530 and / or Lys534 and other mutations disclosed in U.S. Pat. Nos. 5,917,017 or 6,455,673; or fragments disclosed in U.S. Pat. No. 5,843,711), which are detoxified in some manner. ply, e.g., dPLY-GMBS (WO04081515, PCT / EP2005 / 010258) or dPLY-formol, PhtX, including PhtA, PhtB, PhtD, PhtE (the sequences of PhtA, PhtB, PhtD or PhtE are disclosed in WO00 / 37105 or WO00 / 39299) and fusions of Pht proteins, e.g., PhtDE fusions, PhtBE fusions, PhtA-E (WO01 / 98334, WO03 / 54007, WO2009 / 000826), pneumococcal pneumolysin (Kuo et al. (1995) Infect lmmun 63:2706-13), OMPC (meningococcal outer membrane protein usually extracted from N. meningitidis serogroup B - EP0372501), PorB (N.meningitidis), PD (Haemophilus influenzae protein D; see, for example, EP 0594610B) or immunologically functional equivalents thereof, synthetic peptides (EP 0378881, EP 0427347), heat shock proteins (WO 93 / 17712, WO 94 / 03208), pertussis proteins (WO 98 / 58668, EP 0471177), cytokines, lymphokines, growth factors or hormones (WO 91 / 01146), artificial proteins containing multiple human CD4+ T cell epitopes derived from various pathogen-derived antigens (Falugi et al. (2001) Eur J Immunol 31:3816-3824), e.g. the N19 protein (Baraldoi et al. (2004) Infect Immunol 29:1311-1315), 72:4884-7), pneumococcal surface protein PspA (WO02 / 091998), iron uptake protein (WO01 / 72337), Clostridium difficile toxins A or B (WO00 / 61761), transferrin-binding protein, pneumococcal adhesion protein (PsaA), recombinant Pseudomonas aeruginosa exotoxin A, particularly its non-toxic mutants (exotoxin A carrying a substitution at glutamic acid 553, etc. (Uchida Cameron DM, RJ Collier. 1987, J. Bacteriol. 169:4967-4971). Other proteins such as ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or purified protein derivative of tuberculin (PPD) can also be used as carrier proteins. Other suitable carrier proteins include inactivated bacterial toxins such as cholera toxoid (e.g., as described in International Patent Application WO2004 / 083251), E. coli LT, E. coli ST, and exotoxin A from Pseudomonas aeruginosa.
[0186] In some embodiments, the carrier protein is, for example, a CRM 197, diphtheria toxin fragment B (DTFB), DTFB C8, diphtheria toxoid (DT), tetanus toxoid (TT), fragment C of TT, pertussis toxoid, cholera toxoid, or exotoxin A from Pseudomonas aeruginosa; detoxified exotoxin A (EPA) from P. aeruginosa, maltose binding protein (MBP), flagellin, detoxified hemolysin A from S. aureus, clumping factor A, clumping factor B, cholera toxin B subunit (CTB), Streptococcus pneumoniae pneumolysin and its detoxified variants, Campylobacter jejuni AcrA, and C. jejuni native glycoprotein. In one embodiment, the carrier protein is detoxified Pseudomonas exotoxin (EPA). In another embodiment, the carrier protein is not detoxified Pseudomonas exotoxin (EPA). In one embodiment, the carrier protein is flagellin. In another embodiment, the carrier protein is not flagellin.
[0187] In a preferred embodiment, the carrier protein of the glycoconjugate is selected from the group consisting of TT, DT, DT variants (CRM 197and the like), H. influenzae protein D, PhtX, PhtD, PhtDE fusions (particularly those described in WO01 / 98334 and WO03 / 54007), detoxified pneumolysin, PorB, N19 protein, PspA, OMPC, C. difficile toxin A or B, and PsaA. In one embodiment, the carrier protein of the glycoconjugate of the invention is DT (diphtheria toxoid). In another embodiment, the carrier protein of the glycoconjugate of the invention is TT (tetanus toxoid). In another embodiment, the carrier protein of the glycoconjugate of the invention is PD (Haemophilus influenzae protein D - see, e.g., EP0594610B).
[0188] In a preferred embodiment, the capsular saccharide of the invention is 197 Conjugated to protein. CRM 197 The protein is a non-toxic form of diphtheria toxin, but is immunologically indistinguishable from diphtheria toxin. CRM 197 CRM is produced by Corynebacterium diphtheriae infected with the nontoxigenic phage β197tox-, which was created by nitrosoguanidine mutagenesis of the toxigenic corynebacterial phage beta (Uchida, T. et al., 1971, Nature New Biology 233:8-11). 197 The protein has the same molecular weight as diphtheria toxin but differs from it by a single base change in the structural gene (guanine to adenine) that causes an amino acid substitution in the mature protein (glutamic acid to glycine) and eliminates the toxicity of diphtheria toxin. 197 Proteins are safe and effective T cell-dependent carriers for sugars. CRM 197 and further details regarding its production can be found, for example, in US Pat. No. 5,614,382.
[0189] Thus, in a frequent embodiment, the glycoconjugates of the invention comprise a capsular polysaccharide that is a CRM 197 CRM as a carrier protein covalently bound to 197 Includes.
[0190] Compositions and vaccines The inventors have further discovered a composition comprising at least one of the above saccharides and a composition comprising at least one of the above conjugates. In one preferred embodiment, the composition is an immunogenic composition. In another embodiment, the composition is a vaccine.
[0191] In one aspect, the immunogenic composition comprises any of the saccharides disclosed herein. In a preferred aspect, the immunogenic composition comprises any one of the conjugates disclosed herein.
[0192] In one embodiment, the immunogenic composition comprises at least one glycoconjugate derived from E. coli serotype O25, preferably serotype O25b. In one embodiment, the immunogenic composition comprises at least one glycoconjugate derived from E. coli serotype O1, preferably serotype O1a. In one embodiment, the immunogenic composition comprises at least one glycoconjugate derived from E. coli serotype O2. In one embodiment, the immunogenic composition comprises at least one glycoconjugate derived from E. coli serotype O6.
[0193] In one embodiment, the immunogenic composition comprises at least one glycoconjugate selected from any one of the following E. coli serotypes O25, O1, O2, and O6, preferably O25b, O1a, O2, and O6. In one embodiment, the immunogenic composition comprises at least two glycoconjugates selected from any one of the following E. coli serotypes O25, O1, O2, and O6, preferably O25b, O1a, O2, and O6. In one embodiment, the immunogenic composition comprises at least three glycoconjugates selected from any one of the following E. coli serotypes O25, O1, O2, and O6, preferably O25b, O1a, O2, and O6. In one embodiment, the immunogenic composition comprises glycoconjugates derived from each of the following E. coli serotypes O25, O1, O2, and O6, preferably O25b, O1a, O2, and O6.
[0194] In a preferred embodiment, the glycoconjugates of any of the above immunogenic compositions are individually 197 Conjugate to.
[0195] Thus, the composition comprises O antigens from at least one E. coli serotype. In a preferred embodiment, the composition comprises O antigens from more than one E. coli serotype. For example, the composition may comprise O antigens from two different E. coli serotypes (or "v", valency) up to 12 different serotypes (12v). In one embodiment, the composition comprises O antigens from three different serotypes. In one embodiment, the composition comprises O antigens from four different E. coli serotypes. In one embodiment, the composition comprises O antigens from five different E. coli serotypes. In one embodiment, the composition comprises O antigens from six different E. coli serotypes. In one embodiment, the composition comprises O antigens from seven different E. coli serotypes. In one embodiment, the composition comprises O antigens from eight different E. coli serotypes. In one embodiment, the composition comprises O antigens from 9 different E. coli serotypes. In one embodiment, the composition comprises O antigens from 10 different E. coli serotypes. In one embodiment, the composition comprises O antigens from 11 different E. coli serotypes. In one embodiment, the composition comprises O antigens from 12 different serotypes. In one embodiment, the composition comprises O antigens from 13 different serotypes. In one embodiment, the composition comprises O antigens from 14 different serotypes. In one embodiment, the composition comprises O antigens from 15 different serotypes. In one embodiment, the composition comprises O antigens from 16 different serotypes. In one embodiment, the composition comprises O antigens from 17 different serotypes. In one embodiment, the composition comprises O antigens from 18 different serotypes. In one embodiment, the composition comprises O antigens from 19 different serotypes. In one embodiment, the composition comprises O antigens from 20 different serotypes.
[0196] Preferably, the number of E. coli saccharides may range from 1 serotype (or "v", valency) to 26 different serotypes (26v). In one embodiment, 1 serotype is present. In one embodiment, 2 different serotypes are present. In one embodiment, 3 different serotypes are present. In one embodiment, 4 different serotypes are present. In one embodiment, 5 different serotypes are present. In one embodiment, 6 different serotypes are present. In one embodiment, 7 different serotypes are present. In one embodiment, 8 different serotypes are present. In one embodiment, 9 different serotypes are present. In one embodiment, 10 different serotypes are present. In one embodiment, 11 different serotypes are present. In one embodiment, 12 different serotypes are present. In one embodiment, 13 different serotypes are present. In one embodiment, 14 different serotypes are present. In one embodiment, 15 different serotypes are present. In one embodiment, 16 different serotypes are present. In one embodiment, 17 different serotypes are present. In one embodiment, 18 different serotypes are present. In one embodiment, 19 different serotypes are present. In one embodiment, there are 20 different serotypes. In one embodiment, there are 21 different serotypes. In one embodiment, there are 22 different serotypes. In one embodiment, there are 23 different serotypes. In one embodiment, there are 24 different serotypes. In one embodiment, there are 25 different serotypes. In one embodiment, there are 26 different serotypes. The saccharide is conjugated to the carrier protein to form a glycoconjugate as described herein.
[0197] In one aspect, the composition comprises a glycoconjugate comprising an O antigen from at least one E. coli serogroup, the O antigen being conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from more than one E. coli serotype, each O antigen being conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from three different E. coli serotypes, each O antigen being conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from four different E. coli serotypes, each O antigen being conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from five different E. coli serotypes, each O antigen being conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from six different E. coli serotypes, each O antigen being conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from seven different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from eight different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from nine different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from ten different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from eleven different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from twelve different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from thirteen different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from 14 different serotypes, each O antigen conjugated to a carrier protein.In one embodiment, the composition comprises O antigens from 15 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from 16 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from 17 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from 18 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from 19 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O antigens from 20 different serotypes, each of which is conjugated to a carrier protein.
[0198] In another aspect, the composition comprises O polysaccharides from at least one E. coli serotype. In a preferred embodiment, the composition comprises O polysaccharides from more than one E. coli serotype. For example, the composition may comprise O polysaccharides from two different E. coli serotypes up to 12 different E. coli serotypes. In one embodiment, the composition comprises O polysaccharides from three different E. coli serotypes. In one embodiment, the composition comprises O polysaccharides from four different E. coli serotypes. In one embodiment, the composition comprises O polysaccharides from five different E. coli serotypes. In one embodiment, the composition comprises O polysaccharides from six different E. coli serotypes. In one embodiment, the composition comprises O polysaccharides from seven different E. coli serotypes. In one embodiment, the composition comprises O polysaccharides from eight different E. coli serotypes. In one embodiment, the composition comprises O polysaccharides from 9 different E. coli serotypes. In one embodiment, the composition comprises O polysaccharides from 10 different E. coli serotypes. In one embodiment, the composition comprises O polysaccharides from 11 different E. coli serotypes. In one embodiment, the composition comprises O polysaccharides from 12 different serotypes. In one embodiment, the composition comprises O polysaccharides from 13 different serotypes. In one embodiment, the composition comprises O polysaccharides from 14 different serotypes. In one embodiment, the composition comprises O polysaccharides from 15 different serotypes. In one embodiment, the composition comprises O polysaccharides from 16 different serotypes. In one embodiment, the composition comprises O polysaccharides from 17 different serotypes. In one embodiment, the composition comprises O polysaccharides from 18 different serotypes. In one embodiment, the composition comprises O polysaccharides from 19 different serotypes. In one embodiment, the composition comprises O polysaccharides from 20 different serotypes.
[0199] In a preferred embodiment, the composition comprises O polysaccharides from at least one E. coli serotype, with each O polysaccharide conjugated to a carrier protein. In a preferred embodiment, the composition comprises O polysaccharides from more than one E. coli serotype, with each O polysaccharide conjugated to a carrier protein. For example, the composition may comprise O polysaccharides from two different E. coli serotypes up to 12 different E. coli serotypes, with each O polysaccharide conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from three different E. coli serotypes, with each O polysaccharide conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from four different E. coli serotypes, with each O polysaccharide conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from five different E. coli serotypes, with each O polysaccharide conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from six different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from seven different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from eight different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from nine different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from ten different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from eleven different E. coli serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from 12 different serotypes, each O polysaccharide conjugated to a carrier protein.In one embodiment, the composition comprises O polysaccharides from 13 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from 14 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from 15 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from 16 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from 17 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from 18 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from 19 different serotypes, each of which is conjugated to a carrier protein. In one embodiment, the composition comprises O polysaccharides from 20 different serotypes, each of which is conjugated to a carrier protein.
[0200] In a most preferred embodiment, the composition comprises O polysaccharides from at least one E. coli serotype, where the O polysaccharide is conjugated to a carrier protein and comprises an O antigen and a core saccharide. In a preferred embodiment, the composition comprises O polysaccharides from more than one E. coli serotype, where each O polysaccharide is conjugated to a carrier protein and comprises an O antigen and a core saccharide. For example, the composition may comprise O polysaccharides from two different E. coli serotypes up to 12 different E. coli serotypes, where each O polysaccharide is conjugated to a carrier protein and comprises an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from three different E. coli serotypes, where each O polysaccharide is conjugated to a carrier protein and comprises an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from four different E. coli serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from five different E. coli serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from six different E. coli serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from seven different E. coli serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from eight different E. coli serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from nine different E. coli serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from ten different E. coli serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide.In one embodiment, the composition comprises O polysaccharides from 11 different E. coli serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from 12 different serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from 13 different serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from 14 different serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from 15 different serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from 16 different serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from 17 different serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from 18 different serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from 19 different serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In one embodiment, the composition comprises O polysaccharides from 20 different serotypes, each O polysaccharide being conjugated to a carrier protein and comprising an O antigen and a core saccharide. In a preferred embodiment, the carrier protein is a CRM. 197 It is.
[0201] In another preferred embodiment, the composition comprises a CRM 197 In a preferred embodiment, the composition comprises an O polysaccharide conjugated to a CRM comprising the formula O25a, where n is at least 40, and a core sugar. 197In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising the formula O25b, where n is at least 40, and a core sugar. 197 In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising the formula O1a, where n is at least 40, and a core sugar. 197 In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising the formula O2, where n is at least 40, and a core sugar. 197 and a core saccharide conjugated to the O polysaccharide, the O polysaccharide comprising formula O6, where n is at least 40.
[0202] In another embodiment, the composition comprises a CRM 197 In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising the formula O17, where n is at least 40, and a core sugar. 197 In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising the formula O15, where n is at least 40, and a core sugar. 197 In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising the formula O18A, where n is at least 40, and a core sugar. 197 In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising the formula O75, where n is at least 40, and a core sugar. 197 In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising the formula O4, where n is at least 40, and a core sugar. 197 In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising the formula O16, where n is at least 40, and a core sugar. 197In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising the formula O13, where n is at least 40, and a core sugar. 197 and a core saccharide conjugated to the O polysaccharide, the O polysaccharide comprising formula O7, where n is at least 40.
[0203] In another embodiment, the composition comprises a CRM 197 The composition further comprises an O polysaccharide conjugated to a CRM comprising formula O8, where n is at least 40, and a core sugar. In another embodiment, the O polysaccharide comprises formula O8, where n is 1-20, preferably 2-5, more preferably 3. Formula O8 is shown, for example, in FIG. 10B. In another embodiment, the composition further comprises an O polysaccharide conjugated to a CRM comprising formula O8, where n is at least 40, and a core sugar. In another embodiment, the O polysaccharide comprises formula O8, where n is 1-20, preferably 2-5, more preferably 3. Formula O8 is shown, for example, in FIG. 10B. 197 and a core saccharide. In another embodiment, the O polysaccharide comprises formula O9, where n is 1-20, preferably 4-8, more preferably 5. Formula O9 is, for example, shown in FIG. 10B. In another embodiment, the O polysaccharide comprises formula O9a, where n is 1-20, preferably 4-8, more preferably 5. Formula O9a is, for example, shown in FIG. 10B.
[0204] In some embodiments, the O polysaccharide is selected from any one of formulas O20ab, O20ac, O52, O97, and O101, where n is 1-20, preferably 4-8, more preferably 5. See, e.g., Figure 10B.
[0205] As described above, the composition may include any combination of conjugated O polysaccharides (antigens). In one exemplary embodiment, the composition includes a polysaccharide comprising formula O25b, a polysaccharide comprising formula O1A, a polysaccharide comprising formula O2, and a polysaccharide comprising formula O6. More specifically, such a composition includes: (i) a CRM 197 (ii) an O polysaccharide conjugated to CRM 197(iii) an O polysaccharide conjugated to CRM 197 an O polysaccharide conjugated to a CRM comprising the formula O2, where n is at least 40, and a core sugar; and 197 wherein the O polysaccharide comprises a formula O6, where n is at least 40, and a core saccharide.
[0206] In one embodiment, a composition comprises at least one O polysaccharide from any E. coli serotype that is not serotype O25a. For example, in one embodiment, the composition does not comprise a saccharide comprising the formula O25a. Such a composition may comprise, for example, an O polysaccharide comprising the formula O25b, an O polysaccharide comprising the formula O1A, an O polysaccharide comprising the formula O2, and an O polysaccharide comprising the formula O6.
[0207] In one embodiment, the composition comprises a CRM 197 In one embodiment, the composition comprises O polysaccharides from two different E. coli serotypes, each O polysaccharide being conjugated to a CRMP. 197 In one embodiment, the composition comprises O polysaccharides from three different E. coli serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide. 197 In one embodiment, the composition comprises O polysaccharides from four different E. coli serotypes, each O polysaccharide comprising an O antigen and a core saccharide conjugated to a CRMP. 197 In one embodiment, the composition comprises O polysaccharides from five different E. coli serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide. 197 In one embodiment, the composition comprises O polysaccharides from six different E. coli serotypes, each O polysaccharide conjugated to a CRMP. 197In one embodiment, the composition comprises O polysaccharides from seven different E. coli serotypes, each O polysaccharide being conjugated to a CRMP. 197 In one embodiment, the composition comprises O polysaccharides from eight different E. coli serotypes, each O polysaccharide conjugated to a CRMP. 197 In one embodiment, the composition comprises O polysaccharides from nine different E. coli serotypes, each O polysaccharide being conjugated to a CRMP. 197 In one embodiment, the composition comprises O polysaccharides from ten different E. coli serotypes, each O polysaccharide being conjugated to a CRMP. 197 In one embodiment, the composition comprises O polysaccharides from eleven different E. coli serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide. 197 In one embodiment, the composition comprises O polysaccharides from 12 different serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide. 197 In one embodiment, the composition comprises O polysaccharides from 13 different serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide. 197 In one embodiment, the composition comprises O polysaccharides from 14 different serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide. 197 In one embodiment, the composition comprises O polysaccharides from 15 different serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide. 197 In one embodiment, the composition comprises O polysaccharides from 16 different serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide. 197 In one embodiment, the composition comprises O polysaccharides from 17 different serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide.197 In one embodiment, the composition comprises O polysaccharides from 18 different serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide. 197 In one embodiment, the composition comprises O polysaccharides from 19 different serotypes, each O polysaccharide being conjugated to a CRMP, the O polysaccharide comprising an O antigen and a core saccharide. 197 The O polysaccharides include O antigens and core sugars conjugated to O polysaccharides from 20 different serotypes.
[0208] In one aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O25b, where n is 15±2. In one aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O25b, where n is 17±2. In one aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O25b, where n is 55±2. In another aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O25b, where n is 51±2. In one embodiment, the saccharide further comprises an E. coli R1 core saccharide moiety. In another embodiment, the saccharide further comprises an E. coli K12 core saccharide moiety. In another embodiment, the saccharide further comprises a KDO moiety. Preferably, the carrier protein is CRM 197 In one embodiment, the conjugate is prepared by single-end linkage conjugation. In one embodiment, the conjugate is prepared by reductive amination chemistry, preferably in DMSO buffer. In one embodiment, the sugar is conjugated to the carrier protein via a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer. Preferably, the composition further comprises a pharma- ceutically acceptable diluent.
[0209] In one embodiment, the immunogenic composition elicits IgG antibodies in humans, said antibodies being capable of binding to E. coli serotype O25B polysaccharide at a concentration of at least 0.2 pg / ml, 0.3 pg / ml, 0.35 pg / ml, 0.4 pg / ml or 0.5 pg / ml as determined by ELISA assay. Thus, a comparison of OPA activity of pre-immunization and post-immunization sera with the immunogenic composition of the invention can be performed and compared for their response to serotype O25B to assess the possibility of increased responders. In one embodiment, the immunogenic composition elicits IgG antibodies in humans, said antibodies being capable of killing E. coli serotype O25B as determined by in vitro opsonophagocytosis assay. In one embodiment, the immunogenic composition elicits functional antibodies in humans, said antibodies being capable of killing E. coli serotype O25B as determined by in vitro opsonophagocytosis assay. In one embodiment, the immunogenic compositions of the invention provide a method for the production of immunogenic antibodies that are able to inhibit or inhibit the proliferation of E. coli serotype O25B-responsive antibodies compared to a pre-immune population (i.e., in vitro In one embodiment, the immunogenic composition elicits a titer of at least 1:8 against E. coli serotype O25B in at least 50% of subjects as determined by an in vitro opsonophagocytic killing assay. In one embodiment, the immunogenic composition of the invention elicits a titer of at least 1:8 against E. coli serotype O25B in at least 60%, 70%, 80%, or at least 90% of subjects as determined by an in vitro opsonophagocytic killing assay. In one embodiment, the immunogenic composition of the invention increases the proportion of responders (i.e., individuals with sera having a titer of at least 1:8 against E. coli serotype O25B) compared to a pre-immune population ... In one embodiment, the immunogenic composition of the invention significantly increases the proportion of human subjects with sera having a titer of at least 1:8 as determined by OPA. In one embodiment, the immunogenic composition of the invention significantly increases the OPA titer of human subjects against E. coli serotype O25B as compared to a pre-immune population.
[0210] In one aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O1a, where n is 39±2. In another aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O1a, where n is 13±2. In one embodiment, the saccharide further comprises an E. coli R1 core saccharide moiety. In one embodiment, the saccharide further comprises a KDO moiety. Preferably, the carrier protein is a CRM 197 In one embodiment, the conjugate is prepared by single-end linkage conjugation. In one embodiment, the conjugate is prepared by reductive amination chemistry, preferably in DMSO buffer. In one embodiment, the sugar is conjugated to the carrier protein via a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer. Preferably, the composition further comprises a pharma- ceutically acceptable diluent.
[0211] In one embodiment, the immunogenic composition elicits IgG antibodies in humans, said antibodies being capable of binding to E. coli serotype O1A polysaccharide at a concentration of at least 0.2 pg / ml, 0.3 pg / ml, 0.35 pg / ml, 0.4 pg / ml or 0.5 pg / ml as determined by ELISA assay. Thus, a comparison of OPA activity of pre-immunization and post-immunization sera with the immunogenic composition of the invention can be performed and compared for their response to serotype O1A to assess the possibility of increased responders. In one embodiment, the immunogenic composition elicits IgG antibodies in humans, said antibodies being capable of killing E. coli serotype O1A as determined by in vitro opsonophagocytosis assay. In one embodiment, the immunogenic composition elicits functional antibodies in humans, said antibodies being capable of killing E. coli serotype O1A as determined by in vitro opsonophagocytosis assay. In one embodiment, the immunogenic compositions of the invention provide a method for the production of immunogenic antibodies that are able to inhibit the proliferation and proliferation of E. coli serotype O1A-responsive individuals compared to a pre-immune population (i.e., in vitro In one embodiment, the immunogenic composition elicits a titer of at least 1:8 against E. coli serotype O1A in at least 50% of subjects as determined by an in vitro opsonophagocytic killing assay. In one embodiment, the immunogenic composition of the invention elicits a titer of at least 1:8 against E. coli serotype O1A in at least 60%, 70%, 80%, or at least 90% of subjects as determined by an in vitro opsonophagocytic killing assay. In one embodiment, the immunogenic composition of the invention increases the proportion of responders (i.e., individuals with sera having a titer of at least 1:8 against E. coli serotype O1A) compared to a pre-immune population ... In one embodiment, the immunogenic composition of the invention significantly increases the proportion of human subjects with sera having a titer of at least 1:8 as determined by OPA. In one embodiment, the immunogenic composition of the invention significantly increases the OPA titer of human subjects against E. coli serotype O1A as compared to a pre-immune population.
[0212] In one aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O2, where n is 43±2. In another aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O2, where n is 47±2. In another aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O2, where n is 17±2. In another aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O2, where n is 18±2. In one embodiment, the saccharide further comprises an E. coli R1 core saccharide moiety. In another embodiment, the saccharide further comprises an E. coli R4 core saccharide moiety. In another embodiment, the saccharide further comprises a KDO moiety. Preferably, the carrier protein is a CRM 197 In one embodiment, the conjugate is prepared by single-end linkage conjugation. In one embodiment, the conjugate is prepared by reductive amination chemistry, preferably in DMSO buffer. In one embodiment, the sugar is conjugated to the carrier protein via a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer. Preferably, the composition further comprises a pharma- ceutically acceptable diluent.
[0213] In one embodiment, the immunogenic composition elicits IgG antibodies in humans, said antibodies being capable of binding to E. coli serotype O2 polysaccharide at a concentration of at least 0.2 pg / ml, 0.3 pg / ml, 0.35 pg / ml, 0.4 pg / ml or 0.5 pg / ml as determined by ELISA assay. Thus, a comparison of OPA activity of pre-immunization and post-immunization sera with the immunogenic composition of the invention can be performed and compared for their response to serotype O2 to assess the possibility of increased responders. In one embodiment, the immunogenic composition elicits IgG antibodies in humans, said antibodies being capable of killing E. coli serotype O2 as determined by in vitro opsonophagocytosis assay. In one embodiment, the immunogenic composition elicits functional antibodies in humans, said antibodies being capable of killing E. coli serotype O2 as determined by in vitro opsonophagocytosis assay. In one embodiment, the immunogenic compositions of the invention provide a method for the production of immunogenic antibodies that inhibit the expression of E. coli serotype O2 in responders (i.e., in vitro In one embodiment, the immunogenic composition elicits a titer of at least 1:8 against E. coli serotype O2 in at least 50% of subjects as determined by an in vitro opsonophagocytic killing assay. In one embodiment, the immunogenic composition of the invention elicits a titer of at least 1:8 against E. coli serotype O2 in at least 60%, 70%, 80%, or at least 90% of subjects as determined by an in vitro opsonophagocytic killing assay. In one embodiment, the immunogenic composition of the invention increases the proportion of responders (i.e., individuals with sera having a titer of at least 1:8 against E. coli serotype O2) compared to the pre-immune population ... In one embodiment, the immunogenic composition of the invention significantly increases the proportion of human subjects with sera having a titer of at least 1:8 as determined by OPA. In one embodiment, the immunogenic composition of the invention significantly increases the OPA titer of human subjects against E. coli serotype O2 as compared to a pre-immune population.
[0214] In one aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O6, where n is 42±2. In another aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O6, where n is 50±2. In another aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O6, where n is 17±2. In another aspect, the invention relates to a composition comprising a conjugate comprising a saccharide covalently attached to a carrier protein, wherein the saccharide comprises formula O6, where n is 18±2. In one embodiment, the saccharide further comprises an E. coli R1 core saccharide moiety. In one embodiment, the saccharide further comprises a KDO moiety. Preferably, the carrier protein is a CRM 197 In one embodiment, the conjugate is prepared by single-end linkage conjugation. In one embodiment, the conjugate is prepared by reductive amination chemistry, preferably in DMSO buffer. In one embodiment, the sugar is conjugated to the carrier protein via a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer. Preferably, the composition further comprises a pharma- ceutically acceptable diluent.
[0215] In one embodiment, the immunogenic composition elicits IgG antibodies in humans, said antibodies being capable of binding to E. coli serotype O6 polysaccharide at a concentration of at least 0.2 pg / ml, 0.3 pg / ml, 0.35 pg / ml, 0.4 pg / ml or 0.5 pg / ml as determined by ELISA assay. Thus, a comparison of OPA activity of pre-immunization and post-immunization sera with the immunogenic composition of the invention can be performed and compared for their response to serotype O6 to assess the possibility of increased responders. In one embodiment, the immunogenic composition elicits IgG antibodies in humans, said antibodies being capable of killing E. coli serotype O6 as determined by in vitro opsonophagocytosis assay. In one embodiment, the immunogenic composition elicits functional antibodies in humans, said antibodies being capable of killing E. coli serotype O6 as determined by in vitro opsonophagocytosis assay. In one embodiment, the immunogenic compositions of the invention provide a method for the production of immunogenic antibodies that are able to inhibit the proliferation and proliferation of E. coli serotype O6 responders (i.e., in vitro In one embodiment, the immunogenic composition elicits a titer of at least 1:8 against E. coli serotype O6 in at least 50% of subjects as determined by an in vitro opsonophagocytic killing assay. In one embodiment, the immunogenic composition of the invention elicits a titer of at least 1:8 against E. coli serotype O6 in at least 60%, 70%, 80%, or at least 90% of subjects as determined by an in vitro opsonophagocytic killing assay. In one embodiment, the immunogenic composition of the invention increases the proportion of responders (i.e., individuals with sera having a titer of at least 1:8 against E. coli serotype O6) compared to a pre-immune population ... In one embodiment, the immunogenic composition of the invention significantly increases the proportion of human subjects with sera having a titer of at least 1:8 as determined by OPA. In one embodiment, the immunogenic composition of the invention significantly increases the OPA titer of human subjects against E. coli serotype O6 as compared to a pre-immune population.
[0216] In one aspect, the composition is a conjugate comprising a sugar covalently attached to a carrier protein, wherein the sugar is a sugar selected from the group consisting of Formula O1 (e.g., Formula O1A, Formula O1B, and Formula O1C), Formula O2, Formula O3, Formula O4 (e.g., Formula O4:K52 and Formula O4:K6), Formula O5 (e.g., Formula O5ab and Formula O5ac (strain 180 / C3)), Formula O6 (e.g., Formula O6:K2;K13;K15 and Formula O6:K54), Formula O7, Formula O8, Formula O9, Formula O10, Formula O11, Formula O12, Formula O13, Formula O14, Formula O15, Formula O16, Formula O17, Formula O18 (e.g., Formula O18A, Formula O18ac, Formula O18A, 1, Formula O18B, and Formula O18B1), Formula O19, Formula O20, Formula O21, Formula O22, Formula O23 (e.g., Formula O23A), Formula O24, Formula O25 (e.g., Formula O25a and Formula O25b), Formula O26, Formula O27, Formula O28, Formula O29, Formula O30, Formula O32, Formula O33, Formula O34, Formula O35, Formula O36, Formula O37, Formula O38, Formula O39, Formula O40, Formula O41, Formula O42, Formula O43, Formula O44, Formula O45 (e.g., Formula O45 and Formula O45rel), Formula O46, Formula O48, Formula O49, Formula O50, Formula O51, Formula O52, Formula O53, Formula O54, Formula O55, Formula O56, Formula O57, formula O58, formula O59, formula O60, formula O61, formula O62, formula O62D1, formula O63, formula O64, formula O65, formula O66, formula O68, formula O69, formula O70, formula O71, formula O73 (e.g., formula O73 (strain 73-1)), formula O74, formula O75, formula O76, formula O77, formula O78, formula O79, formula O80, formula O81, formula O82, formula O83, formula O84, formula O85, formula O86, formula O87, formula O88, formula O89, formula O90, formula O9 1, Formula O92, Formula O93, Formula O95, Formula O96, Formula O97, Formula O98, Formula O99, Formula O100, Formula O101, Formula O102, Formula O103, Formula O 104, Formula O105, Formula O106, Formula O107, Formula O108, Formula O109, Formula O110, Formula O111, Formula O112, Formula O113, Formula O11 4, Formula O115, Formula O116, Formula O117, Formula O118, Formula O119, Formula O120, Formula O121, Formula O123, Formula O124, Formula O125, Formula O126, formula O127, formula O128, formula O129, formula O130, formula O131, formula O132, formula O133, formula O134, formula O135, formula O1 36, Formula O137, Formula O138, Formula O139, Formula O140, Formula O141, Formula O142, Formula O143, Formula O144, Formula O145, Formula O146,Formula O147, Formula O148, Formula O149, Formula O150, Formula O151, Formula O152, Formula O153, Formula O154, Formula O155, Formula O156, Formula O157, Formula O158, Formula O 159, Formula O160, Formula O161, Formula O162, Formula O163, Formula O164, Formula O165, Formula O166, Formula O167, Formula O168, Formula O169, Formula O170, Formula O17 1, Formula O172, Formula O173, Formula O174, Formula O175, Formula O176, Formula O177, Formula O178, Formula O179, Formula O180, Formula O181, Formula O182, Formula O183, Formula O184, Formula O185, Formula O186, and Formula O187, where n is an integer between 1 and 100. In one embodiment, the saccharide further comprises an E. coli R1 core saccharide moiety. In one embodiment, the saccharide further comprises an E. coli R2 core saccharide moiety. In one embodiment, the saccharide further comprises an E. coli R3 core saccharide moiety. In another embodiment, the saccharide further comprises an E. coli R4 core saccharide moiety. In one embodiment, the saccharide further comprises an E. coli K12 core saccharide moiety. In another embodiment, the saccharide further comprises a KDO moiety. Preferably, the carrier protein is a CRM, 197 In one embodiment, the conjugate is prepared by single end-linked conjugation. In one embodiment, the conjugate is prepared by reductive amination chemistry, preferably in DMSO buffer. In one embodiment, the sugar is conjugated to the carrier protein via a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer. Preferably, the composition further comprises a pharma- ceutically acceptable diluent. In one embodiment, the composition further comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, to at most 30, additional conjugates, each of which comprises a sugar covalently attached to a carrier protein, the sugar comprising a structure selected from any one of the formulas above.
[0217] Dosage of the Composition The amount of glycoconjugate in each dose is selected as an amount that will induce an immunoprotective response without significant adverse side effects in a typical vaccine, and such amount will vary depending on which particular immunogen is used and how it is delivered.
[0218] The amount of a particular saccharide conjugate in an immunogenic composition can be calculated based on the total polysaccharide for that conjugate (conjugated and unconjugated). For example, a saccharide conjugate containing 20% free polysaccharide will have about 80 g of conjugated polysaccharide and about 20 g of unconjugated polysaccharide in a 100 g polysaccharide dose. The amount of saccharide conjugate can vary depending on the E. coli serotype. The saccharide concentration can be determined by uronic acid assay.
[0219] The "immunogenic amounts" of the different polysaccharide components in the immunogenic composition may vary and may each comprise about 1.0g, about 2.0g, about 3.0g, about 4.0g, about 5.0g, about 6.0g, about 7.0g, about 8.0g, about 9.0g, about 10.0g, about 15.0g, about 20.0g, about 30.0g, about 40.0pg, about 50.0pg, about 60.0pg, about 70.0pg, about 80.0pg, about 90.0pg, or about 100.0g of any particular polysaccharide antigen. Generally, each dose will comprise between 0.1g and 100g, particularly between 0.5g and 20g, more particularly between 1g and 10g, and even more particularly between 2g and 5g of polysaccharide for a given serotype. Any whole integer within any of the above ranges is contemplated as an embodiment of the present disclosure. In one embodiment, each dose will contain 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, 15 g or 20 g of polysaccharide for a given serotype.
[0220] Carrier protein amount. Generally, each dose will comprise between 5g and 150g of carrier protein, in particular between 10g and 100g of carrier protein, more in particular between 15g and 100g of carrier protein, more in particular between 25 and 75g of carrier protein, more in particular between 30g and 70g of carrier protein, more in particular between 30 and 60g of carrier protein, more in particular between 30g and 50g of carrier protein, and even more in particular between 40 and 60g of carrier protein. In one embodiment, the carrier protein is CRM 197 In one embodiment, each dose is about 25 g, about 26 g, about 27 g, about 28 g, about 29 g, about 30 g, about 31 g, about 32 g, about 33 g, about 34 g, about 35 g, about 36 g, about 37 g, about 38 g, about 39 g, about 40 g, about 41 g, about 42 g, about 43 g, about 44 g, about 45 g, about 46 g, about 47 g, about 48 g, about 49 g, about 50 g, about 51 g, about 52 g, about 53 g, about 54 g, about 55 g, about 56 g, about 57 g, about 58 g, about 59 g, about 60 g, about 61 g, about 62 g, about 63 g, about 64 g, about 65 g, about 66 g, about 67 g, about 68 g, about 69 g, about 70 g, about 71 g, about 72 g, about 73 g, about 74 g, about 75 g, about 76 g, about 77 g, about 78 g, about 79 g, about 80 g, about 81 g, about 82 g, about 83 g, about 84 g, about 85 g, about 86 g, about 87 g, about 88 g, about 89 g, about 90 g, about 91 g, about 92 g, about 93 g, about 94 g, about 95 g, about 96 g, about 97 g, about 98 g, about 99 g, about 100 g, about 100 g, about 100 g, about 100 g, about 101 g, about 102 g, about 103 g, about 104 In one embodiment, the carrier protein will comprise about 0 g, about 51 g, about 52 g, about 53 g, about 54 g, about 55 g, about 56 g, about 57 g, about 58 g, about 59 g, about 60 g, about 61 g, about 62 g, about 63 g, about 64 g, about 65 g, about 66 g, about 67 g, 68 g, about 69 g, about 70 g, about 71 g, about 72 g, about 73 g, about 74 g, or about 75 g of carrier protein. 197 It is.
[0221] Adjuvants In some embodiments, the immunogenic composition disclosed herein may further comprise at least one, two or three adjuvants. The term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. An antigen may act primarily as a delivery system, primarily as an immune modulator, or have both strong characteristics. Suitable adjuvants include those suitable for use in mammals, including humans.
[0222] Examples of known suitable delivery system type adjuvants that can be used in humans include, but are not limited to, alum (e.g., aluminum phosphate, aluminum sulfate or aluminum hydroxide), calcium phosphate, liposomes, oil-in-water emulsions such as MF59 (4.3% w / v squalene, 0.5% w / v polysorbate 80 (Tween 80), 0.5% w / v sorbitan trioleate (Span 85)), water-in-oil emulsions such as Montanide, and poly(D,L-lactide-co-glycolide) (PLG) microparticles or nanoparticles.
[0223] In an embodiment, the immunogenic compositions disclosed herein comprise an aluminum salt (alum) (e.g., aluminum phosphate, aluminum sulfate, or aluminum hydroxide) as an adjuvant. In a preferred embodiment, the immunogenic compositions disclosed herein comprise aluminum phosphate or aluminum hydroxide as an adjuvant. In an embodiment, the immunogenic compositions disclosed herein comprise 0.1 mg / mL to 1 mg / mL or 0.2 mg / mL to 0.3 mg / mL of elemental aluminum in the form of aluminum phosphate. In an embodiment, the immunogenic compositions disclosed herein comprise about 0.25 mg / mL of elemental aluminum in the form of aluminum phosphate. Examples of known suitable immunomodulatory adjuvants that can be used in humans include, but are not limited to, saponin extract from Aquilla bark (QS21, QuilA), TLR4 agonists such as MPL (monophosphoryl lipid A), 3DMPL (3-O-deacylated MPL) or GLA-AQ, LT / CT mutants, cytokines such as various interleukins (e.g., IL-2, IL-12) or GM-CSF, AS01, and the like.
[0224] Examples of known suitable immunomodulatory adjuvants that exhibit both delivery and immunomodulatory properties that can be used in humans include, but are not limited to, ISCOMS (see, e.g., Sjolander et al. (1998) J. Leukocyte Biol. 64:713; WO90 / 03184, WO96 / 11711, WO00 / 48630, WO98 / 36772, WO00 / 41720, WO2006 / 134423 and WO2007 / 026190) or GLA-EM, which is a combination of a TLR4 agonist and an oil-in-water emulsion.
[0225] For veterinary applications, such as, but not limited to, animal testing, those skilled in the art will recognize various adjuvant options, including Freund's complete adjuvant (CFA), Freund's incomplete adjuvant (IFA), Emulsigen, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP), and other adjuvant-based adjuvants. 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene / Tween 80 emulsion, can be used.
[0226] Additional exemplary adjuvants for enhancing the effectiveness of the immunogenic compositions disclosed herein include, but are not limited to, (1) SAF containing, for example, (a) 10% squalane, 0.4% Tween 80, 5% pluronic blocking polymer L121, and thr-MDP microfluidized to a submicrometer emulsion or vortexed to generate a larger particle size emulsion, and (b) RIBI™ Adjuvant System (RAS) (Ribi™) containing 2% squalene, 0.2% Tween 80, and one or more bacterial cell wall components such as monophosphoryl lipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL+CWS (DETOX™). (2) saponin adjuvants such as QS21, STIMULON™ (Cambridge Bioscience, Worcester, Mass.), ABISCO® (Isconova, Sweden), or particles generated therefrom such as ISCOMATRIX® (Commonwealth Serum Laboratories, Australia) or ISCOMs (immunostimulating complexes) that can be used (ISCOMs may not contain additional detergents (e.g., WO 00 / 07621)); (3) complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA); (4) interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, IL-36, IL-37, IL-38, IL-39, IL-40, IL-41, IL-42, IL-43, IL-44, IL-45, IL-46, IL-47, IL-48, IL-49 ... , IL-7, IL-12 (e.g., WO99 / 44636), interferons (e.g., gamma interferon), macrophage colony-stimulating factor (M-CSF), tumor necrosis factor (TNF); (5) monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) (see, e.g., GB2220211, EP0689454) (see, e.g., WO00 / 56358);(6) 3dMPL in combination with, for example, QS21 and / or oil-in-water emulsions (see, for example, EP 0835318, EP 0735898, EP 0761231); (7) polyoxyethylene ethers or polyoxyethylene esters (see, for example, WO 99 / 52549); (8) polyoxyethylene sorbitan ester surfactants in combination with octoxynol (see, for example, WO 01 / 21207) or polyoxyethylene alkyl ethers or esters in combination with at least one further non-ionic surfactant such as octoxynol. (9) saponin and an immunostimulatory oligonucleotide (e.g., CpG oligonucleotide) (e.g., WO00 / 62800); (10) an immunostimulant and a particle of a metal salt (see, e.g., WO00 / 23105); (11) a saponin and an oil-in-water emulsion (e.g., WO99 / 11241); (12) a saponin (e.g., QS21) + 3dMPL + IM2 (optionally + sterol) (e.g., WO98 / 57659); (13) other substances that act as immunostimulants to enhance the efficacy of the composition. Examples of muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.;
[0227] In an embodiment of the present invention, the immunogenic composition disclosed herein comprises a CpG oligonucleotide as an adjuvant. As used herein, CpG oligonucleotide refers to an immunostimulatory CpG oligodeoxynucleotide (CpG ODN), and thus these terms are used interchangeably unless otherwise indicated. An immunostimulatory CpG oligodeoxynucleotide contains one or more immunostimulatory CpG motifs, which are optionally unmethylated cytosine-guanine dinucleotides, within the context of certain preferred bases. The methylation state of a CpG immunostimulatory motif generally refers to the cytosine residue in the dinucleotide. An immunostimulatory oligonucleotide containing at least one unmethylated CpG dinucleotide is an oligonucleotide that contains a 5' unmethylated cytosine linked to a 3' guanine by a phosphate bond and activates the immune system by binding to Toll-like receptor 9 (TLR-9). In another embodiment, an immunostimulatory oligonucleotide may contain one or more methylated CpG dinucleotides that activate the immune system via TLR9, but not as potently as if the CpG motif was unmethylated. CpG immunostimulatory oligonucleotide may contain one or more palindrome, and then contain CpG dinucleotide.CpG oligonucleotide is described in several published patents, published patent applications, and other publications, including U.S. Patent No. 6,194,388; No. 6,207,646; No. 6,214,806; No. 6,218,371; No. 6,239,116; and No. 6,339,068.
[0228] In one embodiment of the invention, the immunogenic composition disclosed herein comprises any of the CpG oligonucleotides set forth on page 3, line 22 to page 12, line 36 of WO2010 / 125480.
[0229] Various classes of CpG immunostimulatory oligonucleotides have been identified, referred to as A, B, C and P classes, and are described in more detail in WO2010 / 125480, p. 3, line 22 to p. 12, line 36. The methods of the invention encompass the use of these various classes of CpG immunostimulatory oligonucleotides.
[0230] formulation The immunogenic compositions of the invention can be formulated in liquid form (i.e., solution or suspension) or in lyophilized form. Advantageously, liquid formulations can be administered directly from their packaging form, and thus, they are ideal for injection, without the need for reconstitution in an aqueous medium that would otherwise be required for lyophilized compositions of the invention.
[0231] The formulation of the immunogenic composition of the present invention can be achieved using art-recognized methods.For example, the individual conjugates can be formulated with a physiologically acceptable vehicle to prepare the composition.Examples of such vehicles include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol) and dextrose solutions.
[0232] The present disclosure provides immunogenic compositions comprising any of the combinations of glycoconjugates disclosed herein and a pharma- ceutically acceptable excipient, carrier, or diluent.
[0233] In certain embodiments, the immunogenic composition formulation comprises a pharma- ceutically acceptable diluent, excipient or pharma-ceutically acceptable carrier. In one embodiment, the pharma-ceutically acceptable diluent includes sterile water, water for injection, sterile isotonic saline or biological buffer. The polysaccharide-protein conjugate and / or protein immunogen are mixed with such diluent or carrier in a conventional manner. As used herein, the term pharma-ceutically acceptable "carrier" is intended to include solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc., that are compatible with administration to humans or other vertebrate hosts. Suitable carriers will be clear to those skilled in the art and will depend in large part on the route of administration.
[0234] For example, excipients that may be present in the immunogenic composition formulation include preservatives, chemical stabilizers, and suspending or dispersing agents. Typically, stabilizers, preservatives, etc. are optimized to determine the best formulation for efficacy in the target recipient (e.g., human subject). Examples of preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol. Examples of stabilizing ingredients include casamino acids, sucrose, gelatin, phenol red, NZ amine, potassium dihydrogen phosphate, lactose, lactalbumin hydrolysate, and milk powder.
[0235] In certain embodiments, the immunogenic compositions of the invention are in liquid form, preferably in aqueous liquid form.
[0236] The immunogenic compositions of the disclosure may include one or more of the following: a buffering agent, a salt, a divalent cation, a non-ionic detergent, a cryoprotectant such as a sugar, and an antioxidant such as a free radical scavenger or chelating agent, or any combination thereof.
[0237] In one embodiment, the immunogenic composition of the present invention comprises a buffer. In one embodiment, the buffer has a pKa of about 3.5 to about 7.5. In some embodiments, the buffer is a phosphate buffer, a succinate buffer, a histidine buffer, or a citrate buffer. In one particular embodiment, the buffer is a succinate buffer at a final concentration of 1 mM to 10 mM. In one particular embodiment, the final concentration of the succinate buffer is about 5 mM.
[0238] In some embodiments, the immunogenic composition of the present invention comprises a salt. In some embodiments, the salt is selected from any one of magnesium chloride, potassium chloride, sodium chloride, and combinations thereof. In some embodiments, the salt is selected from the group consisting of magnesium chloride, potassium chloride, sodium chloride, and combinations thereof. In one particular embodiment, the salt is sodium chloride. In one particular embodiment, the immunogenic composition of the present invention comprises 150 mM sodium chloride.
[0239] In certain embodiments, the immunogenic compositions of the invention comprise a surfactant, hi some embodiments, the compositions comprise a non-ionic surfactant, such as, but not limited to, a polyoxyethylene sorbitan fatty acid ester. In certain embodiments, the surfactant is selected from any one of polysorbate 20 (TWEEN™ 20), polysorbate 40 (TWEEN™ 40), polysorbate 60 (TWEEN™ 60), polysorbate 65 (TWEEN™ 65), polysorbate 80 (TWEEN™ 80), polysorbate 85 (TWEEN™ 85), TRITON™ N-101, TRITON™ X-100, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate (PEG-15, Solutol H15), polyoxyethylene-35-ricinoleate (CREMOPHOR® EL), soy lecithin, and poloxamer. In certain embodiments, the surfactant is selected from the group consisting of polysorbate 20 (TWEEN™ 20), polysorbate 40 (TWEEN™ 40), polysorbate 60 (TWEEN™ 60), polysorbate 65 (TWEEN™ 65), polysorbate 80 (TWEEN™ 80), polysorbate 85 (TWEEN™ 85), TRITON™ N-101, TRITON™ X-100, octoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptide oleate, polyoxyethylene-660 hydroxystearate (PEG-15, Solutol H15), polyoxyethylene-35-ricinoleate (CREMOPHOR® EL), soy lecithin, and poloxamer. In some embodiments, the composition further comprises any one of polyoxyethylene alkyl ethers, such as, but not limited to, BRIJ58, BRIJ35, TRITON X-100, TRITON X-114, NP40, SPAN85, and the Pluronic series of non-ionic surfactants, e.g., PLURONIC 121. In one particular embodiment, the surfactant is polysorbate 80.In some such embodiments, the final concentration of polysorbate 80 in the formulation is at least 0.0001% to 10% (w / w) polysorbate 80. In some such embodiments, the final concentration of polysorbate 80 in the formulation is at least 0.001% to 1% (w / w) polysorbate 80. In some such embodiments, the final concentration of polysorbate 80 in the formulation is at least 0.01% to 1% (w / w) polysorbate 80. In other embodiments, the final concentration of polysorbate 80 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09% or 0.1% (w / w) polysorbate 80. In another embodiment, the final concentration of polysorbate 80 in the formulation is 1% polysorbate 80 by weight (w / w).
[0240] In certain embodiments, the immunogenic compositions of the invention have a pH of 5.5 to 7.5, more preferably a pH of 5.6 to 7.0, and even more preferably a pH of 5.8 to 6.0.
[0241] In one embodiment, the present invention provides a container filled with any of the immunogenic compositions disclosed herein. In one embodiment, the container is selected from any one of a vial, a syringe, a flask, a fermenter, a bioreactor, a bag, a jar, an ampoule, a cartridge, and a disposable pen. In one embodiment, the container is selected from the group consisting of a vial, a syringe, a flask, a fermenter, a bioreactor, a bag, a jar, an ampoule, a cartridge, and a disposable pen. In certain embodiments, the container is siliconized. In certain embodiments, the container of the present invention is made of glass, metal (e.g., steel, stainless steel, aluminum, etc.) and / or polymer (e.g., thermoplastic, elastomer, thermoplastic-elastomer). In certain embodiments, the container of the present invention is made of glass.
[0242] In one embodiment, the invention provides a syringe filled with any of the immunogenic compositions disclosed herein. In certain embodiments, the syringe is siliconized and / or made of glass.
[0243] A typical dose of the immunogenic composition of the invention for injection has a volume of 0.1 mL to 2 mL, more preferably 0.2 mL to 1 mL, even more preferably a volume of about 0.5 mL. Thus, the container or syringe defined above is filled with any of the immunogenic compositions defined herein in a volume of between 0.1 mL and 2 mL, more preferably between 0.2 mL and 1 mL, even more preferably a volume of about 0.5 mL.
[0244] The compositions of the present invention can be administered to a subject by one or more known methods, such as parenterally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, intranasally, subcutaneously, intraperitoneally, and formulated accordingly.
[0245] In one embodiment, the compositions of the invention are administered by epidermal, intramuscular, intravenous, intraarterial, subcutaneous, or intrarespiratory mucosal injection of a liquid preparation. The compositions of the invention can be formulated as single-dose vials, multi-dose vials, or as pre-filled syringes.
[0246] In another embodiment, the composition of the present invention is administered orally, and thus formulated in a form suitable for oral administration, i.e., as a solid or liquid preparation.Solid oral preparations include tablets, capsules, pills, granules, pellets, etc.Liquid oral preparations include solutions, suspensions, dispersions, emulsions, oils, etc.Pharmaceutically acceptable carriers for liquid preparations are aqueous or non-aqueous solutions, suspensions, emulsions, or oils.Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, and injectable organic esters such as ethyl oleate.
[0247] Aqueous carriers include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Exemplary oils are those of animal, vegetable or synthetic origin, such as peanut oil, soybean oil, olive oil, sunflower oil, fish-liver oil, other marine oils, or lipids derived from milk or eggs.
[0248] The pharmaceutical composition may be isotonic, hypotonic or hypertonic. The pharmaceutical composition for infusion or injection is preferably essentially isotonic when it is administered. For storage, the pharmaceutical composition may be preferably isotonic or hypertonic. If the pharmaceutical composition is hypertonic for storage, it may be diluted to become an isotonic solution before administration. The isotonic agent may be an ionic isotonic agent such as a salt or a non-ionic isotonic agent such as a carbohydrate. Examples of ionic isotonic agents include, but are not limited to, NaCl, CaCl3, KCl and MgCl2. Examples of non-ionic isotonic agents include, but are not limited to, sucrose, trehalose, mannitol, sorbitol and glycerol.
[0249] It is also preferred that at least one pharma- ceutically acceptable additive is a buffering agent. For some purposes, for example, when the pharmaceutical composition is for infusion or injection, it is often desirable for the composition to include a buffering agent capable of buffering the solution to a pH in the range of 4-10, such as 5-9, for example 6-8. The buffering agent can be selected, for example, from any one of Tris, acetate, glutamate, lactate, malate, tartarate, phosphate, citrate, carbonate, glycine, L-histidine, glycine, succinate, and triethanolamine buffers. The buffering agent can further be selected, for example, from USP compatible buffers for parenteral use, especially when the pharmaceutical formulation is for parenteral use. For example, the buffering agent can be selected from any one of monobasic acids such as acetic acid, benzoic acid, gluconic acid, glyceric acid and lactic acid; dibasic acids such as aconitic acid, adipic acid, ascorbic acid, carboxylic acid, glutamic acid, malic acid, succinic acid and tartaric acid, polybasic acids such as citric acid and phosphoric acid; and bases such as ammonia, diethanolamine, glycine, triethanolamine and Tris. Parenteral vehicles (for subcutaneous, intravenous, intraarterial or intramuscular injection) include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose. Examples are sterile liquids such as water and oils, with or without the addition of surfactants and other pharma-ceutically acceptable adjuvants. In general, water, saline, aqueous dextrose and related sugar solutions, glycols such as propylene glycol or polyethylene glycol, polysorbate 80 (PS-80), polysorbate 20 (PS-20), and poloxamer 188 (PI88) are preferred liquid carriers, particularly for injection solutions. Examples of oils are those of animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, olive oil, sunflower oil, fish liver oil, other marine oils, or lipids derived from milk or eggs.
[0250] The formulation may further comprise a surfactant. Preferred surfactants include, but are not limited to, polyoxyethylene sorbitan ester surfactants (commonly referred to as TWEEN), especially PS-20 and PS-80; copolymers of ethylene oxide (EO), propylene oxide (PO), and / or butylene oxide (BO), such as linear EO / PO block copolymers, sold under the trade name DOWFAX™; octoxynol, which may vary in the number of repeating ethoxy (oxy-1,2-ethanediyl) groups (octoxynol-9 (TRITON X-100, or t-octylphenoxypolyethoxyethanol) is of particular interest); (octylphenoxy)polyethoxyethanol (IGEPAL CA-630 / NP-40); phospholipids (lecithins) such as phosphatidylcholine; nonylphenol ethoxylates such as the TERGITOL™ NP series; polyoxyethylene fatty ethers derived from lauryl, cetyl, stearyl and oleyl alcohols (known as BRIJ surfactants), such as triethylene glycol monolauryl ether (BRIJ30); and sorbitan esters (commonly known as SPAN), such as sorbitan trioleate (SPAN85) and sorbitan monolaurate. A preferred surfactant for inclusion in the emulsion is PS-20 or PS-80. A mixture of surfactants can be used, such as a PS-80 / SPAN85 mixture. A combination of polyoxyethylene sorbitan esters, such as polyoxyethylene sorbitan monooleate (PS-80), and octoxynol, such as t-octylphenoxypolyethoxyethanol (TRITON X-100), is also suitable. Another useful combination includes laureth 9 plus a polyoxyethylene sorbitan ester and / or an octoxynol.
[0251] The formulation may also include a pH buffered aqueous salt solution. The buffering agent may be selected from, for example, any one of Tris, acetate, glutamate, lactate, malate, tartarate, phosphate, citrate, carbonate, glycine, L-histidine, glycine, succinate, HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid) and triethanolamine buffers. The buffering agent may buffer the solution to a pH in the range of 4-10, 5.2-7.5, or 5.8-7.0. In certain embodiments, the buffering agent is selected from any one of phosphate, succinate, L-histidine, MES, MOPS, HEPES, acetate, or citrate buffers. The buffering agent can further be selected from, for example, USP compatible buffering agents for parenteral use, especially when the pharmaceutical formulation is for parenteral use. The concentration of the buffering agent will be in the range of 1 mM to 50 mM or 5 mM to 50 mM. In certain embodiments, the buffering agent is an L-histidine buffer at a final concentration of 5 mM to 50 mM, or a succinic acid buffer at a final concentration of 1 mM to 10 mM. In certain embodiments, the L-histidine is at a final concentration of 20 mM ± 2 mM.
[0252] Although saline solutions (i.e., solutions containing NaCl) are preferred, other salts suitable for formulation include, but are not limited to, CaCl3, KCl, and MgCl2, and combinations thereof. Non-ionic isotonicity agents, such as, but not limited to, sucrose, trehalose, mannitol, sorbitol, and glycerol, can be used in place of salt. Suitable salt ranges include, but are not limited to, 25 mM to 500 mM or 40 mM to 170 mM. In one aspect, the saline solution is NaCl, optionally present at a concentration of 20 mM to 170 mM. In a preferred embodiment, the formulation includes an L-histidine buffer containing sodium chloride.
[0253] In another embodiment, the pharmaceutical composition is delivered in a controlled release system. For example, the drug can be administered using intravenous infusion, a transdermal patch, liposomes, or other modes of administration. In another embodiment, for example, polymeric materials in microspheres or implants are used.
[0254] Activity In one embodiment, the saccharide described herein is capable of inducing opsonic activity. In another embodiment, the saccharide described herein is capable of inducing opsonic and phagocytic activity (e.g., opsonophagocytic activity).
[0255] The inventors have surprisingly discovered that a saccharide with an increased number of repeating units compared to the corresponding wild-type saccharide induces an increased immune response in a mammal compared to the wild-type saccharide. The inventors have also surprisingly discovered that a composition comprising a conjugate comprising a carrier protein and a saccharide with an increased number of repeating units compared to the corresponding wild-type saccharide induces an increased immune response in a mammal compared to a mammal administered a composition comprising a conjugate comprising a carrier protein and the corresponding wild-type saccharide. Without being bound by mechanism or theory, a saccharide with an increased number of repeating units may have an increased number of conserved epitopes and may result in an increased immune response.
[0256] Opsonic activity or opsonization refers to the process by which an opsonin (e.g., an antibody or complement factor) binds to an antigen (e.g., a saccharide or conjugate thereof as described herein) and facilitates binding of the antigen to a phagocyte or phagocytic cell (e.g., macrophages, dendritic cells, and polymorphonuclear leukocytes (PMNL). Some bacteria, such as encapsulated bacteria that are not typically phagocytosed due to the presence of a capsule, are more likely to be recognized by phagocytes if coated with an opsonic antibody. In one embodiment, the saccharide induces an immune response, such as, for example, an antibody that is an opsonin. In one embodiment, the opsonic activity is against at least one strain of Gram-negative bacteria, preferably an Escherichia species, more preferably E. coli.
[0257] Phagocytic activity or phagocytosis refers to the process by which a phagocyte engulfs material and encapsulates the material in its cytoplasm. In one embodiment, the saccharide induces an immune response, such as, for example, antibodies, that facilitate phagocytosis. In one embodiment, the phagocytic activity is against at least one strain of Gram-negative bacteria, preferably an Escherichia species, more preferably E. coli. For example, rabbit antibodies raised against the isolated saccharides described herein may be able to specifically mediate opsonophagocytosis of strains expressing the saccharide in the presence of complement, as shown, for example, by in vitro phagocytosis assays.
[0258] In yet another embodiment, the saccharides described herein are capable of inducing a bactericidal immune response, hi one embodiment, the bactericidal activity is against at least one strain of Gram-negative bacteria, preferably an Escherichia species, more preferably E. coli.
[0259] Methods for measuring opsonization, phagocytosis, and / or bactericidal activity are known in the art, such as by measuring the reduction in bacterial load in vivo (e.g., measuring bacteremia levels in a mammal challenged with Echerichia) and / or by measuring bacterial cell killing in vitro (e.g., in vitro opsonophagocytosis assays). In one embodiment, the saccharide is capable of inducing opsonization, phagocytosis, and / or bactericidal activity in comparison to a suitable control, such as, for example, in comparison to antisera raised against heat-killed Gram-negative bacteria.
[0260] Opsonophagocytosis assays, which measure the killing of E. coli cells by phagocytic effector cells in the presence of functional antibodies and complement, may be an alternative means to evaluate the efficacy of E. coli vaccines against specific E. coli serotypes, such as E. coli serotype O25B. In vitro opsonophagocytosis assays can be performed by incubating together a mixture of E. coli cells, heat-inactivated human serum to be tested, differentiated HL-60 cells (phagocytes) and an exogenous complement source (e.g., baby rabbit complement). Opsonophagocytosis proceeds during incubation, and antibody- and complement-coated bacterial cells are killed upon opsonophagocytosis. Colony forming units (cfu) of surviving bacteria that escape opsonophagocytosis are determined by plating the assay mixture. The OPA titer is defined as the reciprocal of the dilution that results in a 50% reduction in bacterial counts compared to control wells without test serum. OPA titers are interpolated from the two dilutions that encompass this 50% killing cutoff.
[0261] An endpoint titer of 1:8 or greater is considered a positive result for these lethal OPAs.
[0262] In some embodiments, a subject may have a serotype-specific OPA titer prior to vaccination, for example, due to natural exposure to E. coli (e.g., in the case of an adult subject).
[0263] Thus, a comparison of OPA activity in pre- and post-immunization sera with the immunogenic compositions of the invention can be performed and the response compared to a particular E. coli serotype, e.g., E. coli serotype O25B, to assess the potential for increased responders.
[0264] In one embodiment, the immunogenic compositions of the invention significantly increase the proportion of responders (i.e., individuals with sera having a titer of at least 1:8 as determined by in vitro OPA) compared to the pre-immune population.
[0265] A comparison of OPA activity in pre- and post-immunization sera with the immunogenic compositions of the invention can also be made by comparing the potential for increased OPA titers.
[0266] Thus, a comparison of OPA activity in pre- and post-immunization sera with the immunogenic compositions of the invention can be performed to assess the potential for increased OPA titer, for example, in comparison to the response of a particular E. coli serotype, such as E. coli serotype O25B. In one embodiment, the immunogenic compositions of the invention can significantly increase OPA titer in a human subject compared to a pre-immunization population.
[0267] In one embodiment, the composition induces an immune response against at least one E. coli serotype, such as, for example, the following E. coli serotypes: O1 (e.g., O1A, O1B, and O1C), O2, O3, O4 (e.g., O4:K52 and O4:K6), O5 (e.g., O5ab and O5ac (180 / C3 strain)), O6 (e.g., O6:K2;K13;K15 and O6:K54), O7, O8, O9, O10, O11, O12, O13, O14, O15, O16, O17, O18 (e.g., O18A, O18ac, O18A1, O18B, and O18B1), O19, ... 0, O21, O22, O23 (e.g., O23A), O24, O25 (e.g., O25a and O25b), O26, O27, O28, O29, O30, O32, O33, O34, O35, O36, O37, O38, O39, O40, O41, O42, O43, O44, O45 (e.g., O45 and O45rel), O46, O48, O49, O50, O51, O52, O53, O54, O55, O56, O57, O58, O59, O60, O61, O62, 62D1, O63, O64, O65, O66, O68, O69, O7 0, O71, O73 (e.g., O73 (73-1 strain)), O74, O75, O76, O77, O78, O79, O80, O81, O82, O83, O84, O85, O86, O87, O88, O89, O90, O91, O92, O93, O95, O96, O97, O98, O99, O100, O101, O102, O103, O104, O105, O106, O107, O108, O109, O110, O111, O112, O113, O114, O115, O116, O117, O118, O119, O120, O121, O1 23, O124, O125, O126, O127, O128, O129, O130, O131, O132, O133, O134, O 135, O136, O137, O138, O139, O140, O141, O142, O143, O144, O145, O146, O 147, O148, O149, O150, O151, O152, O153, O154, O155, O156, O157, O158, O159, O160, O161, O162, O163, O164, O165, O166, O167, O168, O169, O170,The serotype may be any serotype, including any one of O171, O172, O173, O174, O175, O176, O177, O178, O179, O180, O181, O182, O183, O184, O185, O186, and O187. In one embodiment, the serotype is O25a. In another embodiment, the serotype is O25b. In another embodiment, the serotype is O1A. In another embodiment, the serotype is O2. In another embodiment, the serotype is O6. In another embodiment, the serotype is O6. In another embodiment, the serotype is O17. In another embodiment, the serotype is O15. In another embodiment, the serotype is O18A. In another embodiment, the serotype is O75. In another embodiment, the serotype is O4. In another embodiment, the serotype is O16. In another embodiment, the serotype is O13. In another embodiment, the serotype is O7. In another embodiment, the serotype is O8.
[0268] In a preferred embodiment, the composition induces an immune response against at least two E. coli serotypes. In another embodiment, the composition induces an immune response against at least three different E. coli serotypes. In one embodiment, the composition induces an immune response against at least four different E. coli serotypes. In one embodiment, the composition comprises O antigens from five different E. coli serotypes. In one embodiment, the composition induces an immune response against at least six different E. coli serotypes. In one embodiment, the composition induces an immune response against at least seven different E. coli serotypes. In one embodiment, the composition induces an immune response against at least eight different E. coli serotypes. In one embodiment, the composition induces an immune response against at least nine different E. coli serotypes. In one embodiment, the composition induces an immune response against at least ten different E. coli serotypes. In one embodiment, the composition induces an immune response against at least 11 different E. coli serotypes. In one embodiment, the composition induces an immune response against at least 12 different serotypes. In one embodiment, the composition induces an immune response against at least 13 different serotypes. In one embodiment, the composition induces an immune response against at least 14 different serotypes. In one embodiment, the composition induces an immune response against at least 15 different serotypes. In one embodiment, the composition induces an immune response against at least 16 different serotypes. In one embodiment, the composition induces an immune response against at least 17 different serotypes. In one embodiment, the composition induces an immune response against at least 18 different serotypes. In one embodiment, the composition induces an immune response against at least 19 different serotypes. In one embodiment, the composition induces an immune response against at least 20 different serotypes.
[0269] In one embodiment, the immunogenic composition of the invention elicits IgG antibodies in humans, said antibodies being capable of binding to a particular E. coli serotype saccharide, such as E. coli serotype O25B saccharide, for example as determined by an ELISA assay. Preferably, the enhanced immune response may include increased production of IgG1 and / or IgG2a and / or IgM.
[0270] In the ELISA (enzyme-linked immunosorbent assay) method, antibodies from the serum of vaccinated subjects are incubated with polysaccharide adsorbed to a solid support. Bound antibodies are detected using an enzyme-conjugated secondary detection antibody. ELISA measures type-specific IgG anti-E. coli polysaccharide antibodies present in human serum. When dilutions of human serum are added to a type-specific polysaccharide-coated microtiter plate, antibodies specific for that polysaccharide bind to the microtiter plate. Plate-bound antibodies are detected using a goat anti-human IgG alkaline phosphatase-labeled antibody followed by a p-nitrophenyl phosphate substrate. The optical density of the colored end product is proportional to the amount of anti-O antigen polysaccharide antibodies present in the serum.
[0271] In one embodiment, the immunogenic compositions of the invention significantly increase OPA titers in human subjects against E. coli serotypes O25B, O1, O2, and O6 as compared to pre-immune populations.
[0272] In some embodiments, the compositions of the invention are effective to increase production of antibodies against E. coli in a mammal to a geometric mean titer (GMT) level of at least 1,000, preferably at least 5,000 and at most 200,000 after an initial dose, such as, for example, about 30 days after the initial dose, preferably about 60 days after the initial dose. In a preferred embodiment, the compositions are effective to increase production of antibodies against E. coli serotype O25B in a mammal to a geometric mean titer (GMT) level of at least 1,000, preferably at least 5,000 and at most 200,000 after an initial dose.
[0273] In one embodiment, the immunogenic composition elicits IgG antibodies in humans, which are capable of binding to the E. coli serotypes corresponding to the repeating saccharide units in the composition. For example, the composition can elicit IgG antibodies at a concentration of at least 0.2 pg / ml, 0.3 pg / ml, 0.35 pg / ml, 0.4 pg / ml, or 0.5 pg / ml, as determined by ELISA assay. Thus, a comparison of OPA activity of pre- and post-immunization sera with the immunogenic composition of the invention can be performed to compare their response to each serotype and evaluate the possibility of increased responders. In one embodiment, the immunogenic composition elicits IgG antibodies in humans, which are capable of killing the E. coli serotypes corresponding to the repeating saccharide units in the composition, as determined by in vitro opsonophagocytosis assay. In one embodiment, the immunogenic composition elicits functional antibodies in humans, said antibodies capable of killing the E. coli serotype corresponding to the repeating saccharide unit in the composition, as determined by an in vitro opsonophagocytosis assay. In one embodiment, the immunogenic composition of the invention increases the proportion of responders (i.e., individuals with sera having a titer of at least 1:8, as determined by in vitro OPA) against the E. coli serotype corresponding to the repeating saccharide unit in the composition, as compared to a pre-immune population. In one embodiment, the immunogenic composition elicits a titer of at least 1:8 against the E. coli serotype corresponding to the repeating saccharide unit in the composition in at least 50% of subjects, as determined by an in vitro opsonophagocytosis killing assay. In one embodiment, the immunogenic composition of the invention elicits a titer of at least 1:8 against the E. coli serotype corresponding to the repeating saccharide unit in the composition in at least 60%, 70%, 80%, or at least 90% of subjects as determined by an in vitro opsonophagocytic killing assay.In one embodiment, the immunogenic compositions of the invention significantly increase the proportion of responders (i.e., individuals with sera having a titer of at least 1:8 as determined by in vitro OPA) to the E. coli serotype corresponding to the saccharide repeat unit in the composition compared to a pre-immune population. In one embodiment, the immunogenic compositions of the invention significantly increase the OPA titer in human subjects to the E. coli serotype corresponding to the saccharide repeat unit in the composition compared to a pre-immune population.
[0274] method In another aspect, the invention relates to a method of preventing infection in a subject, e.g., a human subject, comprising administering to the subject an effective amount of a composition (e.g., an immunogenic composition) described herein.
[0275] In another aspect, the invention relates to a method of treating an infection in a subject, e.g., a human subject, comprising administering to the subject an effective amount of a composition (e.g., an immunogenic composition) described herein.
[0276] In another aspect, the invention relates to a method of inducing an immune response in a subject, e.g., a human subject, comprising administering to the subject an effective amount of a composition (e.g., an immunogenic composition) described herein.
[0277] In another aspect, the invention relates to a method of inducing the production of opsonophagocytic antibodies in a subject, e.g., a human subject, comprising administering to the subject an effective amount of a composition (e.g., an immunogenic composition) described herein.
[0278] As used herein, the term "effective amount" in the context of administering a composition described herein to a subject refers to an amount of the composition that has a prophylactic and / or therapeutic effect. In certain embodiments, an "effective amount" refers to the following effects: (i) reducing or ameliorating the severity of E. coli infection or symptoms associated therewith; (ii) reducing the duration of E. coli infection or symptoms associated therewith; (iii) preventing the progression of E. coli infection or symptoms associated therewith; (iv) causing regression of E. coli infection or symptoms associated therewith; (v) preventing the development or onset of E. coli infection or symptoms associated therewith; (vi) preventing the recurrence of E. coli infection or symptoms associated therewith; (vii) preventing the recurrence of E. coli infection or symptoms associated therewith; (viii) preventing the recurrence of E. coli infection or symptoms associated therewith; (viii) preventing the recurrence of E. coli infection or symptoms associated therewith; (viiii ... (viii) reducing hospitalization of a subject with an E. coli infection; (ix) reducing the length of hospitalization of a subject with an E. coli infection; (x) increasing survival of a subject with an E. coli infection; (xi) eliminating an E. coli infection in a subject; (xii) inhibiting or reducing E. coli replication in a subject; and / or (xiii) enhancing or improving the prophylactic or therapeutic effects of another therapy.
[0279] In an embodiment, the immunogenic composition disclosed herein is for use as a medicament.The immunogenic composition described herein can be used in various therapeutic or prophylactic methods to prevent, treat, or ameliorate bacterial infection, disease, or condition in a subject.In particular, the immunogenic composition described herein can be used to prevent, treat, or ameliorate E. coli infection, disease, or condition in a subject.
[0280] Thus, in one aspect, the invention provides a method for preventing, treating or ameliorating an infection, disease or condition associated with E. coli in a subject, the method comprising administering to the subject an immunologically effective amount of an immunogenic composition of the invention.
[0281] In one aspect, the invention provides a method of preventing, treating or ameliorating an infection, disease or condition associated with E. coli in a subject, the method comprising administering to the subject an immunologically effective amount of an immunogenic composition of the invention.
[0282] In one aspect, the invention provides a method of inducing an immune response against E. coli in a subject, the method comprising administering to the subject an immunologically effective amount of an immunogenic composition of the invention.
[0283] In one aspect, the immunogenic compositions of the invention are for use in a method for preventing, treating or ameliorating an infection, disease or condition caused by E. coli in a subject, hi another aspect, the compositions of the invention are for use in a method for protecting a mammal against an infection, disease or condition caused by E. coli.
[0284] In one embodiment, any of the immunogenic compositions disclosed herein is for use in a method of immunizing a subject against infection with E. coli.
[0285] In one aspect, the present invention is directed to the use of the immunogenic compositions disclosed herein for the manufacture of a medicament for preventing, treating or ameliorating an infection, disease or condition caused by E. coli in a subject.
[0286] In certain embodiments, the present invention is directed to the use of the immunogenic compositions disclosed herein for the manufacture of a medicament for immunizing a subject against infection with E. coli.
[0287] In an embodiment, the immunogenic composition disclosed herein is for use as a vaccine. More particularly, the immunogenic composition described herein can be used to prevent E. coli infection in a subject. Thus, in one aspect, the present invention provides a method for preventing E. coli infection in a subject, comprising administering to the subject an immunologically effective amount of the immunogenic composition of the present invention.
[0288] In some such embodiments, the infection is selected from any one of urinary tract infection, cholecystitis, cholangitis, diarrhea, hemolytic uremic syndrome, neonatal meningitis, urosepsis, intraperitoneal infection, meningitis, complicated pneumonia, wound infection, post-prostate biopsy related infection, neonatal / infant sepsis, neutropenic fever, pneumonia, bacteremia, and sepsis, and other bloodstream infections. For example, E. coli serotypes associated with neonatal meningitis include serotypes O1, O6, O7, O16, O18, and O83. Thus, in one embodiment, the composition comprises a conjugate comprising a saccharide having a structure selected from any one of formula O1, formula O6, formula O7, formula O16, formula O18, formula O83, and any combination of the conjugates. As another example, E. coli serotypes associated with bacteremia include serotypes O1, O2, O6, O15, and O75. Thus, in another embodiment, the composition comprises at least one conjugate comprising a saccharide having a structure selected from any one of formulas O1, O2, O6, O16 and O75, as well as any combination of the conjugates. As a further example, E. coli O1 and O2 strains, such as O1:K1:H7 or O2:K1:H4, O2:K1:H5, O2:K1:H6 and O2:K1:H7, have been identified as causative pathogens of urinary tract infections, sepsis and neonatal meningitis in humans and animals. Both O1 and O2 serogroups constitute many strains that cause bacteremia and sepsis in human patients. Thus, in one embodiment, the composition comprises a conjugate comprising a saccharide having formula O1 and a conjugate comprising a saccharide having formula O2.
[0289] Thus, by generating an immune response in a mammal by these uses and methods, the mammal can be protected against E. coli infection, including ExPEC and non-ExPEC strains. The present invention is particularly useful for providing broad protection against pathogenic E. coli, including enteropathotypes such as EPEC, EAEC, EIEC, ETEC and DAEC pathotypes. Thus, the mammal can be protected against diseases including, but not limited to, peritonitis, pyelonephritis, cystitis, endocarditis, prostatitis, urinary tract infection (UTI), meningitis (particularly neonatal meningitis), sepsis (or SIRS), dehydration, pneumonia, diarrhea (infant, traveler, acute, persistent, etc.), shigellosis, hemolytic uremic syndrome (HUS), pericarditis, bacteriuria, etc.
[0290] In one embodiment, the subject to be vaccinated is a mammal, such as human, cat, sheep, pig, horse, cow or dog.Preferably, the subject to be vaccinated is a human.When the vaccine is for preventive use, the human is preferably a child (e.g., infant or toddler) or a teenager or an adult; when the vaccine is for therapeutic use, the human is preferably a teenager or an adult.The vaccine intended for children can be administered to adults, for example, to evaluate safety, dosage, immunogenicity, etc.
[0291] The vaccine of the present invention can be used to treat both children and adults. Thus, the human patient may be under 1 year old, 1-5 years old, 5-15 years old, 15-55 years old, or at least 55 years old. Preferred patients to receive the vaccine are elderly (e.g., 50 years old or older, 60 years old or older, preferably 65 years old or older), young people (e.g., 5 years old or younger), hospitalized patients, medical personnel, military personnel, pregnant women, chronically ill people, or immunocompromised people. The vaccine is not only suitable for these groups, but can be used more generally in the population.
[0292] The vaccines of the present invention are particularly useful for patients anticipating surgery or other hospitalized patients. They are also useful in patients who are catheterized. They are also useful in adolescent females (e.g., 11-18 years of age) and patients with chronic urinary tract infections.
[0293] In some embodiments, the immunogenic compositions disclosed herein are administered by intramuscular, intraperitoneal, intradermal or subcutaneous routes. In some embodiments, the immunogenic compositions disclosed herein are administered by intramuscular, intraperitoneal, intradermal or subcutaneous injection. In some embodiments, the immunogenic compositions disclosed herein are administered by intramuscular or subcutaneous injection.
[0294] In one embodiment, the present invention is directed to a method comprising the steps of: (i) injecting a subject with an immunologically effective amount of any of the immunogenic compositions defined herein; (ii) collecting a serum sample from the subject; and (iii) testing the serum sample for opsonophagocytic killing activity against Escherichia coli (E. coli) serotype O25B by an in vitro opsonophagocytic killing assay (OPA).
[0295] subject As disclosed herein, the immunogenic compositions described herein can be used in a variety of therapeutic or prophylactic methods to prevent, treat, or ameliorate a bacterial infection, disease, or condition in a subject.
[0296] In a preferred embodiment, the subject is a human. In a most preferred embodiment, the subject is a newborn (i.e., under 3 months of age), an infant (i.e., between 3 months and 1 year of age) or a toddler (i.e., between 1 and 4 years of age).
[0297] In certain embodiments, the immunogenic compositions disclosed herein are for use as a vaccine.
[0298] In some embodiments, the subject to be vaccinated may be less than 1 year old. For example, the subject to be vaccinated may be about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11 or about 12 months old. In some embodiments, the subject to be vaccinated is about 2, 4 or 6 months old. In another embodiment, the subject to be vaccinated is less than 2 years old. For example, the subject to be vaccinated may be about 12 to about 15 months old. In some cases, only one dose of the immunogenic composition according to the present invention is required, although in some circumstances, a second, third or fourth dose may be administered.
[0299] In certain embodiments, the subject to be vaccinated may be under 18 years of age. For example, the subject to be vaccinated may be about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, or about 17 years of age. For example, the subject to be vaccinated may be about 10 to about 18 years of age. In some cases, only one dose of the immunogenic composition according to the present invention is required, although in some circumstances a second, third, or fourth dose may be administered.
[0300] In another embodiment, the subject to be vaccinated may be a human aged 18 years or older. For example, the subject to be vaccinated may be from about 18 to about 50 years old. In some cases, only one dose of the immunogenic composition according to the present invention may be required, although in some circumstances a second, third or fourth dose may be administered.
[0301] In one embodiment of the invention, the subject to be vaccinated is a human aged 50 years or older, more preferably aged 55 years or older. In one embodiment, the subject to be vaccinated is a human aged 65 years or older, 70 years or older, 75 years or older, or 80 years or older. In one embodiment, the subject to be vaccinated is an immunocompromised individual, a human. An immunocompromised individual is generally defined as a person who exhibits a diminished or reduced ability to mount normal humoral or cellular defenses against challenge by an infectious agent.
[0302] In certain embodiments of the invention, the immunocompromised subject to be vaccinated suffers from a disease or condition that impairs the immune system and results in an insufficient antibody response to protect against or treat a urinary tract infection.
[0303] In one embodiment, the disease is a primary immunodeficiency disorder.Preferably, the primary immunodeficiency disorder is selected from any one of combined T and B cell immunodeficiency, antibody deficiency, well-defined syndrome, immune dysregulation disease, phagocytic injury, congenital immune deficiency, autoinflammatory disorder, and complement deficiency.
[0304] In certain embodiments of the invention, the immunocompromised subject to be vaccinated is suffering from a disease selected from any one of HIV infection, acquired immune deficiency syndrome (AIDS), cancer, chronic heart or lung disorder, congestive heart failure, diabetes, chronic liver disease, alcoholism, cirrhosis of the liver, cerebrospinal fluid leak, cardiomyopathy, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), splenic dysfunction (such as sickle cell disease), lack of splenic function (asplenia), hematological malignancies, leukemia, multiple myeloma, Hodgkin's disease, lymphoma, renal failure, nephrotic syndrome and asthma.
[0305] In certain embodiments of the invention, the subject to be vaccinated suffers from malnutrition.
[0306] In certain embodiments of the invention, the subject to be vaccinated is taking a drug or treatment that lowers the body's resistance to infection.
[0307] In certain embodiments of the invention, the subject to be vaccinated is a smoker.
[0308] In one embodiment of the invention, the subject to be vaccinated is administered 5x10 per liter. 9 Less than 4x10 cells per liter 9 Less than 3x10 cells per liter 9 Less than 2x10 cells per liter 9 Less than 1x10 cells per liter9 Less than cells, or 0.5x10 per liter 9 Less than cells, or 0.3x10 per liter 9 Less than cells, or 0.1x10 per liter 9 Have a white blood cell count (leukocyte count) below cellular.
[0309] White blood cell count (leukocyte count): The number of white blood cells (WBC) in the blood. WBC is usually measured as part of a CBC (complete blood count). WBCs are the infection-fighting cells in the blood and are distinct from the red (oxygen-carrying) blood cells known as erythrocytes. There are various types of white blood cells, including neutrophils (polymorphonuclear leukocytes; PMNs), band cells (slightly immature neutrophils), T lymphocytes (T cells), B lymphocytes (B cells), monocytes, eosinophils, and basophils. All types of white blood cells are reflected in the white blood cell count. The normal range for white blood cell count is usually 4,300 to 10,800 cells per cubic millimeter of blood. This is also called the white blood cell count, and is 4.3 to 10.8 x 10 cells per liter. 9 It can be expressed in international units as cells.
[0310] In one embodiment, the subject to be vaccinated suffers from neutropenia. For example, the subject to be vaccinated suffers from 2x10 per liter neutropenia. 9 Less than 1x10 cells per liter 9 Less than cells, or 0.5x10 per liter 9 Less than cells, or 0.1x10 per liter 9 Less than cells, or 0.05x10 per liter 9 may have a subcellular neutrophil count.
[0311] Low white blood cell count or "neutropenia" is a condition characterized by abnormally low levels of neutrophils in the circulating blood. Neutrophils are a specific type of white blood cell that help prevent and fight infection. The most common reason cancer patients experience neutropenia is as a side effect of chemotherapy. Chemotherapy-induced neutropenia increases a patient's risk of infection and interrupts cancer treatment.
[0312] In one embodiment, the subject to be vaccinated has a immunization rate of 500 / mm 3 CD4+ cell count less than 300 / mm 3 CD4+ cell count less than 200 / mm 3 CD4+ cell count less than 100 / mm 3 CD4+ cell count less than 75 / mm 3 CD4+ cell count less than 50 / mm 3 Have a CD4+ cell count less than
[0313] The CD4 cell test is usually performed at 1 mm 3 Normal CD4 counts are between 500 and 1600, and CD8 counts are between 375 and 1100. CD4 counts drop dramatically in people with HIV.
[0314] In certain embodiments of the invention, the subject with any of the immune disorders disclosed herein is a male or female human.
[0315] Regimen In some cases, only one dose of the immunogenic composition according to the invention is effective, and in other circumstances, such as in more highly immunodeficient states, a second, third or fourth dose may be administered. After the initial vaccination, subjects may receive one or several booster immunizations, well spaced apart.
[0316] In one embodiment, the vaccination schedule for the immunogenic composition according to the invention is a single dose, hi another embodiment, the single dose schedule is for a healthy individual of at least 2 years of age.
[0317] In one embodiment, the vaccination schedule of the immunogenic composition according to the invention is a multiple dose schedule. In another embodiment, the multiple dose schedule comprises a series of two doses separated by an interval of about one month to about two months. In one embodiment, the multiple dose schedule comprises a series of two doses separated by an interval of about one month, or a series of two doses separated by an interval of about two months.
[0318] In another embodiment, the multiple dose schedule comprises a series of three doses separated by intervals of about one month to about two months, hi another embodiment, the multiple dose schedule comprises a series of three doses separated by intervals of about one month, or a series of three doses separated by intervals of about two months.
[0319] In another embodiment, the multiple dose schedule comprises a series of three doses separated by about one month to about two months intervals, followed by a fourth dose about 10 to about 13 months after the first dose. In another embodiment, the multiple dose schedule comprises a series of three doses separated by about one month intervals, followed by a fourth dose about 10 to about 13 months after the first dose, or a series of three doses separated by about two months intervals, followed by a fourth dose about 10 to about 13 months after the first dose.
[0320] In certain embodiments, the multiple dose schedule includes at least one dose (eg, 1, 2 or 3 doses) at a first age, followed by at least one toddler dose.
[0321] In one embodiment, the multiple dose schedule includes a series of 2 or 3 doses separated by about 1 month to about 2 months intervals (e.g., 28-56 days between doses) starting at 2 months of age, followed by an infant dose at 12-18 months of age. In one embodiment, the multiple dose schedule includes a series of 3 doses separated by about 1 month to about 2 months intervals (e.g., 28-56 days between doses) starting at 2 months of age, followed by an infant dose at 12-15 months of age. In another embodiment, the multiple dose schedule includes a series of 2 doses separated by about 2 months intervals starting at 2 months of age, followed by an infant dose at 12-18 months of age.
[0322] In one embodiment, the multiple dose schedule includes four consecutive doses of the vaccine at 2, 4, 6, and 12-15 months of age.
[0323] In one embodiment, an initial dose is given on day 0, and one or more booster doses are given at intervals ranging from about 2 to about 24 weeks, preferably with a dosing interval of 4 to 8 weeks.
[0324] In one embodiment, an initial dose is given on day 0 and a booster dose is given about 3 months later.
[0325] Kits and Processes In certain embodiments, the present invention is directed to a kit comprising the immunogenic composition disclosed herein and an information leaflet.
[0326] In one embodiment, the information leaflet comprises the ability of the composition to elicit functional antibodies against E. coli.
[0327] In one embodiment, the information leaflet comprises the ability of the composition to elicit OPA titres against E. coli serotype O25B in a human population. In one embodiment, the information leaflet comprises the ability of the composition to elicit OPA titres against E. coli serotype O1 in a human population. In one embodiment, the information leaflet comprises the ability of the composition to elicit OPA titres against E. coli serotype O2 in a human population. In one embodiment, the information leaflet comprises the ability of the composition to elicit OPA titres against E. coli serotype O6 in a human population.
[0328] In an embodiment, the present invention is directed to a process for producing a kit comprising an immunogenic composition and an information leaflet, the process comprising the steps of: (i) producing an immunogenic composition of the present disclosure; and (ii) combining said immunogenic composition and an information leaflet in said kit, wherein said information leaflet describes the ability of said composition to elicit functional antibodies against E. coli.
[0329] In one embodiment, the present invention is directed to a process for producing a kit comprising an immunogenic composition and an information leaflet, the process comprising the steps of: (i) producing the immunogenic composition of the present disclosure; and (ii) combining in the kit said immunogenic composition with an information leaflet, wherein said information leaflet describes the ability of the composition to elicit anti-O antigen antibodies against E. coli in a human population.
[0330] In an embodiment, the present invention is directed to a process for producing a kit comprising an immunogenic composition and an information leaflet, the process comprising the steps of: (i) producing the immunogenic composition of the present disclosure; and (ii) combining in the kit said immunogenic composition with an information leaflet, wherein said information leaflet describes the ability of the composition to elicit OPA titers against E. coli in a human population.
[0331] In one embodiment, the present invention is directed to a process for producing a kit comprising an immunogenic composition and an information leaflet, the process comprising the steps of: (i) producing the immunogenic composition of the present disclosure; (ii) printing an information leaflet describing the ability of said composition to elicit functional antibodies against E. coli; and (iii) combining said immunogenic composition and said information leaflet in the kit.
[0332] In one embodiment, the present invention is directed to a process for producing a kit comprising an immunogenic composition and an information leaflet, the process comprising the steps of: (i) producing the immunogenic composition of the present disclosure; (ii) printing an information leaflet describing the ability of the composition to elicit OPA titers against E. coli in a human population; and (iii) combining said immunogenic composition and said information leaflet in the kit. EXAMPLES
[0333] In order to better understand the present invention, the following examples are provided. These examples are merely illustrative and should not be construed as limiting the scope of the present invention in any manner. The following examples are illustrative of some embodiments of the present invention.
[0334] Example 1 E. coli and Salmonella enterica strains The clinical strains and derivatives are listed in Table 3. Additional reference strains included O25K5H1, a clinical O25a serotype strain; and Salmonella enterica serotype Typhimurium strain LT2.
[0335] A gene knockout in an E. coli strain was constructed that removes the target open reading frame but leaves a short scar sequence.
[0336] For simplicity, the hydrolyzed O antigen chains and the core saccharide are shown next to the O polysaccharide (OPS).
[0337] [Table 3]
[0338] Example 2 Oligonucleotide primers for wzzB, fepE and O-antigen gene cluster cloning
[0339] [Table 4]
[0340] Example 3 Plasmids The plasmid vectors and subclones are listed in Table 5. PCR fragments carrying various E. coli and Salmonella wzzB and fepE genes were amplified from purified genomic DNA and subcloned into the high copy number plasmid provided in the Invitrogen PCR® Blunt cloning kit (Figure 1). This plasmid is based on the pUC replicon. Primers P3 and P4 were used to amplify the E. coli wzzB gene along with its native promoter, which are designed to bind to regions in the proximal and distal genes encoding UDP-glucose-6-dehydrogenase and phosphoribosyl adenine nucleotide hydrolase, respectively (annotated in Genbank MG1655 NC_000913.3). The PCR fragment containing the Salmonella fepE gene and promoter was amplified using the primers previously described. Similar E. coli fepE primers were designed based on available Genbank genome sequences or internally generated whole genome data (for GAR2401 and O25K5H1). The low copy number plasmid pBAD33 was used to express O antigen biosynthesis genes under the control of the arabinose promoter. The plasmid was first modified to facilitate cloning (by the Gibson method) of long PCR fragments amplified using universal primers homologous to the 5' promoter and 3' 6-phosphogluconate dehydrogenase (gnd) gene (Table 5). A pBAD33 subclone containing the O25b biosynthesis operon is illustrated in Figure 1.
[0341] [Table 5]
[0342] Example 4 O antigen purification The fermentation broth was treated with acetic acid to a final concentration of 1-2% (final pH of 4.1). Extraction and defatting of OAg was achieved by heating the acid-treated broth to 100°C for 2 hours. At the end of the acid hydrolysis, the batch was cooled to ambient temperature and 14% NH4OH was added to a final pH of 6.1. The neutralized broth was centrifuged and the centrate was collected. To the centrate, CaCl2 in sodium phosphate was added and the resulting slurry was incubated at room temperature for 30 min. Solids were removed by centrifugation and the centrate was concentrated 12-fold using a 10 kDa membrane, followed by diafiltration twice against water. The retentate, retaining the OAg, was then purified using a carbon filter. The carbon filtrate was diluted 1:1 (v / v) with 4.0 M ammonium sulfate. The final ammonium sulfate concentration was 2 M. The ammonium sulfate-treated carbon filtrate was further purified using a membrane with 2 M ammonium sulfate as the running buffer. OAg was collected in the effluent. For the long OAg, the HIC filtrate was concentrated and then buffer exchanged against water (20 dialysis volumes) using a 5 kDa membrane. For the short (native) OAg polysaccharides, the MWCO was further reduced to enhance the yield.
[0343] Example 5 CRM for O25b long chain O antigen 197 Conjugation to First set of long chain O25b polysaccharide-CRM 197 Conjugates were produced using periodate oxidation followed by conjugation using reductive amination chemistry (RAC) (Table 7). The conjugates vary in three activation levels (low, medium and high) by varying the oxidation level. Lyophilized activated polysaccharide and lyophilized CRM reconstituted in DMSO medium using sodium cyanoborohydride as the reducing agent were synthesized. 197The conjugate was produced by reacting with 100K MWCO regenerated cellulose membrane. The conjugation reaction was carried out at 23° C. for 24 h and then capped with sodium borohydride for 3 h. After the conjugation quenching step, the conjugate was purified by UF / DF using 5 mM succinate / 0.9% NaCl, pH 6.0. Final filtration of the conjugate was performed using a 0.22 μm membrane.
[0344] Unless expressly indicated otherwise, the conjugates disclosed throughout the examples below comprise a core sugar moiety.
[0345] 1.1. Long O-antigen expression provided by heterologous polymerase chain length regulators Initial E. coli strain construction focused on the O25 serotype. The goal was to overexpress the heterologous wzzB or fepE genes to see if they would provide longer chain lengths in an O25 wzzB knockout strain. First, blood isolates were screened by PCR to identify strains of the O25a and O25b subtypes. Strains were then screened for susceptibility to ampicillin. One ampicillin-sensitive O25b isolate, GAR2401, was identified in which the wzzB deletion was introduced. Similarly, the wzzB deletion was made in the O25a strain, O25K5H1. For genetic complementation of these mutations, the wzzB genes from GAR2401 and O25K5H1 were subcloned into a high-copy PCR-BluntII cloning vector and introduced into both strains by electroporation. Additional wzzB genes from E. coli K-12 and Salmonella enterica serovar Typhimurium LT2; as well as the fepE genes from E. coli O25K5H1, GAR2401, O25a ETEC, NR-5, O157:H7:K- and Salmonella enterica serovar Typhimurium LT2 were cloned and introduced.
[0346] Genetic complementation of LPS expression in plasmid transformants of wzzB knockout strains O25K5H1 (O25a) and GAR2401 (O25b) is shown in Figure 2. Bacteria were grown overnight in LB medium, and LPS was extracted with phenol, resolved by SDS PAGE (4-12% acrylamide), and stained. Each well of the gel contained an equal number of bacterial cells (approximately 2OD 600 LPS extracted from 1000 ng / ml (1 repeat unit) of 1000 ng / ml sucrose were loaded onto the gel. The size of LPS was estimated from an internal native E. coli LPS standard and by measuring a recognizable ladder from a subset of samples showing a broad chain length distribution (differing by one repeat unit). On the left side of panel A of Figure 3, the LPS profile of a plasmid transformant of O25a O25K5HΔwzzB is shown; on the right side, a similar profile of an O25b GAR2401ΔwzzB transformant is shown. An immunoblot of a replicate gel probed with O25-specific serum is shown in panel B of Figure 3.
[0347] The results of this experiment show that introduction of the homologous wzzB gene into the E. coli O25aΔwzzB host restores expression of the short O25 LPS (10-20x), similar to Salmonella LT2 wzzB. Introduction of the O25b wzzB gene from GAR2401 does not, suggesting that the WzzB enzyme from this strain is defective. Comparison of the E. coli WzzB amino acid sequence suggests that the A210E and P253S substitutions may be responsible. Importantly, Salmonella LT2 fepE and E. coli fepE derived from O25a O25K5H1 confer the ability to express very long (VL) OAg LPS, with Salmonella LT2 fepE producing an OAg that exceeds in size that produced by E. coli fepE.
[0348] A similar pattern of expression was observed for GAR2401ΔwzzB transformants: E. coli O25a or K12 strain wzzB restored the ability to produce short LPS. Salmonella LT2 fepE produced the longest LPS, E. coli fepE produced a slightly shorter LPS, while Salmonella LT2 wzzB yielded an intermediate-sized long LPS (L). The ability of other E. coli fepE genes to produce very long LPS was evaluated in separate experiments using transformants of E. coli O25aΔwzzB. The fepE genes from GAR2401, an O25a ETEC strain, and an O157 Shigella toxin-producing strain also conferred the ability to produce very long LPS, although not as long as that produced for Salmonella LT2 fepE (Figure 4). An alignment of the FepE amino acid sequences is shown in Figure 5.
[0349] Once Salmonella LT2 fepE was established in serotype O25a and O25b strains, which generate the longest LPS of the polymerase regulators evaluated, we next sought to determine whether it also produces very long LPS in other E. coli serotypes. Wild-type bacteremia isolates of serotypes O1, O2, O6, O15, and O75 were transformed with the Salmonella fepE plasmid and extracted LPS. The results, shown in FIG. 6, confirm that Salmonella fepE can confer the ability to make very long LPS in other common serotypes associated with blood infections. The results also show that plasmid-based expression of Salmonella fepE appears to override the chain length control normally exhibited by endogenous wzzB in these strains.
[0350] 1.2. Plasmid-based expression of O-antigens in common E. coli host strains From a bioprocess development perspective, the ability to produce O antigens of different serotypes in a common E. coli host instead of multiple strains would greatly simplify the production of individual antigens. To this end, O antigen gene clusters from different serotypes were amplified by PCR and cloned into a low copy number plasmid (pBAD33) under the control of an arabinose-regulated promoter. This plasmid is compatible with (can coexist with) the Salmonella LT2 fepE plasmid in E. coli, since it carries a different (p15a) replicon and a different selection marker (chloramphenicol vs. kanamycin). In initial experiments, pBAD33 O25b operon plasmid subclones were cotransfected with the Salmonella LT2 fepE plasmid into GAR2401ΔwzzB, and transformants were grown in the presence or absence of 0.2% arabinose. The results shown in FIG. 7 demonstrated that very long O-antigen LPS is produced in an arabinose-dependent manner.
[0351] Cloned O-antigen gene clusters from other serotypes were similarly evaluated, and the results are shown in Figure 8. Co-expression of Salmonella LT2 fepE with pBAD33-OAg plasmid yielded detectable long-chain LPS corresponding to O1, O2 (for two of the four clones), O16, O21, and O75 serotypes. For unknown reasons, pBAD33-O6 plasmid failed to yield detectable LPS in all four isolates tested. Although expression levels were variable, the results indicate that expression of long-chain O-antigens in a common host is feasible. However, in some cases, further optimization to improve expression, for example, by modification of the plasmid promoter sequence, may be necessary.
[0352] Profiles of LPS from different serotype O25 E. coli strains with or without the Salmonella LT2 fepE plasmid are shown in FIG. 11. Two strains were tested for fermentation, extraction and purification of O antigen: GAR2831 for the production of native short O25b OAg; and GAR2401ΔwzzB / fepE for the production of long O25b OAg. The corresponding short and long forms of LPS shown in the SDS-PAGE gel in FIG. 11 are highlighted in red. Polysaccharides were extracted and purified directly from the fermented bacteria with acetic acid. Size-exclusion chromatography profiles of purified short and long or very long O25b polysaccharides are shown in FIG. 12. The properties of two lots of short polysaccharides (from GAR2831) are compared to a single very long polysaccharide preparation (from strain GAR2401ΔwzzB / fepE). The molecular weight of the long O antigen was estimated to be 3.3 times larger than that of the short O antigen, with the number of repeat units estimated to be approximately 65 (very long) and approximately 20. See Table 6.
[0353] [Table 6]
[0354] The very long O25b O antigen polysaccharide was synthesized using a conventional reductive amination process and was synthesized using the diphtheria toxoid CRM 197 Three different lots of sugar conjugates were prepared with varying degrees of periodate activation: medium (5.5%), low (4.4%) and high (8.3%). The resulting preparations and the unconjugated polysaccharide were shown to be free of endotoxin contamination (Table 7).
[0355] A group of four rabbits (New Zealand White females) were vaccinated with 10 mcg of the sugar conjugate and 20 mcg of QS21 adjuvant, respectively, according to the schedule shown in Figure 13A, and serum was collected (VAC-2017-PRL-EC-0723). It is noteworthy that the 10 mcg dose is at the lower end of the range routinely administered to rabbits in the evaluation of bacterial sugar conjugates (20-50 mcg being more typical). One group of rabbits was also vaccinated with unconjugated polysaccharide, using the same dose (10 mcg polysaccharide + 20 mcg QS21 adjuvant) and identical dosing schedule, in a separate study (VAC-2017-PRL-GB-0698).
[0356] Rabbit antibody responses to the three O25b glycoconjugate preparations were evaluated in a LUMINEX assay in which carboxybeads were coated with methylated human serum albumin pre-bound with unconjugated O25b long polysaccharide. The presence of O25b-specific IgG antibodies in serum samples was detected using a phycoerythrin (PE)-labeled anti-IgG secondary antibody. The profile of immune responses observed in sera taken at week 0 (pre-immunization), week 6 (post-dose 2, PD2), week 8 (post-dose 3, PD3) and week 12 (post-dose 4, PD4) in the best responding rabbits (one from each group of four) is shown in Figure 14. No significant pre-immunization serum IgG titers were detected in any of the 12 rabbits. In contrast, O25b antigen-specific antibody responses were detected in post-vaccination sera from rabbits in all three groups, with responses in the low activation glycoconjugate group tending to be slightly higher than those in the medium or high activation glycoconjugate groups. The maximum response was observed by the post-dose 3 time point. One rabbit in the low activation group and one rabbit in the high activation group failed to respond to vaccination (non-responders).
[0357] CRM for immunogenicity of long O25b OAg polysaccharide 197To assess the impact of carrier protein conjugation, the presence of antibodies in sera from rabbits vaccinated with unconjugated polysaccharide was assessed using the low activation CRM 197 The glycoconjugates were compared with sera from vaccinated rabbits (Figure 15). Surprisingly, the free polysaccharide was not immunogenic and did not elicit a substantial IgG response in immune and pre-immune sera (Panel A). In contrast, over a range of serum dilutions (1:100 to 1:6400), O25b OAg-CRM 197 Approximately 10-fold higher O25b OAg-specific IgG mean fluorescence intensity values (MFI) than pre-immune serum levels were observed in PD4 sera from three of four rabbits vaccinated with O25b OAg. These results demonstrate the necessity of carrier protein conjugation to generate IgG antibodies against O25b OAg polysaccharide at the 10 mcg dose level.
[0358] Bacteria grown on TSA plates were suspended in PBS and cultured to an OD of 2.0. 600 and fixed in 4% paraformaldehyde in PBS. After blocking for 1 h in 4% BSA / PBS, bacteria were incubated with serial dilutions of pre-immune and PD3 immune sera in 2% BSA / PBS, and bound IgG was detected with a PE-labeled secondary F(ab) antibody.
[0359] O25b OAg-CRM 197 The specificity of the O25b antibody elicited by was demonstrated in flow cytometry experiments with intact bacteria. Binding of IgG to whole cells was detected with PE-conjugated F(ab')2 fragment goat anti-rabbit IgG in an Accuri flow cytometer.
[0360] As shown in Figure 16, pre-immune rabbit antibodies were unable to bind to wild-type serotype O25b isolates GAR2831 and GAR2401 or the K-12 E. coli strain, whereas the matched PD3 antibody stained O25b bacteria in a concentration-dependent manner. The negative control K-12 strain, lacking the ability to express OAg, showed only very weak binding of the PD3 antibody, most likely due to the presence of exposed inner core oligosaccharide epitopes on its surface. Introduction of the Salmonella fepE plasmid into wild-type O25b isolates resulted in significantly enhanced staining, consistent with a higher density of immunogenic epitopes provided by the longer OAg polysaccharide.
[0361] Conclusion: The described results show that Salmonella fepE is not only a determinant of very long O-antigen polysaccharides in Salmonella species, but can also confer the ability to make very long O-antigens to E. coli strains of different O-antigen serotypes. This property can be exploited to produce O-antigen vaccine polysaccharides with improved properties for bioprocess development by facilitating purification and chemical conjugation to suitable carrier proteins, as well as potentially enhancing immunogenicity through the formation of higher molecular weight conjugates.
[0362] Example 6 Initial rabbit studies have demonstrated the first polyclonal antibody reagents and RAC O25b OAg-CRM 197 generated an IgG response against Long-chain O25b polysaccharide-CRM 197 The conjugates were produced using periodate oxidation followed by conjugation using reductive amination chemistry (RAC) (Table 7). See also Table 17.
[0363] [Table 7]
[0364] In rabbit study 1 (VAC-2017-PRL-EC-0723) (also described above in Example 5), 5 rabbits / group using 10 μg of L-, M- or H-activated RAC (+QS21) received the composition according to the schedule shown in Figure 13 A. Unconjugated free O25b polysaccharide was observed to be not immunogenic in a follow-up rabbit study (VAC-2017-PRL-GB-0698) (see Figure 18).
[0365] In rabbit study 2 (VAC-2018-PRL-EC-077), 2 rabbits / group using L-RAC (AlOH3, QS21, or no adjuvant) received the composition according to the schedule shown in Figure 13B.
[0366] Rabbits 4-1, 4-2, 5-1, 5-2, 6-1, and 6-2 received the very long unconjugated O25b polysaccharide described in Example 5 and sera were tested at week 18.
[0367] More specifically, a composition comprising 50 μg of unconjugated O25b and 100 μg of AlOH3 adjuvant was administered to rabbit 4-1. A composition comprising 50 μg of unconjugated O25b and 100 μg of AlOH3 adjuvant was administered to rabbit 4-2. A composition comprising 50 μg of unconjugated O25b and 50 μg of QS-21 adjuvant was administered to rabbit 5-1. A composition comprising 50 μg of unconjugated O25b and 50 μg of QS-21 adjuvant was administered to rabbit 5-2. A composition comprising 50 μg of unconjugated O25b and no adjuvant was administered to rabbit 6-1. A composition comprising 50 μg of unconjugated O25b and no adjuvant was administered to rabbit 6-2.
[0368] Example 7 Rabbit testing with O25b RAC conjugate: dLIA serum dilution titers O25b dLIA serum dilution titers from rabbit study 2 (VAC-2018-PRL-EC-077) versus the best responding rabbit from study 1 (VAC-2017-PRL-EC-0723). For these experiments, a modified direct binding Luminex assay was performed in which a polylysine conjugate of O25b long chain O antigen was passively adsorbed onto Luminex carboxy beads instead of the previously described methylated serum albumin long chain O antigen mixture. The use of polylysine-O25b conjugate improved the sensitivity of the assay and the quality of the IgG concentration-dependent response, and allowed the determination of serum dilution by the use of curve fitting (4-parameter non-linear equation). O25b IgG titers in serum from the highest titer rabbit from the first study are compared to serum from rabbits in the second study in Table 8.
[0369] [Table 8]
[0370] Higher doses in a second rabbit study (50 / 20 μg vs. 10 μg) did not improve IgG titers.
[0371] A two month break enhances the IgG response (not observed for shorter intervals).
[0372] Alum appears to enhance the IgG response in rabbits compared to QS21 or no adjuvant.
[0373] An opsonophagocytosis assay (OPA) was established using baby rabbit complement (BRC) and HL60 cells as a source of neutrophils to measure the functional immunogenicity of O-antigen glycoconjugates. Pre-frozen bacterial stocks of E. coli GAR2831 were grown in Luria Broth (LB) medium at 37°C. Cells were pelleted and cultured at 1 OD per ml in PBS supplemented with 20% glycerol. 600Pre-titrated and thawed bacteria were suspended at 0.5x10 in HBSS (Hank's Balanced Salt Solution) containing 1% gelatin and frozen at 0.5x10 5 Dilute to CFU / ml and 10 μL (10 3 CFU) were mixed with 20 μL of serially diluted serum in a U-bottom tissue culture microplate, and the mixture was shaken at 700 rpm (BELLCO Shaker) for 30 min at 37°C in a 5% CO2 incubator. 10 μl of 2.5% complement (baby rabbit serum, PEL-FREEZ 31061-3, prediluted in HBG) and 20 μL of HL-60 cells (0.75x10 7 100 μL of each reaction was then transferred to the corresponding well of a pre-wetted MILLIPORE MULTISCREENHTS HV filter plate, which had been prepared by adding 100 μL of water, vacuum filtering, and adding 150 μL of 50% LB. The filter plate was vacuum filtered and incubated overnight at 37° C. in a 5% CO2 incubator. The colonies were counted the following day after fixing, staining, and destaining with COOMASSIE dye and destaining solution using an IMMUNOSPOT® analyzer and IMMUNOCAPTURE software. To establish the specificity of OPA activity, immune sera were preincubated with 100 μg / mL purified long-chain O25b O antigen before mixing with the other assay components in an OPA reaction. The OPA assay includes control reactions that do not contain HL60 cells or complement to demonstrate the dependence of the observed killing on these components.
[0374] Matched pre-immune and post-vaccination serum samples from representative rabbits from both rabbit studies were evaluated in the assay and serum dilution titers were determined (Table 9, Figures 19A-B). Pre-incubation with unconjugated O25b long chain O antigen polysaccharide blocked bactericidal activity indicating the specificity of OPA (Figure 19C). Table 9 shows the OPA titers.
[0375] Rabbit 2-3 was dosed as follows: Rabbit 2-3 dosing: 10 / 10 / 10 / 10 μg RAC conjugate + QS21, bled post dose 4 (PD). Rabbit 1-2 was dosed as follows: 50 / 20 / 20 / 20 μg RAC conjugate + Al(OH)3, bled on PD4.
[0376] [Table 9]
[0377] Example 8 O-antigen O25b IgG levels elicited by unconjugated O25b long-chain O-antigen polysaccharide and induced O25b RAC / DMSO long-chain O-antigen glycoconjugates Groups of 10 CD-1 mice were administered 0.2 or 2.0 μg / animal O25b RAC / DMSO long chain O antigen saccharide conjugate by subcutaneous injection at weeks 0, 5 and 13 and bled at weeks 3 (after dose 1, PD1), 6 (after dose 2, PD2) and 13 (after dose 3, PD3) for immunogenicity studies. Levels of antigen-specific IgG were determined by quantitative Luminex assay (see details in Example 7) using O25b-specific mouse mAb as an internal standard. Baseline IgG levels (dotted line) were determined in pooled serum from 20 randomly selected non-vaccinated mice. Free unconjugated O25b long chain O antigen polysaccharide immunogen did not induce IgG above baseline levels at any time point. In contrast, IgG responses were observed after two doses of the O25b-CRM197 RAC long chain conjugate glycoconjugate: robust and homogenous IgG responses were observed by PD3, with intermediate and more variable IgG levels observed at PD2. GMT IgG values (ng / ml) are shown with 95% CI error bars. See Figure 20.
[0378] Example 9 Specificity of O25b baby rabbit complement (BRC) OPA A-B) O25b RAC / DMSO long chain O antigen post-immune sera from rabbits 2-3 and 1-2 (but not matched pre-immune control sera) show bactericidal OPA activity. C) OPA activity of immune sera from rabbits 1-2 was blocked by pre-incubation with 100 μg / mL long chain O antigen O25b polysaccharide. GAR2831 bacterial strain was incubated with serial dilutions of HL60, 2.5% BRC and serum for 1 h at 37°C and viable bacteria were enumerated by counting microcolonies (CFU) on filter plates. See Figure 19.
[0379] Example 10 RAC and eTEC O25b long-chain glycoconjugates are more immunogenic than single-terminal glycoconjugates BRC OPA assay with carbapenem-resistant fluoroquinolone-resistant MDR strain Atlas187913. Groups of 20 CD-1 mice were vaccinated with 2 μg of glycoconjugate according to the same schedule as shown in FIG. 21, and OPA responses were determined after dose 2 (PD2) (panel A) and after dose 3 (PD3) (panel B). Bars indicate GMTs with 95% CI. Percentage of responders above non-vaccinated baseline is shown. Log-transformed data from different groups were evaluated to assess whether differences were statistically significant using unpaired t-tests with Welch's correction (Graphpad Prism). Results are summarized in Table 10. See FIG. 21. In mice vaccinated with 2 μg of eTEC O1a long-chain glycoconjugate, OPA titers against O1a at PD2 and PD3 (data not shown) were observed to be higher than OPA titers against O25b at PD2 and PD3, respectively, as shown in Table 10.
[0380] [Table 10]
[0381] Example 11 OPA immunogenicity of eTEC chemistry can be improved by modifying the level of polysaccharide activation BRC OPA assay with carbapenem-resistant fluoroquinolone-resistant MDR strain Atlas187913. Groups of 20 CD-1 mice were vaccinated with 0.2 μg or 2 μg of the indicated long-chain O25b eTEC glycoconjugates and OPA responses were determined at PD2. Pooled log-transformed data from 4% and 17% activation groups were evaluated to confirm that differences in OPA responses were statistically significant using an unpaired t-test with Welch's correction (Graphpad Prism). GMTs and percentage of responders for individual groups are summarized in Table 11. See Figure 22.
[0382] [Table 11]
[0383] Example 12 Challenge studies show that long-chain E. coli O25b eTEC conjugates elicit protection after three doses Groups of 20 CD-1 mice immunized with a dose of 2 μg according to the indicated schedule were administered 1 × 10 9 Mice were challenged with bacteria of GAR2831 strain via IP. Survival was monitored over a 6 day period. Groups of mice vaccinated with activated eTEC glycoconjugates at levels of 4%, 10% or 17% were protected from lethal infection, whereas unvaccinated control mice or mice vaccinated with 2 μg of unconjugated O25b long chain polysaccharide were not. See FIG. 23.
[0384] (Example 13) Process for the preparation of eTEC-linked glycoconjugates Sugar activation and thiolation with cystamine dihydrochloride. Sugars are reconstituted in anhydrous dimethyl sulfoxide (DMSO). The water content of the solution is determined by Karl Fischer (KF) analysis and adjusted to reach a water content of 0.1-1.0%, typically 0.5%.
[0385] To initiate activation, a solution of 1,1'-carbonyl-di-1,2,4-triazole (CDT) or 1,1'-carbonyldiimidazole (CDI) is freshly prepared in DMSO at a concentration of 100 mg / mL. Activate the sugar with various amounts of CDT / CDI (1-10 molar equivalents) and allow the reaction to proceed for 1-5 h at rt or 35 °C. Water was added to quench the residual CDI / CDT in the activation reaction solution. Determine the amount of water to be added and perform calculations so that the final water content is 2-3% of the total water content. Allow the reaction to proceed for 0.5 h at rt. Freshly prepare cystamine dihydrochloride in anhydrous DMSO at a concentration of 50 mg / mL. React the activated sugar with 1-2 molar equivalents of cystamine dihydrochloride. Alternatively, react the activated sugar with 1-2 molar equivalents of cystamine hydrochloride. The thiolation reaction is allowed to proceed at rt for 5-20 h to produce thiolated sugars, with the thiolation level determined by the amount of CDT / CDI added.
[0386] Reduction and purification of activated thiolated sugars. To the reaction mixture of thiolated sugars, a solution of 3-6 molar equivalents of tris(2-carboxyethyl)phosphine (TCEP) is added and allowed to proceed at rt for 3-5 h. The reaction mixture is then diluted 5-10-fold by addition to pre-chilled 10 mM sodium dihydrogen phosphate and filtered through a 5 μm filter. Diafiltration of the thiolated sugar is performed against 30-40 dialysis volumes of pre-chilled 10 mM sodium dihydrogen phosphate. An aliquot of the retentate of activated thiolated sugar is removed and sugar concentration and thiol content are determined (Ellman assay).
[0387] Activation and purification of bromoacetylated carrier protein. Free amino groups of the carrier protein are bromoacetylated by reaction with a bromoacetylating agent, such as bromoacetic acid N-hydroxysuccinimide ester (BAANS), bromoacetyl bromide, or another suitable reagent.
[0388] Carrier protein (in 0.1 M sodium phosphate, pH 8.0±0.2) is first kept at 8±3°C at pH 7 prior to activation. To the protein solution, N-hydroxysuccinimide ester of bromoacetic acid (BAANS) is added as a dimethylsulfoxide (DMSO) stock solution (20 mg / mL) at a ratio of 0.25-0.5 BAANS:protein (w / w). The reaction is mixed gently at 5±3°C for 30-60 min. The resulting bromoacetylated (activated) protein is purified, for example, by UF / DF using a 10 kDa MWCO membrane using 10 mM phosphate (pH 7.0) buffer. After purification, the protein concentration of the bromoacetylated carrier protein is estimated by Lowry's protein assay.
[0389] The degree of activation is determined by a total bromide assay by ion exchange liquid chromatography (ion chromatography) with suppressed conductivity detection. Bound bromide on activated bromoacetylated proteins is cleaved from the proteins in the assay sample preparation and quantified together with any free bromide present. Remaining covalently bound bromide on the protein is liberated by converting it to ionic bromide by heating the sample in alkaline 2-mercaptoethanol.
[0390] Bromoacetylated CRM 197 Activation and purification of CRM using 10 mM phosphate buffered 0.9% NaCl pH 7 (PBS). 197 was diluted to 5 mg / mL and then brought to 0.1 M NaHCO3 pH 7.0 using a 1 M stock solution. BAANS was diluted to 0.1 M NaHCO3 pH 7.0 using a 20 mg / mL DMSO stock solution of BAANS. 197 The CRMP was added at a ratio of 1:0.35 (w:w) to BAANS. The reaction mixture was incubated at 3°C to 11°C for 30 min to 1 h and then purified by UF / DF using a 10K MWCO membrane and 10 mM sodium phosphate / 0.9% NaCl, pH 7.0. The purified activated CRMP was 197The protein was assayed by Lowry assay to determine protein concentration and then diluted to 5 mg / mL in PBS. Sucrose was added as a cryoprotectant to 5% wt / vol, and the activated protein was frozen and stored at -25°C until required for conjugation.
[0391] CRM 197 Bromoacetylation of lysine residues in was highly consistent, resulting in activation of 15–25 lysines from the 39 available lysines. The reaction produced high yields of activated protein.
[0392] Conjugation of activated thiolated sugars to bromoacetylated carrier proteins. The bromoacetylated carrier protein and activated thiolated sugars are then added. The sugar / protein input ratio is 0.8±0.2. The reaction pH is adjusted to 9.0±0.1 using 1M NaOH solution. The conjugation reaction is allowed to proceed at 5° C. for 20±4 hours.
[0393] Capping of remaining reactive functional groups. Unreacted bromoacetylated residues on the carrier protein are quenched by reacting with 2 molar equivalents of N-acetyl-L-cysteine as a capping reagent for 3-5 hours at 5°C. Remaining free sulfhydryl groups are capped with 4 molar equivalents of iodoacetamide (IAA) for 20-24 hours at 5°C.
[0394] Purification of eTEC-bound glycoconjugates. The conjugation reaction (post IAA capping) mixture is filtered through a 0.45 μm filter. Ultrafiltration / diafiltration of the glycoconjugate is performed against 5 mM succinate-0.9% saline, pH 6.0. The glycoconjugate retentate is then filtered through a 0.2 μm filter. An aliquot of the glycoconjugate is removed for assay. The remaining glycoconjugate is stored at 5° C. See Table 14, Table 15, Table 16, Table 17, and Table 18.
[0395] Example 14 Preparation of E. coli-O25B ETEC conjugate Activation process - Activation of E. coli-O25b lipopolysaccharide. Lyophilized E. coli-O25b polysaccharide was reconstituted in anhydrous dimethyl sulfoxide (DMSO). The moisture content of the lyophilized O25b / DMSO solution was determined by Karl Fischer (KF) analysis. The moisture content was adjusted by adding WFI to the O25b / DMSO solution to achieve a moisture content of 0.5%.
[0396] To initiate activation, 1,1'-carbonyldiimidazole (CDI) was freshly prepared as a 100 mg / mL solution in DMSO. Prior to the thiolation step, E. coli-O25b polysaccharide was activated with various amounts of CDI. CDI activation was carried out at rt or 35°C for 1-3 h. Water was added to quench residual CDI in the activation reaction solution. The amount of water to be added was determined and calculations were performed to ensure the final water content was 2-3% of the total water content. The reaction was allowed to proceed for 0.5 h at rt.
[0397] Thiolation of activated E. coli-O25b polysaccharide. Cystamine dihydrochloride was freshly prepared in anhydrous DMSO, and 1-2 molar equivalents of cystamine dihydrochloride were added to the reaction solution of activated polysaccharide. The reaction was allowed to proceed at rt for 20±4 h.
[0398] Reduction and purification of activated thiolated E. coli-O25b polysaccharide. A solution of 3-6 molar equivalents of tris(2-carboxyethyl)phosphine (TCEP) was added to the reaction mixture of thiolated sugars and allowed to proceed at rt for 3-5 h. The reaction mixture was then diluted 5-10 fold by addition to pre-chilled 10 mM sodium dihydrogen phosphate and filtered through a 5 μm filter. Diafiltration of the thiolated sugars was performed against 40 dialysis volumes of pre-chilled 10 mM sodium dihydrogen phosphate using a 5K MWCO ultrafiltration membrane cassette. The thiolated O25b polysaccharide retentate was removed for both sugar concentration assays and thiol (Ellman) assays. A flow diagram of the activation process is provided in Figure 25A.
[0399] Conjugation process - thiolated E. coli-O25b polysaccharide with bromoacetylated CRM 197 Conjugation to CRM by bromoacetylation as described in Example 13. 197 The carrier proteins were activated separately and then reacted with activated E. coli-O25b polysaccharide for the conjugation reaction. 197 and thiolated O25b polysaccharide were mixed together in a reaction vessel. The sugar / protein input ratio was 0.8±0.2. The reaction pH was adjusted to 8.0-10.0. The conjugation reaction was allowed to proceed at 5° C. for 20±4 hours.
[0400] Bromoacetylated CRM 197 and capping of reactive groups on thiolated E. coli-O25b polysaccharide. CRM 197 Unreacted bromoacetylated residues on the protein were capped by reaction with 2 molar equivalents of N-acetyl-L-cysteine at 5°C for 3–5 h, followed by capping of remaining free sulfhydryl groups of the thiolated O25b-polysaccharide with 4 molar equivalents of iodoacetamide (IAA) at 5°C for 20–24 h.
[0401] Purification of eTEC-bound E. coli-O25b glycoconjugates. The conjugation solution was filtered through a 0.45 μm or 5 μm filter. Diafiltration of the O25b glycoconjugates was performed using a 100K MWCO ultrafiltration membrane cassette. Diafiltration was performed against 5 mM succinate-0.9% saline, pH 6.0. The E. coli-O25b glycoconjugate 100K retentate was then filtered through a 0.22 μm filter and stored at 5° C.
[0402] A flow diagram of the conjugation process is provided in Figure 25B.
[0403] result Reaction parameters and characterization data for several batches of E. coli-O25b eTEC glycoconjugates are shown in Table 12. CDI activation-thiolation with cystamine dihydrochloride produced glycoconjugates with sugar yields of 41-92% and less than 5% to 14% free sugars. See also Tables 14, 15, 16, 17, and 18.
[0404] [Table 12]
[0405] Example 15 E. coli O antigen polysaccharide-CRM 197 Procedure for preparation of eTEC conjugates (applies to O antigens derived from E. coli serotypes O25b, O1a, O2, and O6) Polysaccharide Activation E. coli O-antigen polysaccharide is reconstituted in anhydrous dimethyl sulfoxide (DMSO). To initiate activation, various amounts of 1,1'-carbonyldiimidazole (CDI) (1-10 molar equivalents) are added to the polysaccharide solution and the reaction is allowed to proceed for 1-5 h at rt or 35 °C. Water (2-3%, v / v) is then added to quench any residual CDI in the activation reaction solution. The reaction is allowed to proceed at rt for 0.5 h before adding 1-2 molar equivalents of cystamine dihydrochloride. The reaction is allowed to proceed at rt for 5-20 h before treating with 3-6 molar equivalents of tris(2-carboxyethyl)phosphine (TCEP) to produce thiolated saccharides. The thiolation level is determined by the amount of CDI added.
[0406] The reaction mixture is then diluted 5-10 times by addition to pre-chilled 10 mM sodium dihydrogen phosphate and filtered through a 5 μm filter. Diafiltration of the thiolated sugar is performed against 30-40 dialysis volumes of pre-chilled 10 mM sodium dihydrogen phosphate. An aliquot of the retentate of activated thiolated sugar is removed and the sugar concentration and thiol content are determined (Ellman assay).
[0407] Carrier Proteins (CRM 197 ) activation CRM 197 (in 0.1 M sodium phosphate, pH 8.0 ± 0.2) is initially kept at pH 8 and 8 ± 3 °C prior to activation. To the protein solution, N-hydroxysuccinimide ester of bromoacetic acid (BAANS) is added as a dimethyl sulfoxide (DMSO) stock solution (20 mg / mL) at a ratio of 0.25-0.5 BAANS:protein (w / w). The reaction is mixed gently at 5 ± 3 °C for 30-60 min. The resulting bromoacetylated (activated) protein is purified, for example, by UF / DF using a 10 kDa MWCO membrane using 10 mM phosphate (pH 7.0) buffer. After purification, the protein concentration of the bromoacetylated carrier protein is estimated by Lowry's protein assay.
[0408] Conjugation Next, the activated CRM 197 and activated E. coli O antigen polysaccharide are added to the reactor and mixed. The sugar / protein input ratio is 1 ± 0.2. The reaction pH is adjusted to 9.0 ± 0.1 using 1 M NaOH solution. The conjugation reaction is allowed to proceed for 20 ± 4 hours at 5 °C. Unreacted bromoacetylated residues on the carrier protein are quenched by reacting with 2 molar equivalents of N-acetyl-L-cysteine as a capping reagent for 3-5 hours at 5 °C. Remaining free sulfhydryl groups are capped with 4 molar equivalents of iodoacetamide (IAA) for 20-24 hours at 5 °C. The reaction mixture is then purified using UF / DF performed against 5 mM succinate-0.9% saline, pH 6.0. The purified conjugate is then filtered through a 0.2 μm filter. Please see Tables 14, 15, 16, 17, and 18.
[0409] (Example 16) General procedure - Conjugation of O-antigen (from E. coli serotypes O1, O2, O6, 25b) polysaccharides by reductive amination chemistry (RAC) Conjugation in dimethylsulfoxide (RAC / DMSO) Polysaccharide Activation Polysaccharide oxidation was carried out in 100 mM sodium phosphate buffer (pH 6.0±0.2) by sequential addition of calculated amounts of 500 mM sodium phosphate buffer (pH 6.0) and water for injection (WFI) to obtain a final polysaccharide concentration of 2.0 g / L. If necessary, the reaction pH was adjusted to approximately pH 6.0. After pH adjustment, the reaction temperature was cooled to 4° C. The oxidation was initiated by the addition of approximately 0.09-0.13 molar equivalents of sodium periodate. The oxidation reaction was carried out at 5±3° C. for approximately 20±4 h.
[0410] Concentration and diafiltration of the activated polysaccharides were performed using a 5K MWCO ultrafiltration cassette. Diafiltration was performed against 20x diavolume of WFI. The purified activated polysaccharides were then stored at 5±3° C. The purif...
Claims
1. (a) Formula O25b shown in Table 1, where n is an integer from 31 to 70. (b) a conjugate comprising a carrier protein covalently linked to an E. coli O antigen polysaccharide of formula O1A as shown in Table 1, where n is an integer between 31 and 50; (c) a conjugate comprising a carrier protein covalently linked to an E. coli O antigen polysaccharide of formula O2 as shown in Table 1, where n is an integer between 31 and 70; and (d) a conjugate comprising a carrier protein covalently linked to an E. coli O antigen polysaccharide of formula O6:K2, formula O6:K13, formula O6:K15, or formula O6:K54 as shown in Table 1, where n is an integer between 31 and 60.
2. 10. The composition of claim 1, further comprising a conjugate comprising a carrier protein covalently attached to an E. coli O-antigen polysaccharide having a structure selected from any one of formulas O16 (wherein n is an integer between 31 and 70), O17 (wherein n is an integer between 31 and 50), O18 (wherein n is an integer between 31 and 50), and O75 (wherein n is an integer between 31 and 70) as shown in Table 1.
3. 2. The composition of claim 1, comprising up to 25% free saccharides compared to the total amount of O-antigen polysaccharides in the composition.
4. 4. A medicament for raising an immune response against Escherichia coli in a mammal, comprising an effective amount of the composition of any one of claims 1 to 3.
5. The method of claim 4, wherein the immune response comprises opsonophagocytic antibodies against E. coli.
6. The method of claim 4, wherein the immune response protects the mammal from E. coli infection.
